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Abstract 
Vascular cell senescence has been observed in vascular healing, atheroma and 
advanced age. Other groups have demonstrated that senescence is a process 
characterized by metabolic dysfunction. We therefore investigate whether it may 
occur as a consequence of metabolic stress. Controversy existed as to whether nitric 
oxide was able to prevent senescence in vascular cells. As nitric oxide is able to 
inhibit mitochondrial respiration, we investigated its effects both as an oxidant and 
metabolic stressor.  
We observed that cells exposed to nitric oxide donors senesce over a concentration 
range of DETA-NO 0.5-0.75mM or GSNO 1mM, showing an exponential increase in 
senescence until succumbing to cell death as concentrations of DETA-NO increase. 
This was confirmed by cell morphology, senescence-associated β-galactosidase 
activity, total β-galactosidase activity, cell proliferation assays and expression of 
p16INK4a and p21WAF. We investigated whether this effect could be reproduced by 
cells induced to express iNOS in vitro. 
Using these tools, we investigated the mechanism of NO-induced senescence 
looking at soluble guanylate cyclase activation, increased generation of ROS, protein 
transnitrosation and glutathione depletion. We investigated ways in which nitric 
oxide-induced senescence could be circumvented by using antioxidants (NAC, 
selenomethionine, uric acid), activating AMP kinase with metformin and AICAR and 
reducing protein transnitrosation by exposing the cells to cold light. We used 
pharmacological means to mimic lysosomal dysfunction and to stimulate autophagy. 
My findings show that nitric oxide can cause senescence in vascular cells by a 
mechanism that involves protein transnitrosation. The effect of nitric oxide on 
senescence is independent of ROS generation, AMP kinase activation, soluble 
guanylate cyclase activation and glutathione depletion. 
My findings may have important implications in vascular disease, particularly in 
cases of short periods of high nitric oxide production, such as sepsis, but also in the 
case of low-grade chronic inflammation such as that seen in atherosclerosis. 
However, their physiological relevance needs to be confirmed. The pathway by 
which protein transnitrosation induces senescence has yet to be fully elucidated. 
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1 Introduction 
1.1 Senescence overview 
Cellular senescence, for the purpose of this document, can be defined as an 
irreversible loss of replicative capacity with the maintenance of cell viability.  This 
state can occur in response to a variety of stimuli, for instance genotoxic and 
oxidative stress. However, the original description of cellular senescence pertains to 
what is known as replicative senescence. Hayflick described the observation that 
normal diploid cells grown in culture and serially passaged, eventually cease 
replicating – replicative senescence.1 
Replicative senescence describes senescence which occurs as a consequence of 
repeated cell divisions.  It has been thought that replicative senescence could be the 
biological limit to mortality. 
Stress-induced senescence describes the occurrence of irreversible cell cycle arrest 
after a noxious stimulus. 
The influence of both types of senescence on aging in general have been explored 
but aging is a complex processes and is often accompanied by disease, whether 
directly as a consequence of age or as a result of more time being available for 
disease to take hold. This makes the task of assessing the effect of each individual 
factor associated with initiating senescence difficult. 
The hypothesis that older mammals may have an increased number of cells which 
have undergone senescence and that this may contribute to diseases seen in the 
elderly population has been encouraged by harvesting cells from elderly humans and 
establishing their replicative capacity relative to those harvested from younger 
donors.2 However, this may be due to either replicative or stress-induced 
senescence. 
For example, if one applies a noxious stimulus to a cell, such as radiation or an 
oxidative stressor, the cell may alter its function in order to defend itself and the 
organism as a whole.  The cell may thus be forced to choose between programmed 
cell death or senescence.  The choice of apoptosis limits the potential for the 
accumulation of cells with genetic damage and therefore avoids the possibility of cell 
transformation. However, a proportion of cells undergo stress-induced senescence.  
Therefore if one harvests cells from older individuals, there may have been a mix of 
healthy cells able to replicate and stress induced senescent cells.  Serial passage of 
those cells to calculate replicative capacity will not answer the question of mode of 
senescence. Senescent cells present in the initial sample will not replicate and 
therefore, normal cells will account for an increasing proportion of the total cells if the 
cells are serially passaged until ceasing replication altogether. At time of assay, the 
cells analysed in the population which initially had more stress-induced senescent 
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cells will actually have none of the original cells which senesced in this manner and a 
higher proportion of cells which have senesced through more replication cycles. 
Either mode of senescence may help to explain the increased incidence of 
senescent cells seen in vascular disease, which can have its origins in young 
individuals, manifesting later in life. Vascular smooth muscle cells obtained from 
atheromatous plaques have been subject to histological analysis. 18% of these cells 
were observed to be senescent in that they expressed senescence-associated β-
galactosidase and p16INK4a and p21WAF, while no such evidence of senescence was 
found in  cells from non-atheromatous arteries.3 Furthermore, vascular smooth 
muscle cells cultured from atheromatous plaques rapidly accumulated a senescent 
phenotype with 80.5% demonstrating senescence-associated β-galactosidase on 
first passage, compared to 5.2% in healthy sections of artery. 
Another argument against replicative senescence being the predominant factor in 
aging is that in many cell types, and for instance endothelial cells, the number of 
cells replicating at any one point in time in vivo is very small. This is because in adult 
endothelium, cell turnover tends to be by necessity, for instance in the context of 
growth of new vessels damage and repair of existing vessels. Cells largely tend to 
be in a quiescent state. In vitro, we are often able to see several scores of population 
doublings before replicative senescence intervenes. Cells grown in vitro are grown at 
a relatively low density to avoid contact inhibition and subsequently increase in 
number at exponential rates.  In contrast, cells analysed in situ in the vasculature of 
rat and pig aortae show a mitotic rate of 0.01% and 0.55% respectively.4;5  The 
standard doubling time of a rat aortic endothelial cell is around 28hrs.  If this was a 
constant rate, rats would produce a new endothelial layer every 32 years and pigs 
every 7 months.  Clearly, if these data are accurate, for rats, endothelial replicative 
senescence is unlikely to occur but in pigs, there is a possibility it would occur. This 
assumes that cells in all parts of endothelium are repaired equally. However, disease 
states are likely to place demands on focal areas and imperfect repair is likely to lead 
to higher rates of attrition. 
Atheroma tends to occur at branch points of arteries.6  It has been shown that these 
cells suffer a higher rate of attrition than cells in straight sections of blood vessels 
due to changes in shear stress or turbulence and thus may be required to undergo 
more cell divisions than their neighbouring cells, finally reaching replicative 
senescence.  Alternatively, noxious stimuli such as pro-inflammatory cytokines and 
the associated rise in oxidative radicals may lead these cells to undergo stress-
induced senescence.  Regardless of the cause of senescence, it remained to be 
shown whether senescent cells actively participate in the development of disease, 
whether they are in fact protective or whether they are simply innocent bystanders. 
We became interested in investigating factors involved in the initiation of senescence 
and the role of stressors likely to be encountered by vascular cells. 
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Methods to investigate senescence are limited by the source of cells and the 
artificiality of the system used to grow them.  The ideal system would allow the 
analysis of a subset of young cells of similar replicative age to be analysed in a 
phenotypically pure population for the early changes associated with the 
development of senescence and for the subsequent proportion of senescent cells.  
In this respect, obtaining young healthy human cells limits us to obtaining cells from 
umbilical cords. 
Assessment of senescence by replicative capacity relies on a number of cell 
manipulations which may introduce error.  Standard practice is to keep cells in vitro 
under continual mitogenic stimulus.  Cells are not allowed to become confluent in 
culture as there is contact inhibition between cells and this would make any 
calculation of cell replication rate inaccurate.  Cells which become confluent may 
also not recover their replicative ability.  Thus experiments to assess the effect of 
stressors on senescence are carried out when cells are at a relatively low density 
(not in contact).  The cells are then repeatedly dissociated using trypsin EDTA, 
another artificial agent and suffer mechanical stress for a number of passages until 
replicative senescence.  This contrasts with the situation in vivo where cells are in 
contact, forming a layer of quiescent cells.  Cells in a confluent monolayer may be 
better suited to survive any noxious stimulus and also may express their defences in 
a way more alike to in vivo.  The ability to assess senescence immediately after any 
intervention would decrease the chances of culture artefact. 
 Identifying cell senescence 1.1.1
There appear to be many different ways to senesce. Whether the final senescent 
phenotype is uniform or variable is also not conclusive. However, cells which 
senesce tend to display some or all of the following rather descriptive features 
(abridged from Rodier and Campisi JCB 2011).7 These features are discussed after 
the summary. 
 β-galactosidase activity increases. 
 Some of the increase in mass is due to an increase in the size of 
lysosomes and this can be demonstrated by staining for β-
galactosidase. 
 Senescent cells tend to increase in mass. 
 Irreversible cell cycle arrest.  
 The first essential component point but can sometimes be overcome by 
interfering with factors required to maintain the cell in growth arrest, 
resulting in cellular transformation. 
 p16INK4a 
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 Cells which have senesced tend to express the tumour suppressor 
p16INK4a which in turn activates retinoblastoma protein (pRb). 
 DNA-SCARS 
 DNA segments with chromatin alterations reinforcing senescence. 
 SASP 
 There is also an altered secretory pattern in senescent cells 
(senescence associated secretory phenotype). 
 Senescence-associated β-galactosidase 1.1.2
Senescence-associated -galactosidase can be visualized by histology and 
represents an increase in the amount of -galactosidase activity which is normally 
active at an acidic pH within lysosomes but, in senescence, can be detected at a 
relatively alkaline pH of 6.8  This correlates well with replicative senescence and has 
been used to detect the other forms of senescence.9  Further analysis of this 
phenomenon has revealed that the increase in senescence-associated -
galactosidase staining actually represents an increase in the mass and activity of β-
galactosidase.10  Furthermore, the increase is accommodated by an increase in 
lysosomal mass.  It is not known why cells have an increased amount of -
galactosidase enzyme but the subcellular localization of β-galactosidase remains 
within the lysosomes which tend to enlarge once senescence occurs.  One 
possibility is that senescence is associated with a defect in the function of lysosomes 
or that they become overwhelmed by an increased demand.  This phenomenon has 
been demonstrated to be non-causal by work on cells unable to manufacture -
galactosidase.  In this study, cells continued to replicate until cell cycle arrest was 
observed.11 However, this did not exclude the possibility that lysosomal dysfunction 
had occurred and could remain the causative mechanism. I therefore decided to 
investigate the effect of pharmacological manipulation of lysosomal function on 
vascular cell senescence. 
 Telomere function and senescence 1.1.3
The telomere is a complex structure at the ends of chromosomal DNA.  It serves as 
a cap to cover the ends of DNA and thus prevent the loose ends being recognized 
as strand breaks, which would trigger DNA repair mechanisms or cell death via 
apoptosis.  More than this, DNA replication begins at the telomeric end of DNA and 
the action of the DNA replication machinery requires a certain minimum length of 
bases to grip onto the strand of DNA and begin replication.  The first bases are 
thereby not copied in the successive generation and this process leads to 
progressive shortening of the telomeric DNA, finally rendering it too short to allow the 
DNA replication machinery to latch on. This makes the cell unable to support 
replication and leads to senescence. 
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In more detail, DNA replication by DNA polymerase occurs with the aid of a RNA 
primer template. DNA synthesis is unidirectional. The DNA polymerase is only able 
to synthesise nucleotides which start with a 5’ base and lead to a 3’ base, therefore 
they start in sequence on a complimentary portion of DNA, closest to the 3’ end, 
proceeding towards the 5’ end. This occurs at multiple sites during different stages of 
S phase. Initially, the double strand is pulled apart, allowing space for RNA primers 
to recognise the starting point. 
The leading strand is that which is using the DNA template generally progressing 
towards the 5’ end and therefore requires only a single starting point and could in 
theory continue in this direction with minimal DNA strand separation to the end of the 
molecule, although, in practice, it tends to meet a previously synthesized segment 
first. 
The other strand is referred to as the lagging strand. As the DNA is being separated 
in the opposing direction to that which DNA polymerase is able to replicate, it uses 
multiple starting points separated by short gaps to make short segments. Each 
segment contains an RNA primer, followed by DNA. 
After synthesis of DNA, the RNA templates are removed and the gaps in DNA filled 
by ligase. This is completed in the main portion of DNA where ligase has a preceding 
DNA segment in order to replace the RNA primer. However, at the end of the 
chromosome, there is no preceding DNA segment and therefore the final portion of 
DNA cannot be filled in this manner, leaving an single-strand overhang and relatively 
shorter DNA. 
Thus, the expectation would be that with each replication, DNA would gradually lose 
length in the region of the telomere. However, the number of base pairs lost in this 
manner would be minimal and asymmetric (loss occurring only in the lagging end of 
DNA as the leading end would have no primer to resect). Further loss of the 5’ end of 
DNA is regulated by MRN, a DNA damage response protein and Protection of 
Telomeres 1 (POT1), one of the capping proteins which seems to regulate a 
minimum 3’ overhang length, perhaps to ensure a t-loop structure suitable for 
capping.12;13 
In this way, without any other mechanism to restore telomeric length, telomeric 
shortening leads to a predetermined number of cell replications and a maximum 
organismal age.  This is countered in many replicating cell types by restoring 
telomeric length using the enzyme telomerase. Loss or dysfunction of telomerase, in 
those cells which express it, eventually occurs with increasing age and this, in turn, 
allows the telomere to be eroded to a critical length, promoting senescence. 
Telomerase assays and telomere length studies showed that cells with high 
telomerase activity tended to able to replicate indefinitely and that this was related to 
maintenance of telomere length.14-18  Thus cancer cells commonly have a high level 
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of telomerase and normal cells transfected to constitutively express telomerase are 
able to circumvent senescence and replicate indefinitely. 
Telomerase comprises a catalytic subunit (hTERT) and also contains a RNA 
template designed to recognise 1½ repeats of TTAGGG and in this way can 
recognize the telomere and can add more of the 6-base pair units which make up the 
telomere.  It functions as a reverse transcriptase and much of its structure was 
elucidated by Blackburn et al.19-22  Working in parallel, Szostak developed a non-
functioning mutant of telomerase and showed that cells lacking functioning 
telomerase progressively lost telomere length.  The cells were able to replicate up to 
a certain point but lost this ability earlier than yeasts without the mutation – an 
alteration to their replicative capacity clearly related to accelerating shortening of 
telomeres.23;24 
Telomere attrition has been demonstrated in cells localised to atherosclerotic 
plaques. Whilst not conclusive proof of a causal relationship, telomere attrition is not 
seen in healthy portions of artery and may well play a part in the disease generation, 
maintenance or even defence. Interestingly, telomere restriction fragment length 
varied between individuals more than between disease processes when patients 
undergoing heart transplant were examined to compare atherosclerotic vessels with 
normal vessels. However, the variation within individuals which was assessed by 
comparing diseased and healthy portions of vessel from the same patient was more 
impressive and corresponded to the expected finding of senescence within vascular 
smooth muscle cells sourced from atherosclerotic plaques.  Therefore there is no 
reliable method of investigating the presence of senescence simply by measuring 
the current telomere length, rather the telomere shortening compared to the starting 
length or the process which permits this to occur needs to be assessed.3 
However, the telomere’s role in the organism may well be less to do with limiting the 
age it could potentially attain and more to do with maintaining health. The prevention 
of unlimited cellular replication is an important step to avoiding neoplastic growth.  
This is amply demonstrated by numerous observations of cancer cell lines being 
able to circumvent senescence by a variety of mechanisms, including the expression 
of telomerase. 
It is important to differentiate between the Hayflick description of replicometer 
senescence and other forms of senescence seen in vivo or in stress situations in 
vitro. Whether cells which have previously undergone a number of divisions are 
more susceptible to stress-induced senescence is not known.  Cells grown serially in 
culture have shortened telomeres but lack a DNA damage response at the stage of 
senescence.25 Factors which are thought to encourage this include tissue culture 
conditions. Repeated trauma to cells, a lack of shear stress on endothelial cells and 
a lack of the surrounding connective tissue and other cell types are artifices which 
make the tissue culture situation different to that seen in vivo. Moreover, incubating 
cells in 21% oxygen is a significantly higher dissolved concentration of oxygen than 
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cells would generally encounter in vivo, although the availability of oxygen in vivo is 
greatly enhanced and regulated by release of oxygen by haemoglobin.  
Telomere erosion, as mentioned above, tends to occur in replicative senescence and 
leads to a senescence characterised by increased expression and activity of p53 and 
is aided by p21WAF. However, this can be reversed by inactivating p53 or partly 
reversed by expressing oncogenic RAS, a powerful mitogenic stimulus.26 
Therefore cells can senesce in response to DNA damage, telomere attrition due to 
repeated cell divisions and also in response to tumour suppressor gene loss. 
It is always tempting to ascribe an evolutionary purpose to biological phenomena but 
it seems that senescent cells do afford some protection against tumours, particularly 
those which may affect life during the childhood and reproductive years.  However, 
the same benevolent process may encourage the development of cancer in later 
years (antagonistic pleiotropy).  
Telomere length is important to maintain telomere function as it serves as the site for 
telomere capping proteins to cover the end of the DNA molecule. Shortened 
telomeric DNA leads to an increasing risk that capping proteins will no longer be able 
to cover the DNA which in turn can be recognized as double-strand DNA breaks and 
could initiate the DNA damage response mechanism and cell cycle arrest. 
Alternatively, the exposed DNA could lead to telomeric fusion with other exposed 
telomeres and cell cycle arrest by this mechanism.27  Telomerase presents a 
mechanism by which this could be prevented, by adding tails of DNA to their 3’ 
ends.28 
Interestingly, telomere length was not the only predictor of proliferative capacity.  
Cells which are transfected with a fully functional hTERT catalytic subunit of 
telomerase can elongate their telomeres and become immortal.  However, cells 
expressing a hypomorphic, less functional hTERT exhibit a degree of telomere 
attrition but after a period of telomeric shortening, stabilise and achieve immortality.  
Telomerase thus can be assumed to perform more than one anti-replicative 
senescence function.  Telomere protein subunits TRF1 and TRF2 protect the 
structure of the terminal loop of telomeres and its capping of the bare overhang on 
the 3’ end may prove to be the more important protective function performed by 
telomerase.29;30 
 Senescence and cell cycle regulation 1.1.4
Senescence has been ascribed many potential roles in health and disease.  In the 
context of cancer biology, senescence is a barrier to unlimited replication and as 
such may be a barrier to neoplasia which must be overcome by successful 
tumours.31-36  
On the other hand, in aging, senescence is purported to be one of the mechanisms 
of tissue decay by which organisms are limited to a certain lifespan.  Therefore in 
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this context, circumventing the mechanisms behind senescence may offer a means 
of promoting healthy ageing and extending lifespan.33;34 
Perhaps more importantly, senescence could play a part in age-related diseases 
such as atherosclerosis.35;37;38  This could offer an answer to the question of why 
cardiovascular disease is so common in the elderly, even when other, known risk 
factors have been treated or were previously normal.  
Within these broad questions lies an intrinsic problem.  If senescence acts as a 
barrier to neoplastic growth but plays a causative role in cardiovascular disease, 
treatment to prevent cancer which encourages senescence and to prevent 
atherosclerosis which retards senescence will rely on there being intrinsic 
differences in the mechanisms of senescence between cell types.  Fortunately, there 
does seem to be a degree of heterogeneity between cell types in the mechanism by 
which they undergo this change.39-41  
As one may expect, the irreversible cell cycle arrest seen in senescence involves the 
cell cycle regulatory molecules.  An early signal of senescence, specific for 
endothelial cells and vascular smooth muscle cells, has not been identified but 
investigation of the cell cycle regulatory proteins could provide a signature of the 
initial signal, the initial response and finally, senescence. 
The tumour suppressor, p16INK4a has been implicated in the development of cell 
cycle arrest in the context of senescence and when it is overcome, cells may be 
transformed and immortalized and no longer show any features of senescence.32  
Moreover, cells in senescent vascular cells express p16INK4a.37 
Ectopic expression of p21WAF and p16INK4a, which are cyclin dependent kinase 
inhibitors induces senescence without needing to initiate a DNA damage response 
and again suggests an independent pathway to senescence. 
In cells which have senesced and where p16INK4a is not part of their expression 
repertoire (eg the BJ fibroblast cell line from human foreskin), inactivation of p53 is 
able to reverse the growth arrest and allow cell proliferation to resume.42 Therefore 
p53-led senescence is reversible when the brake is released. However when 
p16INK4a is able to be expressed by a cell type, p53 senescence is not reversible. 
p16INK4a therefore acts as an additional and more definite growth arrest signal.  
Suppressing continued expression of p16INK4a by using shRNA does not reverse 
senescence any further than the DNA S-phase.  This also suggests p16/pRb 
pathway acts in more than one phase of cell replication, preventing entry to S phase 
and then later in the cycle. Senescence associated with intrinsic expression of 
p16INK4a is therefore more secure against inactivation. 
Ectopic expression of p16INK4a does not proffer the same secure growth arrest when 
expressed after the onset of senescence as it can be reversed by shRNA against 
p16INK4a. This suggests p16INK4a acts not so much as a brake to cell proliferation and 
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more akin to a decommissioning agent which requires the cell cycle machinery to be 
running and at a certain stage of replication to act, perhaps by altering chromatin 
such that DNA replication becomes impossible.42;43 
 Chromatin modification 1.1.5
Chromatin is a structure combining DNA and histones. Histones aid the wrapping of 
the DNA molecule into ever-tighter loops around the histone proteins which serve to 
compact the molecule in an ordered structure and conceal genes from transcriptional 
machinery until it is required, when it unwraps to reveal the DNA. 
Senescence associated heterochromatin foci (SAHF) are densely DAPI-staining foci 
seen in senescent cell nuclei.  Initially merely an interesting observation useful in 
identifying senescent cells, this morphological change appears to have a functional 
significance. Alterations to the histone proteins have been widely observed, but other 
proteins have also been seen to enter the chromatin structure and may represent a 
means of blocking DNA replication in senescence. Narita et al44 describe the 
involvement of high-mobility group A proteins (HMGA) in senescent cells. HMGA 
proteins localize to the chromatin structure and act to hinder DNA replication, an 
effect which was amplified by the presence of p16INK4a. They also inhibit proliferative 
signals and help with senescence maintenance. 
Replicative genes such as cyclin A are hidden into SAHF complexes, facilitated by 
pRb.43 The formation of SAHF in senescent cells takes place on a chromosome by 
chromosome basis, rather than collecting related genes across chromosomes.45 One 
of the major groups of histone proteins, the HP1 proteins, demonstrate changes in 
cellular location (in PML bodies) followed by selective phosphorylation leading up to 
the development of senescence. On senescence, HP1 relocates to the chromatin 
structure and to what become SAHF. The phosphorylation appears to improve 
efficiency of transport of HP1 which accumulates in high levels within SAHF.45 
Interestingly, these high levels of HP1 are not necessarily required for senescence-
associated β-galactosidase expression, although this may not necessarily mean that 
it is not essential at low levels. 
Therefore SAHF block replicative genes from replicative machinery, a process which 
is aided by the presence of cell cycle proteins known to be associated with the 
senescent phenotype, but at a stage earlier than the increased activity of β-
galactosidase seen in more mature senescence. Thus it made sense for us to 
confirm senescence in our investigations by detection of p16INK4a and p21WAF. 
 Senescence associated secretory phenotype 1.1.6
Senescent cells may occur in disease environments and may be a phenomenon of 
aging but are they of any functional significance? 
Evidence suggests they alter their secretory profile and play an active role in the 
pathogenesis of disease. 
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Frippiat et al46 described the effects of both oxidative stress in the form of hydrogen 
peroxide and TGF-β1 on the expression of several protein markers of senescence. 
While both hydrogen peroxide and TGF-β1 increased the numbers of senescent 
cells when measured by senescence-associated β-galactosidase, other proteins 
were also called upon with increased levels of mRNA for fibronectin, osteonectin, 
SM22 and apolipoprotein J. In fact, the effect of hydrogen peroxide was mediated by 
TGF-β1 and required hypophosphorylation of pRb. This was demonstrated by 
antibodies to TGF-β1 or its receptor circumventing the effect. pRb’s role was 
elucidated by knocking it down and the observed increase in TGF-β1 was no longer 
seen. 
Blanco et al47 describe an alteration of TGF-β auxiliary receptors in senescent 
endothelial cells of mice, endoglin. Mice which were induced to express S-endoglin 
(the senescent form of endoglin) also display a hypertensive, pro-thrombotic state 
with increases in PAI-1, extracellular matrix production and decreases in eNOS. 
While the mice expressing S-endoglin maintain the ability to vasodilate in response 
to nitric oxide donors, inhibition of nitric oxide synthases by L-NAME results in a 
lesser hypertensive response in the mice induced to express S-endoglin. These mice 
then have impaired endothelial dilation in response to acetyl-choline, an effect 
normally mediated by increasing production of nitric oxide via eNOS. The S-endoglin 
form of this receptor was observed in human coronary artery endothelium and in 
HUVEC grown to replicative senescence in culture. 
Cells expressing p16INK4a have been demonstrated to secrete pro-inflammatory 
cytokines such as interleukin-6 (IL-6).48;49 This was observed in HUVEC subjected to 
replicative senescence and radiation-induced senescence. IL-6 and IL-8 were 
demonstrated to play a part in maintenance of senescence and this could be 
circumvented by replacing depleted levels of Klotho protein. Klotho deficient mice 
had previously been shown to have a premature aging phenotype which included 
atherosclerosis and endothelial dysfunction. The way in which Klotho led to 
increases in interleukin-6 was further elucidated by the group. They demonstrated in 
murine brain and kidney that interfering with expression of the ataxia telangiectasia 
mutant (ATM) protein prevented the pro-inflammatory phenotype and that further 
upstream, the pathway also used retinoic acid-inducible gene-I (RIG-I) as 
demonstrated by knocking down expression of RIG-I in senescent HUVEC. NF-κB 
was also implicated in the pathway and increased expression of NF-κB was 
demonstrated in senescent cells. Knock down or expression of RIG-I by Klotho 
managed to increase the proliferative capacity of pre-senescent cells. Klotho has 
been implicated in suppression of the Wnt pathway, interacts with insulin-like growth 
factor and is protective against some forms of cellular oxidative stress.50 Thus the 
pro-inflammatory secretory phenotype of HUVEC is seen both in replicative and 
stress-induced senescence. The process is regulated by Klotho and RIG-I in an 
inverse manner with Klotho maintaining the younger non-inflammatory phenotype 
and giving way to RIG-I in aging cells, a process which can be reversed by 
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reintroducing Klotho into the system. Not only does suppression of RIG-I by Klotho 
lead to reduced cytokine expression, but it also restores replicative capacity. 
The role of NF-κB as a promoter of senescence was investigated by Hasegawa et 
al.32 They demonstrated that, in mice transgenically bred to have deficient 
endothelial responses to NF-κB, there was a lower incidence of insulin resistance 
and preserved eNOS expression in response to high fat diets, and their lifespans 
were increased. Analysis of adipose tissue in genetically obese mice with deficient 
NF-κB responses revealed a reduction of macrophage recruitment and decreased 
iNOS expression. The expression of MnSOD and glutathione peroxidase was also 
decreased in the aorta, suggesting lower degrees of oxidative stress. Moreover, NF-
κB suppression in the obese mice reduced age-related vascular senescence, 
measured by senescence-associated β-galactosidase which was consistent with the 
increase in lifespan. 
NF-κB is constitutively inactive in the cytosol, bound to an inhibitor protein I-κB. 
Phosphorylation of I-κB leads to disassociation from NF-κB allowing it to relocate to 
the nucleus and to become active. Factors associated with I-κB phosphorylation 
include TNF-α, lipopolysaccharide and inflammatory cytokines. 
ATM protein, in common with mammalian target of rapamycin (mTOR), is a member 
of the PIKK family of kinases. The role of ATM as a central coordinator of the DNA 
damage response to oxidative stress was explored by Zhan et al.51 Using HUVEC 
with H2O2 100µM as an oxidative agent, they demonstrate that ATM protein is 
associated with oxidative stress-induced senescence. ATM levels increase in 
response to oxidative stress, being shown in other studies to be localised to foci on 
DNA of senescent cells exposed to genotoxic stress which results in double-strand 
DNA breaks.52 As a consequence of auto-phosphorylation of ATM in response to this 
stress, ATM phosphorylates Akt and p53 and increased levels of p21WAF follow. 
Inhibitors of ATM, including caffeine, were seen to prevent this response and knock 
down of ATM was also able to prevent senescence induced by H2O2. This was 
confirmed in vitro and further supported by ATM knock-out mice with streptazosin-
induced diabetes (streptazosin is a drug which is toxic to pancreatic islet cells, the 
source of insulin). Diabetic mice showed senescence-associated β-galactosidase 
positive cells which also expressed p16INK4a and p21WAF. This phenomenon was not 
observed in the ATM negative mice. 
Furthermore, ATM also autophosphorylates in response to cellular hypoxia. 
Bencokova et al53 report that extreme hypoxia (0.02%) caused ATM to 
autophosphorylate and that this was independent of mitochondrial signalling or other 
PIKK family members. This also occurred in response to DNA strand breaks and 
was unaffected by the hypoxia-inducible factor (HIF-1α)-inducing agent cobalt 
chloride, even at higher oxygen concentrations. Furthermore, phosphorylation of 
ATM occurred in hypoxia in HIF-1α knock-out cell lines. However, ATM does not 
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relocate to DNA strand breaks in hypoxia but remains distributed throughout the 
nucleus. 
Microarray studies have shown an increase in the expression of monocyte adhesion 
molecules in senescent endothelial cells. Mun et al54 demonstrated in HUVEC grown 
to replicative senescence either with our without laminar shear stress that there was 
an increased expression of the CD44 gene. This led to an increase in mRNA and 
protein levels. Furthermore, this increased the ability of monocytes to attach to the 
senescent cells. They also demonstrated that cells from older rats express increased 
CD44 in their aortae.  
However, in contrast to other groups, Coleman et al55 report that cells subjected to 
oxidative stress-induced senescence display an anti-inflammatory phenotype, being 
resistant to the effects of TNF-α and lacking correct localization of cell adhesion 
molecules for recruiting pro-inflammatory leukocytes. By investigating the influence 
of SENEX, a RhoGAP protein, which may be involved in the DNA damage response, 
they noted that increased expression of SENEX promoted senescence and down-
regulation led to apoptosis. SENEX was increased in response to moderate doses of 
H2O2 and this led to cell senescence. 
Therefore, senescent cells have an altered secretory phenotype and mostly, this 
appears to lead to both a constitutive preference for a pro-inflammatory state and to 
an enhanced ability to respond to pro-inflammatory stimuli. Senescence also 
appears to be accelerated in response to these pro-inflammatory stimuli. However, in 
certain conditions, there may also be cells which are senescent but anti-inflammatory 
and may remain at sites subjected to a stressful stimulus perhaps to support the 
structural integrity of the endothelial layer. 
As nitric oxide-related reactive nitrogen species are increased by inflammation, we 
decided to investigate this further. 
1.2 Nitric oxide and senescence 
Nitric oxide is a cell signalling molecule, a reactive oxygen species, able to inhibit cell 
respiration and produced in higher quantities in the inflammatory response. Nitric 
oxide is produced in many cell types involved in health and disease of the 
vasculature, endothelial cells, vascular smooth muscle cells and 
monocytes/macrophages. Therefore its effect on vascular senescence is of interest. 
However, nitric oxide at a wide range of doses exerts a powerful anti-proliferative 
action on growing cells.56;57  This effect has been observed in endothelial and 
vascular smooth muscle cells.  This creates problems for the in vitro model of 
growing cells continually in the log-phase, particularly if one wishes to investigate the 
effect of nitric oxide on replicative senescence.  Thus I developed a method of 
investigating senescence after cells have become confluent.  Studies have 
previously shown that confluent cells express a greater basal amount of 
senescence-associated -gal irrespective of replicative age.58  I overcame this by 
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treating cells during confluence and re-plating them for analysis during log-phase 
growth. This may have led to a continued elevated level on replating but differences 
between cells treated in differing manners did not become evident until after the 
replating phase (see results section). 
The production of nitric oxide in vivo results from the conversion of arginine to 
citrulline via a range of nitric oxide synthases with the consumption of oxygen to 
produce nitric oxide. 
 
 
The reaction is catalysed by endothelial nitric oxide synthase, inducible nitric oxide 
synthase and neuronal/mitochondrial nitric oxide synthases.  These isoforms are 
present to varying degrees in various cell types.  eNOS is the main constitutive 
isoform found within endothelial cells and is calcium-dependent.59   
 How much nitric oxide is produced in vivo? 1.2.1
The endothelial cell layer is in close contact with a ready supply of nitric oxide 
scavengers such as haemoglobin and thus the nitric oxide produced is quickly 
absorbed.  The levels of nitric oxide produced by resting endothelium are at the 
lower limit of sensitivity for most methods to directly measure nitric oxide and 
therefore shear stress or pharmacological stimuli are used to increase nitric oxide 
release to a more physiological level in many studies. Artificially-mimicked shear 
stress can increase eNOS levels and nitric oxide synthesis, an effect which is 
decreased in aged rats.60;61  If cells are harvested and grown in vitro, a progressive 
change in eNOS expression is seen.  This introduces another artifice.  The simplest 
method to assess the effect of nitric oxide on growing cells would be to grow 
endothelial cells and add nitric oxide from an exogenous source and assess the 
effect on replicative capacity as a marker of senescence.  This method, published by 
Vasa et al appeared to confirm a beneficial effect of exogenous nitric oxide on the 
replicative lifespan of endothelial cells grown in vitro.  This remained the only 
demonstration of this effect until 2006 when again, low levels of nitric oxide were 
shown to decrease senescence.62;63 
32 
 
The levels of nitric oxide encountered by cells varies widely and presents many 
technical problems in relation to measurement and reproducing these conditions in 
vitro.  As nitric oxide has a short half-life both in vivo and in vitro, concentrations 
encountered within cells, between cells in the interstitium and between cells in 
contact in culture may be much higher than that measured a short distance away in 
serum or in medium.  The peak concentration of nitric oxide may therefore be higher 
at the cell surface and in endothelium, a thin layer of high concentration nitric oxide 
bathes cell surfaces.  Experiments designed to investigate this have used fine tip 
electrodes and discovered concentrations of 500-600nM nitric oxide measured in rat 
and mouse renal tubules and in human in vivo studies have suggested a peak 
bioavailable nitric oxide concentration as high as 800nM.64;65  These peaks of nitric 
oxide are followed by a relatively quick decrease and therefore the choice of an 
exogenous nitric oxide donor would ideally mimic repeated bursts of nitric oxide 
release followed by a decrease.  The nitric oxide donor diethylenetriamine NONOate 
(DETA-NO) provides a stable level of nitric oxide release with a half-life of 20 hours 
at room temperature in PBS and normal medium at 20°C.  The half-life of DETA-NO 
is shorter at higher temperatures.66 
 
DETA-NO  + DETA+   2DETA + 2NO 
 
Laminar shear stress affects the endothelial cell monolayer, with increasing levels of 
stress leading to enhanced nitric oxide production and expression of nitric oxide 
synthase and other permissive enzymes, for example arginosuccinate synthase 
(ASS1)67 and is largely held to be protective against atheroma formation and 
senescence.  Atheroma and senescence tend to occur more readily at arterial 
branch points, where laminar shear stress is instead replaced by oscillatory shear 
stress.68 Giant endothelial cells were observed in human atheromatous plaques by 
scanning electron microscopy, presumed by the authors to be senescent cells, in the 
absence of techniques to verify this at the time.69 The oscillatory stress occurs at 
relatively low tensions when compared to laminar shear stress areas and fails to 
generate the favourable phenotypic adaptation seen in endothelial cells exposed to 
laminar shear stress which express NOS, permitting generation of nitric oxide, which 
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in turn regulates vascular tone and is one factor associated with reducing the pro-
thrombotic state. 
 The protective role of nitric oxide 1.2.2
The presence of eNOS generally declines with advancing replicative and organismal 
age.  In addition, some models of senescence show an increase in eNOS protein but 
a reduction in eNOS function and thus this is postulated to be a mechanism behind 
reducing endothelial function with age.70;71  eNOS-related nitric oxide formation 
varies widely in vivo in response to a variety of stimuli.  However, young endothelial 
cells are thought to release a basal amount of nitric oxide.72;73  The amount of nitric 
oxide produced basally has been reproduced in vitro by using nitric oxide donors and 
this has been shown to retard the development of replicative senescence in HUVEC 
grown in culture.  This effect was thought to be telomerase-mediated as telomerase 
activity was increased by nitric oxide donors.62;63  A lack of nitric oxide increases the 
rate of apoptosis in endothelial cells exposed to a variety of stresses and this has 
been shown to be reversible with the addition of exogenous nitric oxide donors.74-77 
Analysis of endothelial cells in vivo have confirmed the concentration and activity of 
nitric oxide synthase varies.  Cells from younger animals tend to have a higher 
amount of endothelial nitric oxide synthase and this has been shown by some 
groups to be progressively lost with advancing age.78  eNOS re-expression by gene 
transfer was shown to encourage a regression of atherosclerosis in rabbits.79  eNOS 
expression can also be increased by the presence of shear stress and this effect is 
attenuated with advanced age.  In turn, the effect of advanced age may be reversed 
by exercise training in rats, increasing eNOS expression.61;80-82  Thus it is assumed a 
basal level of nitric oxide is synthesized in young, healthy arteries and this can be 
physiologically modulated to accommodate varying amounts of shear stress.60;61;83  
There is a question as to whether a certain level of nitric oxide may be required at a 
maintenance level for signalling or to prevent aging.  For instance, nitric oxide may 
maintain a healthy relaxed state of artery which is able to accommodate increases in 
vessel flow without unduly increasing vessel pressure and conversely, to be able to 
constrict to increase pressure in cases of reduced flow.  Thus it is essential that a 
vessel remains in a mid-state, capable of changing in both directions.  
Nitric oxide also aids signalling by S-nitrosylation and transnitrosation of proteins 
such as NF-κB, p21ras and eNOS to modulate their function and may potentially 
compete with oxidative species in this respect.  Transnitrosation produces a more 
readily-modifiable alteration than the corresponding oxidation reaction.84-89 
As a further example, transnitrosation of arginase has been shown to have an 
important regulatory role in the activity of iNOS. Arginine is a substrate in the urea 
cycle and is the source of nitric oxide for iNOS. While the Km for each enzyme is of a 
different order of magnitude (much higher in the case of arginase), increasing 
arginase activity could potentially rob iNOS of substrate and lead to a reduction in its 
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ability to generate nitric oxide. Santhanam et al90 report that transnitrosation of two 
distinct cysteine residues of arginase lead to an increase in enzyme activity. This can 
be achieved either by the addition of GSNO 50µM or by inducing iNOS. Aged rats 
have a higher concentration of cysteine-nitric oxide (cys-SNO) residues than young 
rats and have a reduced level of nitric oxide production, a deficiency which can be 
reversed by inhibiting arginase with boronethyl cysteine (BEC). Using the fact that 
aged rats also express higher levels of iNOS enzyme, the group went on to 
demonstrate that this was associated with increased transnitrosation of arginase. 
Furthermore, inhibiting iNOS with 1400W successfully prevented the increased 
transnitrosation of arginase. Inhibiting iNOS thereby effectively decreased arginase 
activity, which in turn increased arginine concentrations which would then be 
available as a substrate for NOS to resume nitric oxide production. Higher 
concentrations of exogenous nitric oxide were also investigated and were found to 
begin to inactivate arginase at GSNO concentrations of 100µM. This may reflect that 
one of the cysteine residues (C303) is more readily transnitrosated at lower 
concentrations and this increases the activity of arginase, whereas a second residue 
becomes transnitrosated at higher concentrations and inactivates the enzyme 
(C168). 
Therefore the action of iNOS may be buffered by its effect on arginase activity and 
the corresponding change in substrate availability. Substrate availability reduces 
iNOS activity at increasing concentrations of nitric oxide until this is overcome and 
arginase activity begins to be inhibited and substrate availability is restored. The 
latter effect may be part of the host defence against sepsis, able to allow much 
higher concentrations of nitric oxide in order to be cytotoxic to local pathogens. 
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Figure 1.2.2-1: Effect of increasing degree of transnitrosation of arginase. 
Top panel is a schematic of the effect of arginase on the balance of arginine as a substrate of both 
arginase and iNOS. After a single transnitrosation (middle panel), the activity of arginase increases 
and therefore the balance shifts towards the formation of ornithine at the expense of substrate 
availability of arginine for iNOS to convert to nitric oxide and citrulline. At higher concentrations of 
nitric oxide (lower panel), such as that seen in sepsis, where there may also be the addition of nitric 
oxide from surrounding inflammatory cells, arginase is transnitrosated on a second cysteine residue. 
This reduces its activity and arginine is therefore once again available to iNOS for the formation of 
nitric oxide. 
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1.3 Inflammation, iNOS activity and senescence 
Kim et al91 demonstrate a simple correlation between the addition of bacterial 
lipopolysaccharide to a cell culture in a pulmonary epithelial cell line and the 
generation of hydrogen peroxide. This dose-dependent increase in hydrogen 
peroxide was eventually associated with a dose which induced apoptosis. A sub-
lethal dose was however, associated with an increase in cell diameter, lysosomal 
content and senescence-associated β-galactosidase percentage. This effect was 
inhibited by the addition of glutathione as an antioxidant. The implication of this is 
that hydrogen peroxide may have been a marker of oxidative stress induced by nitric 
oxide and that nitric oxide had increased superoxide production by inhibiting 
mitochondrial respiration. The addition of glutathione would effectively counter the 
oxidative stress by removing the source, nitric oxide. The senescence induced in this 
model was not associated with a loss of telomere length. 
Vascular iNOS and eNOS mRNA has been observed to increase in old, or at least 
middle-aged rats. This occurs in the absence of inflammation or hypertension.92 
Older rats’ vascular smooth muscle cells also have an enhanced response to high 
glucose-mediated increases in iNOS mRNA expression.93 
Elderly (non-transformed) human embryonic fibroblast cells from the line WI38 
exposed to inflammatory cytokines exhibit a reduced proliferation rate and increased 
rate of apoptosis. This effect was reduced when the NOS inhibitor L-NMMA was 
added, suggesting it is at least in part mediated by a nitric oxide synthase. Moderate 
levels of exogenous nitric oxide released by SNP and SNAP donors improved 
proliferation rates in pre-senescent cells but higher levels produced a non-significant 
decrease in proliferation. These older rat fibroblasts reacted more readily to 
inflammatory and anti-cancer cytokines than younger cells. iNOS expression was 
found to be readily increased by TNF-α and IFN-γ. This effect was much more 
pronounced in cells which had undergone several passages as opposed to younger 
cells. This resulted in increased levels of nitric oxide production in the region of 14-
15-fold when compared to younger cells.94 A similar response has been seen in 
mouse macrophages.95 
Other rat studies have shown increased levels of nitric oxide production in elderly 
animals as measured by nitrite and nitrate assays. While both eNOS and iNOS 
protein levels increased, the activity of eNOS was decreased and this was 
associated with decreased vasorelaxation, suggesting that the nitric oxide produced 
by iNOS was reducing the ability of eNOS to regulate vascular tone.96 
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Figure 1.2.2-1: Schematic diagram of the interplay between inflammation, aging and nitric oxide 
generation. 
Arrows and white circles with plus signs demonstrate increasing activity, filled circles with minus sign, 
inhibition. 
Further associations between aging and iNOS have been elucidated. The p66shc 
protein recognizes phosphorylated protein tyrosine residues and appears to aid in a 
PKC-β-mediated signalling cascade leading to apoptosis. PKC-β phosphorylates 
p66shc, allowing it to enter mitochondriae. Pro-apoptotic signals then allow p66shc to 
disassociate from a protein complex to become active. Active p66shc causes a 
reduction in mitochondrial membrane potential, an increase in hydrogen peroxide 
production, opening of mitochondrial membrane pores and the release of pro-
apoptotic proteins and finally apoptosis. Knock out of p66shc leads to a reduction in 
iNOS expression in older mice, is associated with reduced ROS production and 
results in increases in longevity.97 Moreover, p66shc expression appears to be 
inversely related to SIRT1 expression.98 
p66shc has been seen to have increased expression in elderly human subjects. The 
levels continue to increase, even in centenarians, suggesting a compensatory 
mechanism may have developed in humans capable of extremely advanced age.99 
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Increased iNOS expression and activity has been shown to contribute to cardiac 
dysfunction and damage in the context of adrenergic stimulation in a model of 
cardiac ischaemia in aged versus young rats, an effect which was associated with 
increased nitric oxide and ONOO- production.100 The effect was avoided if the iNOS 
inhibitor 1400W was given prior to ischaemia. Similar effects have been observed in 
dogs.101 
Wnt signalling is primarily involved in development and polarity in animal tissues. 
However, the Wnt pathway is also activated in tissues obtained from elderly animals. 
Microarray analysis of mammary arteries obtained from human subjects who were 
undergoing coronary artery bypass grafting revealed that Wnt signalling was more 
active in elderly subjects, compared to a middle-aged group. Vascular smooth 
muscle cells obtained from the more aged group showed increases in senescence-
associated-β-galactosidase activity and were unable to proliferate in culture.102 
C1q (the initiating component of the classical complement pathway) and C3 (a key 
component of the alternative complement pathway) have long been known to 
increase in response to advancing age in humans.103 
More recently, Naito et al104 describe a link between the Wnt signalling pathway, 
inflammation and aging. They elucidated a pathway involving Wnt activation by the 
complement component C1q. Activation of the Wnt pathway by C1 in their mouse 
model prevented regeneration of skeletal muscle.  
Thus key elements of the inflammatory cascade interact with elements of 
developmental pathways, conspiring to bring about senescence. 
The relevance of inflammation in our investigation is that it is a process likely to 
generate high concentrations of nitric oxide, potentially rendering the organism more 
susceptible to age-related phenotypes in recovering from severe sepsis. 
Alternatively, in the case of chronic inflammatory diseases, multiple pulses of higher 
nitric oxide concentrations could both reduce vascular reactivity and could lead to 
accumulated damage and senescence. 
 Deleterious effects of nitric oxide 1.3.1
Nitric oxide has a number of potential targets within cells.  Soluble guanylate cyclase 
acts as a receptor for nitric oxide and mediates its action on smooth muscle 
relaxation in smooth muscle cells and many of the physiological actions of nitric 
oxide.  Nitric oxide competes with O2 in the electron transport chain and thereby 
inhibits respiration.105;106  The reduction in respiratory capacity may lead to an 
increased AMP:ATP ratio and thereby activate AMPK.  The inhibition of 
mitochondrial respiration leads to an increase in superoxide generation and this in 
turn may cause toxic effects or activate defence mechanisms which may lead to 
senescence.  Nitric oxide also acts via the Akt pathway and this may mediate some 
of its toxic effects and facilitate activation of constitutive eNOS to further increase 
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nitric oxide production in response to pathophysiological conditions such as 
anaphylaxis.83  Nitric oxide has been shown to cause apoptosis via the MEK/HIF-1 
pathway.107 
 
Figure 1.3.1-1: Schematic of the pathways by which nitric oxide could signal metabolic stress. 
Investigating each of these potential pathways as a means to assessing the 
mechanism of potential roles of nitric oxide – as a protector and as a protagonist to 
senescence – could start with blocking the action of sGC using the synthetic 
compound ODQ. Heller et al108 describe the observation that a number of exogenous 
sources of nitric oxide caused cell cycle arrest when nitric oxide was generated by 
the nitric oxide donors GSNO, SNAP and sodium nitroprusside at 1mM 
concentrations.  However, cells recovered their replicative capacity as soon as the 
source of nitric oxide was removed. Investigating the mechanism of this 
phenomenon led them to investigate sGC as a potential target of the anti-mitogenic 
properties of nitric oxide. However, application of the specific sGC inhibitor, ODQ 
failed to prevent the anti-proliferative effect of nitric oxide. This was despite a clear 
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abolition of sGC activity at a concentration of 1µM.  cGMP levels were measured to 
ensure ODQ had performed the desired inhibition of sGC and the ten-fold increase 
of cGMP seen in nitric oxide donor-exposed cells was completely abolished when 
cells were exposed to ODQ. 
As stated above, eNOS is associated with a young phenotype and may play a role in 
maintenance of this phase. However, Erwin et al109 have demonstrated that eNOS 
tends to be S-nitrosylated in vascular endothelial cells and that the nitrosylation 
determines its subcellular location in caveolae. Once released from this location, 
eNOS is exposed to a more reducing environment with glutathione able to 
denitrosylate the enzyme which in turn is thought to be able to increase its activity. 
Thus high local concentrations of nitric oxide could be used to negatively feedback 
on enzyme activity. 
Van der Loo et al110 demonstrated an association between advancing age and 
protein transnitrosation in aging rats. They demonstrated that there is a high 
concentration of transnitrosated proteins, particularly in the vascular endothelium 
and the highest concentrations were seen in endothelial cell mitochondriae.  
Therefore direct effects of nitric oxide on cells can be assessed by looking at soluble 
guanylate cyclase inhibition and protein transnitrosation. 
1.4 Reactive oxygen and nitrogen species 
Reactive nitrogen species can be generated from a variety of sources including 
many nitrites and nitrates – both dietary and pharmacological - but the most 
important source I consider here is nitric oxide via nitric oxide synthases.  Nitric oxide 
is a highly reactive free radical which readily reacts with superoxide to form 
peroxynitrite.  The source of superoxide is generally the mitochondrial production of 
O2
- during oxidative phosphorylation.  At low concentrations of nitric oxide and O2
-, 
nitric oxide may quench O2
- but at higher concentrations, nitric oxide reacts with 
ubiquinol which receives the unpaired electron and readily donates it to oxygen to 
form the superoxide radical.  Nitric oxide inhibits cytochrome c oxidase and also 
mitochondrial electron transport chain complex I causing an electron leak which 
increases superoxide formation. Superoxide readily reacts with nitric oxide to form 
peroxynitrite and this in turn, increases the electron leak to form the superoxide 
radical, thus increasing both substrates’ concentration to form more peroxynitrite.111 
The relationship between ROS exposure and chronic oxidative stress was examined 
in healthy and atherosclerotic plaque vascular smooth muscle cells by the pulsed 
administration of 18-80mmol/L tert-butyl hydrogen peroxide by Matthews et al.3 They 
demonstrated a marked increase in vascular smooth muscle reactive oxygen 
species and consequently, an increase in senescence-associated β-galactosidase 
positive cells (11.9%, increasing to 55.5%).  This increased p21WAF but not p16INK4a 
and had a negative effect on the activity of telomerase without decreasing telomere 
length. 
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Lener et al112 describe the effect of knocking down expression of the NADPH 
oxidase 4 (Nox4), which they first determined was the dominant isoform in HUVEC. 
This led to a decrease in ROS production and reductions in oxidative DNA damage. 
This was also associated with increased cell proliferation rates and proliferative 
capacity, although the latter may have been due to transformation in one of the 
donor cell populations. There was continuing telomere erosion in both control cells 
and cells unable to express Nox4, appropriate to replicative age. As such, cells 
which did not express Nox4 were seen to replicate through more cell divisions and 
therefore had shorter telomeres. 
Nitric oxide donors were used by Boriquel et al113 to investigate the effect of nitric 
oxide on cellular oxidative defences. A range of concentrations of DETA-NO were 
used to investigate their effect, up to 1mM. They settled on a concentration of 61µM. 
They observed that short term exposure to those concentrations of nitric oxide led to 
a reduction in expression of peroxisome proliferators-activated receptor γ (PPARγ) 
cofactor 1-α (PGC-1α) which in turn down-regulated the expression of many 
antioxidant defences, suggesting that nitric oxide initially acts as an antioxidant, or 
removes the signals to generate the antioxidant defence. However, as exposure 
times increased beyond 24hrs, the reverse became true and antioxidant defences 
were activated with increased expression of mRNA for MnSOD, catalase, 
thioredoxin, thioredoxin reductase and uncoupling protein-2. Downward regulation 
on short exposures was mediated via soluble guanylate cyclase as shown by 
inhibiting the effect using ODQ 1µM. However, no effect was seen on cell respiration 
despite a relatively high concentration of nitric oxide. The opposite effects were 
observed by using L-NAME to inhibit eNOS – short exposures led to upregulation of 
antioxidant defences and long exposures led to downregulation. In contrast, ectopic 
PGC-1α expression was seen to up-regulate eNOS expression and to increase nitric 
oxide production. Whether this dual time-dependent effect of nitric oxide donors is of 
physiological relevance is uncertain as concentrations of nitric oxide were high. 
However, the effect was explained as a means of preconditoning the cell to an 
oxidative insult. Stage one involves a burst of nitric oxide which in turn reduces 
antioxidant capacity, allowing other reactive oxidant species to escape mitochondria 
and begin to generate a damage response. Thereafter, stage two leads to an 
increase in PGC-1α and all that this entails – increased mitochondrial biogenesis and 
improved antioxidant defences, finally leading to increased expression of the 
protective eNOS. 
1.5 Protein modifications involving nitric oxide 
 Metal centre interactions 1.5.1
Soluble guanylate cyclase and cytochrome c oxidase contain a haem moiety which 
acts as the target for nitric oxide’s action. Nitric oxide is thought to activate soluble 
guanylate cyclase via inducing conformational change after binding to the haem site, 
allowing an increase in cGMP production and the resultant vasodilation in vascular 
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cells. In contrast, an inhibiting interaction occurs when nitric oxide induces 
conformation change by binding in the haem moiety of cytochrome c oxidase, the 
terminal enzyme in the electron transport chain. 
 Protein transnitrosation 1.5.2
This process describes the nitrosative modification of thiol residues in cysteine within 
proteins. Reviewed in G decke et al114 and Gow et al,115 protein transnitrosation is 
postulated as most likely to occur between nitrosylated proteins or via the 
nitrosonium ion (NO+) reacting with reduced thiol residues rather than spontaneous 
interactions with nitric oxide itself. Nitrosonium ions are formed via nitric oxide 
reacting with itself or oxygen to form N2O3 and N2O4 which is a slow reaction in 
physiological ranges of nitric oxide concentration. 
The reaction can be catalysed by iron or copper ions (Cu(I)), although the most 
available source of the former is haemoglobin and the latter, caeruloplasmin, neither 
of which are present in vascular cells. Reduced glutathione and cytochrome c 
oxidase do however, bind copper ions. Copper zinc superoxide dismutase has a 
higher affinity for copper ions than glutathione or cytochrome c oxidase and this is 
the likely site for most intracellular Cu(I)-catalysed reactions with glutathione acting 
as a store.116 Conditions which make transnitrosation of proteins more likely include 
the sequence of amino acids before and after the cysteine residue and the 3-D 
structure of the protein where the cysteine lies, in particular whether the cysteine is 
in an exposed part of the molecule. This is discussed later in chapter 5.117  
 Tyrosine nitration 1.5.3
Protein and peptide tyrosine residues are vulnerable to a number of modifications 
including targeted phosphorylation and also nitration. The nitration of tyrosine 
residues has been shown to have both an enzymatic dependent and a simpler, 
chemical mechanism. Myeloperoxidase, myoglobin, manganese superoxide 
dismutase and cytochrome P-450 are capable catalysts which promote the formation 
of tyrosine nitrate residues in the presence of nitrates or nitrites. One of the products 
of the reaction of carbon dioxide and peroxynitrite, nitroso-peroxocarboxylate, also 
readily leads to tyrosine nitration. Nitration of a tyrosine which forms part of MnSOD 
is associated with a reduction in function and has been observed in the mitochondria 
of aging rat vasculature.118,119 
Tyrosine nitration has also been shown to behave as a biomarker for 
atherosclerosis. Shishehbor et al120 report that circulating protein tyrosine nitration is 
an independent risk marker for the presence of atherosclerotic disease. They also 
demonstrated decreased levels of protein nitration when subjects were treated with 
an HMG Co-A reductase inhibitor (atorvastatin), postulating that this may account for 
some of the beneficial effects of statin therapy. 
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 Transnitrosation as nitric oxide store 1.5.4
The pre-addition of low doses of GSNO (1µM) has been shown to cause persistent 
hyporeactivity to phenylephrine-induced contraction of angiotensin-stressed rat aortic 
rings without endothelium. The authors demonstrate that this is likely to be due to 
nitric oxide release from transnitrosated proteins which act as a store of nitric oxide, 
perhaps in the form of a nitrosated carrier, such as glutathione.  In aortic rings with 
endothelium, the hyporeactive effect was less pronounced where there was 
endogenous nitric oxide generation as proven by subsequent nitric oxide synthase 
inhibition.  
Authors Sarr et al121 describe the above phenomenon and demonstrate that aortic 
rings in these conditions have increased cysteine-nitric oxide residue formation and 
that NAC 1mM is able to cause relaxation in these rings. They postulate that NAC is 
able to release the nitric oxide stored in cysteine-nitric oxide residues and thereby 
nitric oxide is free to act as a vasorelaxor. Cells pre-exposed to GSNO also showed 
a decrease in angiotensin-induced superoxide staining, measured by DHE 
fluorescence. Thus, low concentrations of exogenously-supplied nitric oxide led to 
the formation of a sink of nitric oxide in cells which could be mobilised to protect 
against vasoconstriction and potentially acted to decrease oxidative stress.  The 
difference was not seen in cells which had functioning endothelial nitric oxide 
synthase, suggesting that basal eNOS regulates nitric oxide levels both by nitric 
oxide formation and by influencing the rate of release from stores. 
1.6 Antioxidants 
A number of vitamins and other chemicals have been assessed for their beneficial 
effects in disease and in vitro.  The free radical theory of ageing supports the idea 
that antioxidants ought to prevent or delay the deleterious effects of accumulating 
oxidative damage.  However, attempts to confirm that this effect could be translated 
to the in vivo situation, particularly in cardiovascular disease have proved 
unsuccessful.  This blunt observation would seem to suggest that the free radical 
hypothesis may not be valid but there are a number of reasons to retain the theory.  
Firstly, as we have already discussed, nitric oxide is required as a part of normal 
signalling and this includes the increased production of other reactive oxygen and 
nitrogen species; thus interference with this may promote disease in healthy 
systems.  Secondly, the antioxidants used may not be active against the molecules 
causing the most damage and therefore it is important to investigate the effect of 
antioxidants at a cellular level and against the different reactive species. Thirdly, 
ensuring an adequate concentration of antioxidant where it is needed may not be 
possible via systemic non-targeted administration. Loss of the reducing potential of 
antioxidants could result from oxidation by oxidants involved in tissues and blood 
during normal signalling and function well before they were able to reach areas of 
high oxidative stress. 
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 N-acetyl cysteine 1.6.1
N-acetyl cysteine (NAC) is a glutathione precursor which adds to the glutathione 
pool.  The action of NAC on hepatocytes has been widely investigated as it is an 
effective treatment for paracetamol overdose which depletes the glutathione pool 
and can lead to fulminant hepatic failure.  The damage caused by glutathione 
depletion is thought to be free radical mediated.122 
Glutathione is used to regulate the amount of bioavailable nitric oxide and as a pool 
of S-nitroso groups by forming S-nitrosoglutathione.  This pool is dependent on the 
amount of glutathione and the activity of the enzyme S-nitrosoglutathione reductase 
and is in equilibrium with the amount of transnitrosated protein.  Thus glutathione 
depletion could result as a consequence of an increase in the amount of S-
nitrosoglutathione and therefore S-nitroso-proteins. 
 
NAC also directly reduces the production of nitric oxide and also the amount of iNOS 
produced in cells in response to the inflammatory cytokines IL1- and TNF.123  This 
effect can be reversed by thioredoxin which acts via denitrosylating iNOS and has 
anti-apoptotic effects.  Thioredoxin itself is modified by two transnitrosations, one 
activating and the second, blocking its activity.  
The reduction in nitric oxide concentration and synthesis by glutathione may 
therefore be important in reducing the toxic effect of paracetamol. Glutathione will 
reduce superoxide production by nitric oxide and decrease the availability of nitric 
oxide to form reactive nitrogen species and protein transnitrosation.  However, the 
opposite effect has been seen in vascular smooth muscle cells with an increase in 
iNOS expression and nitric oxide generation in cells treated with IL-1 and NAC 
compared to IL-1 alone.124  
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Nitric oxide has also been reported to reduce IL-1 activity. There appear to be two 
steps in the effect - first there is an increase in ROS production, then this causes 
protein oxidation of downstream phosphatases.  If NAC reduces nitric oxide levels, 
this mechanism would increase IL-1 activity which could further induce iNOS 
synthesis and further increase the rate of nitric oxide production.  
This complex picture may help to provide an explanation of one of the central 
inconsistencies with the research into nitric oxide and senescence.  The beneficial 
effects of nitric oxide reported by Vasa et al125 and Hayashi et al63 was observed in 
healthy and relatively young cells whereas the high levels of nitric oxide which may 
be induced by a cytokine mix and iNOS may help to explain the expected deleterious 
effects of nitric oxide at a higher concentration.  Other groups have contradicted or 
been unable to reproduce these findings.  Members of the same group could not 
replicate the decrease in telomerase activity postulated to be due to nitric oxide 
synthase inhibition, nor could they demonstrate the effect of nitric oxide donor-
induced decreases in telomerase in endothelial progenitor cells.126;127  This was 
stated in the Vasa et al paper to be a possible mechanism behind nitric oxide 
protection against senescence. Moreover, data from our group (Trivier unpublished) 
suggests a dose-dependent nitric oxide-mediated decrease in telomerase activity.   
If we assumed the primary task of an inflammatory response was to combat 
infection, the cytotoxic effects of high dose nitric oxide are desirable to aid clearing 
infection and a senescent response in neighbouring cells in preference to apoptosis 
may allow structures to maintain their integrity while perhaps lacking some of their 
more refined functions. 
 Uric acid 1.6.2
Uric acid is present in serum of normal adults at a concentration range of 120-420μM 
and higher than normal levels have been linked to an increased risk of 
cardiovascular disease.  However, the mechanism of increasing risk is uncertain and 
it is surprising given the potential benefits of uric acid with respect to lowering 
oxidative and nitrosative stress.  Despite this, uric acid levels are increased in severe 
septic illnesses and higher levels are associated with an increase in mortality in 
patients with severe sepsis.128 Uric acid accounts for an overall increase in serum 
antioxidant capacity when measured in patients with sepsis, a phenomenon which 
may represent a response to the increased oxidative stress of such illnesses or may 
be a bystander effect more indicative of renal dysfunction or increased cell turnover. 
In cell-free assays, uric acid acts as a peroxynitrite scavenger at concentrations well 
below those seen in serum at an IC50 of 13μM but also acts as a hydroxyl scavenger 
at a higher IC50 of 134μM.
129  In this higher concentration range, uric acid has been 
observed to prevent apoptosis induced by nitric oxide released by DETA-NO at a 
concentration of 1mM in hypoxic endothelial cells.130  Thus the hydroxyl effect may 
be more important in vivo than the peroxynitrite scavenging ability.  Uric acid, at an in 
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vitro concentration of 100μM, also acts on anti-proliferative pathways in renal tubular 
cells on NF-κB and p38MAPK.131  Uric acid at a concentration of 50μM was found to 
be a potent antagonist to the formation of S-nitrosyl tyrosine in response to 
endothelial cell shear stress, a stimulant to eNOS-mediated nitric oxide production.  
This effect was obviated by the addition of L-NMMA, a non-specific antagonist to 
nitric oxide formation by nitric oxide synthases.60 
The chemical interactions between nitric oxide and uric acid are complex. Uric acid 
been thought of as an antioxidant as it is able to react with superoxide, peroxynitrite, 
hydrogen peroxide and the hydroxyl radical.132;133 However, in anaerobic cell-free 
systems, the reaction of uric acid with nitric oxide leads to decomposition and 
formation of free radicals such as the aminocarbonyl radical.134 The formation of 
aminocarbonyl was unhindered by adding substances thought to cause oxidative 
stress, peroxynitrite and hydrogen peroxide. The reaction could be partially 
prevented by the addition of antioxidants, especially glutathione. 
In the presence of oxygen, the reaction between uric acid and nitric oxide leads to a 
nitrosated form of uric acid, designated UA-NO. This in turn is capable of reacting 
with glutathione to form GSNO and restores uric acid to its original form.135 Thus the 
theory is advanced that UA is able to act as a carrier molecule for nitric oxide, which 
can then nitrosate other target molecules at a site distant to its manufacture. Suzuki, 
who investigated the formation of UA-NO from the mixture of UA and nitric oxide in a 
cell-free in vitro experiment, later repeated the experiment in the presence of human 
serum and urine with similar consequences, albeit at less efficient levels due to the 
presence of ascorbic acid and glutathione in those fluids. Uric acid was consumed by 
peroxynitrite, but the product of the reaction was not UA-NO. Previous investigations 
had revealed that the products of the reaction between UA and peroxynitrite were 
rather allantoin and other oxidation products including trieuret. Skinner et al136 
described the readiness with which uric acid both oxidized and nitrosated 
peroxynitrite. The nitrosated product was able to act as a vasodilator in endothelium-
denuded arteries and this was shown to be due to the spontaneous release of nitric 
oxide. Cysteine and glutathione were ineffective in increasing the release of nitric 
oxide, but light significantly decreased the half-life of the nitrosated uric acid. 
Uric acid acts as a scavenger of peroxynitrite but this is not in a direct way owing to 
substrate competition with carbon dioxide. However, some of the products of the 
reactions between peroxynitrite and carbon dioxide are amenable to scavenging and 
in particular, uric acid seems to be able to scavenge the most potentially damaging 
products, the CO3
.- and nitrogen dioxide radicals.137 
Transnitrosation of cysteine residues is readily reversed with liberation of nitric oxide 
but tyrosine residues are readily nitrated by peroxynitrite and there are a number of 
potential protein targets which may be regulated in this way. For instance, 
manganese superoxide dismutase is inactivated in this way in transplant-rejected 
kidney. In vivo, peroxynitrite reacts readily with carbon dioxide to form the carbonate 
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and nitrogen dioxide radicals and these can nitrate tyrosine. The reaction of tyrosine 
nitration by peroxynitrite is more efficient than nitration by nitric oxide, where nitric 
oxide is relatively inefficient. Teng et al138 investigated this phenomenon in brain and 
heart homogenates from rats. Investigating under anaerobic conditions, they found 
tyrosine nitration by the addition of peroxynitrite was significantly reduced in the 
heart homogenates. They demonstrated that this was due to the presence of uric 
acid by using uricase to remove uric acid from the heart homogenate. The addition of 
uricase, which allows conversion of uric acid to allantoin, allowed tyrosine nitration to 
take place.  
The increases in such radicals may help explain why high serum urate levels are 
associated with many age and inflammatory-related conditions.139;140;140 Uric acid 
interacts with vascular smooth muscle cells in vitro by acting to promote replication 
and by increasing oxidative stress.141 Furthermore, reduction in serum urate levels 
by the xanthine oxidase inhibitor allopurinol is a useful vasodilator treatment for 
coronary artery disease induced angina, perhaps by preventing the interaction 
between nitric oxide and uric acid and by reducing the generation of O2
-.142 
 Selenomethionine 1.6.3
Selenomethionine is a potent peroxynitrite scavenger and also prevents protein 
nitration at higher concentrations. It is more effective than methionine and acts in 
concert with glutathione which aids its cycling between its reduced and oxidized 
forms, a reaction catalysed by glutathione peroxidase. Serum levels have been 
observed in the range of 0.3µM but higher concentrations have been shown to be 
more effective antioxidants in chemical studies. We chose to investigate the effect of 
a 30µM concentration as this afforded most of the effect on peroxynitrite scavenging 
and approached the IC50 for prevention of protein nitration (50µM).
143;144 
1.7 Bioenergetic crisis and senescence 
 Autophagy and aging 1.7.1
Autophagy plays an important role in normal cellular metabolism and its dysfunction 
leads to some of the features seen in ageing cells.  Autophagy describes the process 
of cellular removal of cytoplasmic waste products. The first step in the autophagy 
process is the formation of a membrane followed by engulfment of the waste product 
within this membrane (the membranous phagophore becomes an autophagosome 
when it engulfs its targeted waste substance). Later there is presentation to the 
lysosome which then becomes an autophagolysosome for final degradation of the 
waste product. This digestive process is cyclical and release of the end products can 
be a means of recycling dysfunctional molecules and also can be useful if the cell 
lacks external energy sources and is forced to enter a catabolic state.145 
The autophagy response to energy depletion is mediated by multiple pathways, 
suggesting this is an important function. Mammalian target of rapamycin (mTOR) is 
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the main autophagy-preventing molecule in humans. As one may expect, to allow 
catabolic conditions to make use of autophagy as an energy source, mTOR is 
effectively inhibited in starvation.  The converse happens when insulin-like growth 
factor (IGF) is secreted in times of energy availability. IGF acts via insulin-like growth 
factor receptors which activate Akt which indirectly inhibits autophagy via activating 
mTOR.  
Many drugs are known to affect the autophagy process. Hundeshagen et al146 
performed a screen of many drugs commonly used in cardiology and oncology to 
assess the effect on autophagy. In addition to using rapamycin as a known 
autophagy inducer and bafilomycin as its antithesis, they discovered that cardiac 
glycosides (e.g. digoxin) are potent autophagy inducers. They are joined in the group 
by other beneficial cardiac drugs, such as the aldosterone antagonist, spironolactone 
and the antiplatelet drug, ticlopidine. Flavonoids such as resveratrol were inducers. 
However, many cardiotoxic drugs used in oncology such as doxorubicin were also 
seen to induce autophagy, although this may have been a secondary effect due to 
cytotoxicity increasing the demand for autophagy. 
Drugs which inhibit autophagy included the corticosteroids and the anti-inflammatory 
drug colchicine. During nutrition deprivation, cells inhibit mTOR and autophagy 
increases via phospho-inositol 3 kinases. The PI3K inhibitor, wortmannin was 
observed only to inhibit autophagy in conditions of nutrition deprivation, in contrast to 
bafilomycin which was capable of autophagy inhibition in all conditions. 
AMPK plays a direct role in stimulating autophagy when energy depletion (which 
activates AMPK by increasing AMP:ATP ratios) results in its activation.147 Sirtuin 1 
(SIRT1) encourages autophagy and levels fall in metabolic syndrome, with a 
corresponding reduction in autophagy.148 
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Figure 1.7.1-1: Schematic diagram of processes and drugs influencing autophagy. 
Shaded objects represent a net negative effect on autophagy. Arrows demonstrate increasing activity, 
filled circles with minus sign, inhibition. 
The importance of autophagy in clearing potential toxins and thus avoiding cellular 
transformation is suggested by the complex interactions with tumour suppressor, 
p53. Extremes of p53 function modify autophagy - increasing p53 activity is able to 
both increase and decrease autophagy.  Increasing p53 activity increases mTOR 
activity via AMPK activation by increasing Akt.  However, p53 increases are also 
able to decrease autophagy by activating phosphatase and tensin homology (PTEN) 
which decreases Akt activity and TSC.  Inhibition of p53 activity also increases 
autophagy.149;150 
Mutations in genes which encode other proteins involved in permitting autophagy 
seen in yeasts are associated with premature aging phenotypes.151 
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Autophagy has therefore been associated with increases in longevity, which may 
occur via a number of potential processes, including an improvement in cell 
hormesis (for example as seen in ischaemic preconditioning), this describes a 
process whereby cells survive a sub-lethal insult, triggering an autophagy-led clear 
up of damaged proteins and organelles, such that the remaining organelles have an 
aggregated improved efficiency and the cell as a whole is able to survive greater 
insults in the near future.152 However, it has also been implicated in the avoidance of 
cellular senescence. PTEN loss-induced cellular senescence (PICS) requires mTOR 
activation to exert its effect.  This will lead to a reduction in autophagy which 
suggests a role for autophagy in the maintenance of a young cellular 
phenotype.153;154  In addition, inducible p21-induced cellular senescence can be 
avoided by exposing cells to rapamycin, the mTOR inhibitor which could be expected 
to aid the autophagic process.155 
Senescence without a DNA damage response can occur when the tumour 
suppressor phosphatase and tensin homologue (PTEN) is lost.  PTEN is a protein 
tyrosine phosphatase which itself acts via pro-growth and pro-survival kinases.  
Loss-of-function mutations in PTEN can cause multiple benign tumours 
(hamartomas). Cells within hamartomas tend to display a high degree of 
senescence.  In a PTEN knock down model, increased senescence was seen and 
this could be overcome by inhibiting the action of the mammalian target of rapamycin 
(mTOR) with rapamycin42;153 
PTEN also indirectly affects the ability of p66shc to increase ROS and to trigger 
apoptosis. By acting via PINK1 (PTEN-induced kinase), PTEN prevents the 
activation (phosphorylation) of p66shc. Fibroblasts from a patient suffering from the 
hamartoma-associated loss-of-function PTEN mutation showed an increase in 
phosphorylated p66shc.156 
Caloric restriction promotes longevity and autophagy.  There is some evidence that 
the two are correlated in a causal manner as inhibition of autophagy-associated 
proteins is able to prevent the gain in longevity normally associated with caloric 
restriction. Caloric restriction acts via AMPK or SIRT1 which are able to detect the 
relative lack of available energy.157-159 As mentioned above, IGF inhibits autophagy.  
The effect of IGF was investigated in C. elegans and it was seen that inhibiting the 
IGF pathway was able to cause an increase in longevity.  This effect appeared to be 
due to autophagy as reduced expression of autophagy associated proteins was 
associated with a loss of the effect on longevity.160 This effect was seen in 
mammalian species and human cells. 
While measurement of the degree of autophagy taking place and its activity relative 
to what is required for a given situation is not directly available, modification of the 
process is possible pharmacologically. One is able to increase autophagic activity 
using either rapamycin to inhibit mTOR or AICAR to activate AMP kinase.  
Subsequent effects on the degree of cellular senescence in response to a given 
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stressor allow some estimation of the degree of senescence which can be avoided 
by improving the autophagic response. 
 AMP kinase and cellular senescence  1.7.2
AMP kinase is a central co-ordinator of the cellular response to metabolic stress and 
acts as a switch from synthetic processes to energy production in times of increased 
demand for fuel. The main signal for AMP kinase activation is a fall in ATP levels in 
comparison to AMP. AMP kinase is a heterotrimer which requires phosphorylation 
for activation. AMP is able to bind to AMP kinase locking it in a shape which is 
unfavourable for de-phosphorylation and inducing a favourable change in the 
arrangement of the 3 subunits; α, β and γ, increasing the activity of the kinase. 
Phosphorylation of AMP kinase is mediated by LKB1 and the calmodulin-dependent 
kinase kinases (and therefore by increasing intracellular calcium).161;162 Hardie et al 
demonstrated that many drugs and toxins which activate AMP kinase depend on 
inhibition of the electron transport chain and synthesis of ATP. The consequential 
increase in AMP:ATP ratio which activates AMP kinase requires the γ subunit of 
AMP kinase to have an AMP binding site. When AMP binds to the AMP binding site, 
it encourages the γ subunit to reveal the catalytic (α) subunit to the targets for 
phosphorylation. Examples of drugs able to act in this manner include metformin and 
troglitazone (oral hypoglycaemic drugs) and resveratrol. AICAR also requires the 
AMP binding site, but did not require inhibition of the electron transport chain as its 
metabolite is an AMP mimetic, able to bind to the AMP site. Hydrogen peroxide was 
also only able to activate AMP kinase when the AMP binding site was available, also 
by inhibiting the electron transport chain. However, CaMKK-dependent activation of 
AMP kinase did not require the AMP binding site, as demonstrated by the action of 
the calcium ionophore A23187.163 
AMPK activity has been shown to increase with advancing organismal age in 
response to hypoxic stress.164  AMPK is activated by the tumour suppressor gene 
LKB1 and this is also responsive to the effects of AICAR.  LKB1 activation confers 
an anti-apoptotic effect and we postulated this could in turn allow cells posed with 
excessive bioenergetic or oxidative stress to be able to choose senescence instead 
of apoptosis.165   
Zu et al link senescence, SIRT1, LKB1 and AMP kinase activation. By using porcine 
aortic endothelial cells and culturing them to a pre-senescent state, they analysed 
old versus young cells and separately, the effect that constitutive expression or 
knock down of SIRT1 would have on levels and activity of LKB1 and phosphorylation 
of AMP kinase. As before, up-regulation of SIRT1 was able to prevent senescence 
and promote proliferation. This was accompanied by an inverse correlation in the 
activities of LKB1 and AMP kinase. However, expression of a SIRT1 mutant protein 
which had loss-of-function led to increased levels of phosphorylated AMP kinase and 
LKB1, leading to senescence. Interestingly, they postulate that the pro-senescent 
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effect of LKB1 is mediated by increasing AMP kinase activity and they supported this 
using AICAR, the AMP analogue to demonstrate a marked increase in senescence-
associated β-galactosidase staining (approx. 5-fold increase in percentage of 
senescent cells).166 
However, these findings were to a certain extent contraindicated by the following 
work. 
AMP kinase was shown to activate eNOS by phosphorylation by Morrow et al. It was 
also found to act as a protector against oxidative stress and prevents vascular 
smooth muscle cell proliferation.167-169 eNOS phosphorylation by AMP kinase 
activation was demonstrated by exposing human aortic endothelial cells to the AMP 
analogue, AICAR. The increase in eNOS phosphorylation led to increased nitric 
oxide generation. The effect was associated with phosphorylation of protein kinase B 
but, crucially, was not seen in cells without the ability to express the α1 catalytic 
subunit of AMP kinase. The effect of AMP kinase on protection against oxidative 
stress-induced cell death required prolonged (20h) AMP kinase activation prior to the 
oxidant; in this case, hydrogen peroxide in vitro and angiotensin II or 
lipopolysaccharide in vivo. This was seen with either AICAR or metformin-induced 
AMP kinase activation. In this model, H2O2 reduced mitochondrial membrane 
potential and this was prevented by both metformin and AICAR. The metformin 
effect seen is in contrast to papers published by Hawley et al163 and El-Mir et al170 
whereby in the absence of an oxidative stressor, metformin is seen to inhibit the 
activity of complex I of the electron transport chain, an action observed to reduce the 
mitochondrial membrane potential. However, in the context of an insult mediated by 
hydrogen peroxide, AMP kinase activation was observed to prevent the cell death 
signal mediated by c-Jun N-terminal kinase (JNK) activation. Chronic AMP kinase 
activation allowed signalling to result in increased mitochondrial synthesis and this 
led to resistance of cells to the oxidative stressor.168 
Kr ller-Sch n et al171 describe the effect of AMP kinase α1 subunit knock out in mice 
and their response to exercise. Knocking out the α subunit renders the AMP kinase 
unresponsive to phosphorylative activation. Mice without a functional AMP kinase 
failed to demonstrate the benefits of exercise with respect to exercise-induced 
improvements in endothelial function. This effect was due to a lack of up-regulation 
and phosphorylation of eNOS seen in cells with functioning AMP kinase in response 
to exercise. In fact, this seemed to be consistent with a younger phenotype of 
endothelial cell in mice with functioning AMP kinase in response to exercise. Other 
effects seen were an increase in the activity of telomerase and reduced oxidative 
stress due to better antioxidant defences (haem oxygenase-1). In line with the 
younger phenotype, there were reductions in the expression of p53 and p16INK4a and 
a reduced endothelial progenitor cell count and capacity for endothelial repair. The 
authors suggested that the effect of exercise on vascular function and vascular 
senescence were parallel mechanisms but a linear mechanism starting with 
decreased antioxidant defence, reduced telomerase activity and falling nitric oxide 
53 
 
bioavailability could equally give rise to a linear progression from failed AMP kinase 
response to cell stress and finally arriving at senescence.  
AMP kinase is not uniform in all cell types. The 1 subunit is expressed in 
endothelial cells and both 1 and 2 subunits are expressed in liver, 
cardiomyocytes, and skeletal muscle. The 2 subunit is more responsive to 
bioenergetic stress than the 1 subunit.172 
Therefore we see a dichotomous response to AICAR with respect to senescence 
research between groups with the majority suggesting that AMP kinase activation by 
AICAR helps to maintain a young phenotype by protecting against oxidative stress, 
perhaps by increasing mitochondrial synthesis and mimicking energy crisis, 
activating a protective response and helping circumvent some aspects of the 
apoptotic response.  
We therefore decided to investigate the influence of AMPK and autophagy on 
vascular cell senescence in general and in particular, its effect on cells exposed to 
oxidative and nitrosative stress. 
1.8 New insights 
 Nitrosative stress 1.8.1
Chronic nitrosative stress has been observed in patients suffering from inflammatory 
bowel disease. Using tissue samples from human subjects, Sohn et al173 found that 
nitrosative stress and a DNA-damage response-type senescence was due to 
macrophage accumulation. The degree of macrophage infiltration was then graded. 
Greater infiltration correlated with greater senescence markers. Coculture of 
fibroblasts with macrophages also induced senescence and this could be prevented 
by the addition of nitric oxide synthase inhibitors. Furthermore, in the absence of 
macrophages, fibroblast senescence could be induced using an exogenously-added 
nitric oxide donor. 
There was a greater degree of senescence in patients who suffered one type of 
inflammatory bowel disease (Crohn’s disease) versus the other (ulcerative colitis) 
and this appeared to correlate to an enhanced degree of iNOS in the colonic 
epithelium. A microRNA microarray analysis revealed that MiRNA-21 was associated 
with the development of senescence in both types of inflammatory bowel disease. 
Targets for MiRNA-21 include PTEN and TGFβ2 receptors, both of which are tumour 
suppressor genes and are mentioned previously. 
MiRNA-21 has also been found to be up-regulated in a mice sepsis model. However, 
the expression of MiRNA-21 was unaffected in mice unable to express iNOS.174 The 
effect could, however, be prevented by the addition of NAC. It may be that mice 
failing to express iNOS up-regulate other NOS isoforms in the context of sepsis. In 
this study, nitric oxide generation was not measured. In addition, MiRNA-29b was 
54 
 
up-regulated and MiRNA-29c down-regulated in wild type mice exposed to the septic 
stress and these changes were not observed in the iNOS knock-out mice. These 
MiRNA interact with tumour suppressors (preventing lung tumours and promoting 
acute myeloid leukaemia) and the pro-apoptotic factor VDAC (voltage-dependent 
anion channel) which is associated with increasing mitochondrial membrane 
permeability for cytochrome c, which is pro-apoptotic when released from 
mitochondriae.175 
The role of nitrosative stress in age-related diabetes was investigated after the 
observation that older mice have both a tendency to insulin resistance and 
increasing iNOS.176 Using a model based on iNOS knock down and also the 
exposure of wild-type mice to increasing doses of GSNO as a nitric oxide donor, the 
authors demonstrated increasing insulin resistance was related to the ability to 
synthesise nitric oxide with iNOS, which increased with age in wild type mice. The 
effect could also be mimicked in younger wild type mice using the exogenous nitric 
oxide donor. Using the biotin switch method to detect protein transnitrosation, they 
demonstrated that the effect was associated with transnitrosation of several insulin 
signalling proteins (insulin receptor β, insulin receptor substrate S-1 and Akt). 
 Transnitrosation effects 1.8.2
Recent data have shown that glutathione-S-transferase can be subject to 
transnitrosation by GSNO at two cysteine sites. This impairs the function of the 
enzyme which acts as a significant detoxification enzyme and can prevent the pro-
apoptotic action of c-Jun N-terminal kinase (JNK). One site, Cys47 has a larger effect 
on enzymatic activity but more readily dissociates. The other, Cys101, is very stable 
and may therefore have an additional function as a means of storing or transferring 
nitric oxide.177  
The role of soluble guanylate cyclase (sGC) as a mediator of nitric oxide’s action has 
been discussed but mainly as a means of a classical ligand-receptor model. 
Crassous et al178 explored the effect of nitrosative stress on the enzyme and 
observed that not only is sGC susceptible to activation by S-nitrosylation by nitric 
oxide, it is also susceptible to transnitrosation and loss of activity by nitrosative 
stress. They provide evidence that this mechanism my play a part in the observed 
loss of vasorelaxation response to nitric oxide in angiotensin II-induced stress. 
Another mechanism for transnitrosation-dependent control of enzymatic function has 
been described by Jandu et al.179 Tissue transglutaminase is a predominantly 
cytosolic protein and appears to localise within cell walls when it is nitrosated. 
However, in the presence of nitric oxide synthase inhibitors, the enzyme is 
denitrosated and is able to translocate out of cells and assumes its active state. 
Conversely, any extracellular enzyme is depleted in the presence of increasing nitric 
oxide concentration, either with laminar shear stress on endothelial cells, the addition 
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of GSNO or coculture of smooth muscle cells with endothelial cells expressing 
eNOS. 
 Transnitrosation without increasing oxidative stress 1.8.3
S-nitrosated N-acetyl cysteine has been investigated as an agent with both 
antioxidant and pro-nitrosating agent.180 In a murine model of left ventricular 
hypertrophy, S-nitrosated N-acetyl cysteine was found decrease superoxide and 
hydrogen peroxide generation and increase Gi-coupling and transnitrosation of the 
β-adrenoreceptor, making cells less responsive to catecholaminergic stimulation (a 
key driver to cardiac rhythm disturbance and heart failure). This had the combined 
effect of reducing apoptosis. 
 Genetic ablation of senescent cells 1.8.4
The evidence for a role of senescent cells in disease has been strengthened in a 
pro-gerioid mouse model by selective ablation of cells which express p16INK4a.181 In 
these mice, adipose, skeletal, muscular and cataract changes could be prevented if 
cells which attempted to express p16INK4a were subjected to selective apoptosis by 
using a gene construct on the p16INK4a promoter which allowed drug-induced 
apoptosis. There were no adverse effects from this loss of cells expressing p16INK4a 
but equally, loss of vascular stiffness could not be prevented. 
1.9 Conclusion 
There are many phenotypical changes seen in cells which senesce and the 
significance of senescent cells in health and disease remains to be fully elucidated. 
Whilst senescent cells are clearly found in vascular cells of older individuals or in 
cases of repeated vascular injury, this may be a protective response to injury. 
However, the accumulation of senescent cells appears more likely to have a 
deleterious effect on vascular health as the secretory profile of senescent cells infers 
that they are active participants in disease states. 
Controversy also existed as to the significance of culture-based replicative 
senescence, which is either identical to or at least very closely resembles the 
phenotype of cells found to senesce in vivo. The link between β-galactosidase and 
senescence is curious as it hadn’t been shown to be a causal relationship. 
Further conflicts as to the role of nitric oxide in protecting cells from senescence 
were prevalent in the literature when we embarked on this path of investigation. 
There were claims that some concentrations of nitric oxide were protective and a 
lack of nitric oxide encouraged cells to senesce. This finding was consistent with the 
hypothesis that endothelial cells which were younger possessed more functional 
eNOS than older vascular cells. This was a finding that other groups were unable to 
replicate. 
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If this could be replicated, what was the underlying pathway by which nitric oxide 
conferred protection against senescence and could nitric oxide also have deleterious 
effects? 
1.10 Aims 
1. Vascular cell senescence plays a role in health and disease. I will attempt to 
identify a means to readily identify senescent cells in culture. 
2. Using a successful test, I will assess whether exogenously supplied and 
endogenously-produced nitric oxide exerts an effect on senescence. 
a. I will investigate the features of cells which senesce, including its 
relation to autophagy and apoptosis. 
3. If a nitric oxide-induced effect is observed, I will investigate the mechanism. 
a. Does it relate to the generation or prevention of the formation of 
reactive oxygen species? 
b. Is the effect mediated by soluble guanylate cyclase? 
c. Is the effect due to metabolic stress? 
d. Is the effect due to general toxicity and transnitrosation? 
4. I will investigate the influence of metabolic stress on vascular cell 
senescence.
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2 Methods 
2.1 Primary cell culture 
2.1.1 Human umbilical artery smooth muscle cells 
2.1.1.1 Cell isolation 
Equipment 
Scalpel 
2x tissue forceps 
Fine scissors 
McIlwain tissue chopper 
Razor blade 
1x 100mm tissue culture plate 
50mL falcon tube 
T-25 tissue culture flasks 
Reagents 
HBSS with no calcium, no magnesium, no phenol red (Gibco 14175-053). 
Dissecting medium 
DMEM (Invitrogen 41966-029) 
10% foetal calf serum 
20mM HEPES buffer 
1% penicillin / streptomycin / amphotericin 
Culture medium 
DMEM (Invitrogen 41966-029) 
20% foetal calf serum 
1% penicillin / streptomycin / amphotericin 
1% MEM Non-essential Amino Acids (100x) (Gibco 11140-035) 
Trypsin/EDTA 0.05%, phenol red (Gibco 25300)  
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Trypsin neutralizing solution (Promocell TNS C-41100) (0.05 % trypsin 
inhibitor, 0.1% BSA) 
Umbilical arteries were obtained after appropriate ethical approval and informed 
consent from mothers undergoing elective caesarean section at the Elizabeth Garrett 
Anderson Hospital, University College London Hospitals NHS Trust.  Umbilical cords 
were collected after birth and placed in 50mL Falcon tubes with an amount of sterile 
Phosphate Buffered Saline (PBS) solution sufficient to submerge the cord.  The cord 
was then taken to the laboratory for dissection. 
Dissection was carried out using aseptic technique under sterile conditions in a 
laminar flow hood using standard vascular surgical instruments.  Human umbilical 
arteries are present in pairs within the Wharton’s jelly of the umbilical cord.  Careful 
stripping of the jelly from the underlying vessels could almost always give a length of 
5-10cm undamaged artery.  This was then placed in dissecting medium until using 
the tissue chopper to create rings of vessel of around 1mm long.  Rings of vessel 
were then placed in growth medium and plated on either T-25 flasks at 40 rings per 
flask, 6-well plates at 3 rings per well or 12 well plates with 1 ring per plate. 
Outgrowth was seen after 1 week but it took at least 3 weeks to observe significant 
numbers of cells explanting from the rings.  Medium was changed carefully at weekly 
intervals in order to avoid displacing adhered rings of artery.  Cells were harvested 
by removing the ring of tissue and then washing twice in HBSS and adding 
trypsin/EDTA dissociation solution for 5-7 minutes.  Flasks or plates were tapped 
gently to assist the cell detachment and cells were then aspirated with a 5mL pipette 
into a Falcon tube.  Trypsin was neutralised using trypsin neutralizing solution, and 
cells were then counted using a variety of methods (see below section). Cells were 
replated at passage at 3500 cells/cm2 and thereafter fed three times weekly until 
80% confluent, when they were passaged again. 
2.1.1.2 Confirming phenotype 
Phenotype was confirmed primarily by morphology.  Cells were fusiform and formed 
hill and valley whorls when approaching confluence.  
Further confirmation was obtained using fluorescence microscopic visualization of 
cells grown on coverslips and stained with an antibody to smooth muscle actin or α-
tubulin followed by a fluorescein or TRITC-conjugated secondary antibody as 
follows. 
Equipment: 
18mm glass coverslips 
Standard 12-well tissue culture plates 
Confocal microscope 
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Reagents: 
 Primary antibodies 
Mouse monoclonal anti-smooth muscle actin antibody CGA7 (Santa 
Cruz sc-53015) 
 Rat monoclonal anti-α-tubulin antibody 3H3087 (Santa Cruz sc-69971) 
 Secondary antibodies 
 TRITC-conjugated goat anti-mouse antibody (Santa Cruz sc-3796) 
 FITC-conjugated goat anti-rat antibody (Santa Cruz sc-2011) 
DAPI (Molecular Probes) 
PBS (Invitrogen) 
Paraformaldehyde prepared as described below (Sigma) 
0.1% Tween-20 
1% bovine serum albumin (Sigma) 
All steps were carried out in 12 well tissue culture plates but with coverslips in the 
base of each well. Cells were not allowed to dry between steps.  Culture medium 
was aspirated and coverslips were washed with 3 changes of 2 mL PBS at room 
temperature.  Cells were fixed for 10 min at room temperature with 2 mL 4% 
paraformaldehyde (PFA) in PBS.  Fixative was aspirated and coverslips were 
washed with 2 changes of 2 mL PBS at RT.  Cells were post-fixed with 2 mL 
methanol (-20 °C) for I min at 4 °C.  Methanol was aspirated and coverslips were 
washed with 2 changes of 2mL PBS / 0.1% Tween-20 at RT.   
Coverslips were blocked overnight at 4°C with 1% BSA in PBS / 0.1 % Tween-20 (or 
blocked for 1hr at RT).  Following blocking, slides were incubated with 0.25mL 
primary antibody at the appropriate dilution in PBS / 1%BSA / 0.1% Tween-20 for 1hr 
at RT in a humidified chamber. A parallel sample was incubated with diluent alone 
(blank sample). Primary antibodies were aspirated and coverslips were washed with 
3 changes of 2 mL PBS / 0.1% Tween-20 at room temperature over 5 min.  Slides 
were incubated with 0.25mL secondary fluorescent antibodies at the appropriate 
dilution in PBS / 1% BSA / 0.1% Tween-20 for 1hr at room temperature in the 
humidified chamber and in a dark room (or overnight at 4°C). Secondary antibody 
was aspirated and coverslips were washed at room temperature over 5 min with two 
changes of 2mL PBS / 0.1% Tween-20 and once with PBS.  Coverslips were 
removed from the wells, wiped dry, and mounted onto a microscope slide with 20μl 
DAPI/Vectashield and sealed with nail varnish. 
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Figure 2.1.1-1: Fluorescence microscopy of explanted smooth muscle cells. 
The above figure shows DAPI nuclear staining (top left panel), FITC-conjugated α-tubulin staining (top 
right panel), TRITC-conjugated smooth muscle actin staining (bottom left panel) and a composite 
image in the bottom right panel. Performed with assistance from Neale Foxwell, Wolfson Institure of 
Biomedical Reserch (UCL). 
2.1.2 Human umbilical vein endothelial cells 
First passage single donor endothelial cells were purchased from Promocell and 
cultured in EGM-2 (Cambrex or Promocell) made with EBM containing 2% FBS and 
EGM-2 BulletKit (CC-3162) consisting of hEGF, hydrocortisone, GA-1000 
(Gentamicin and Amphotericin-B), VEGF, hFGF-B, R3 -IGF-1, ascorbic acid and 
heparin as supplied by the manufacturer. 
At passage, cells were washed twice in PBS and trypsin / EDTA 0.05% was used to 
dissociate the cells from the bottom of the tissue culture plate. 0.5mL was used in 
the case of 6-well plates and the amount was adjusted per growth surface area if 
using alternatively-sized plates or flasks. An equal volume of trypsin neutralizing 
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solution was used at the end of dissociation before counting cells by 
haemocytometer or Coulter particle analyser. Cells were reseeded at 3500 cells/cm2. 
2.1.3 Freezing and thawing cells 
For freezing, VSMC or HUVEC from one 75 cm2 flask were trypsinised, spun down 
and resuspended in ice-cold freezing medium (1.1 mL DMSO, 8 mL DMEM, 2 mL 
foetal calf serum). 1 mL aliquots were frozen in cryovials first at -20°C for one day, 
then at -80°C overnight before long term storage at -196°C in liquid nitrogen. For 
thawing, cells were warmed to 37°C and immediately dissolved in pre-warmed 
culture medium. After resuspension, cells were placed in culture medium and placed 
in a 75 cm2 flask. 
2.2 Counting cells 
Cells were counted by two separate methods. 
2.2.1 Trypan blue cell counting 
  
Figure 2.2.1-1: Haemocytometer design. 
Representation of a haemocytometer with differing sizes of squares to allow counting of particles of 
different sizes and number. 
Trypan blue is taken up by dead cells but not viable cells. Cells exposed to Trypan 
blue for extended periods of time, may begin to take up dye, even if they are viable. 
Reagents 
Trypan blue solution 0.4% (Gibco 15250-061) 
Hanks’ balanced salt solution, no phenol red (HBSS) (Gibco 14025-050) 
0.5mL trypan blue solution was transferred to a 12x75mm test tube and 0.3mL 
HBSS was added to 0.2mL cell suspension (dilution factor of 5) and mixed 
thoroughly.  The suspension was allowed to stand for 5-15 minutes.  With a coverslip 
in place, a small amount of cell suspension (about 10 microliter) was transferred to 
both chambers of the haemocytometer. 
Corner 
Middle 
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The total number of cells was counted in the 4 corner squares first, then the stained 
(non-viable) cells.  This was repeated in the opposite chamber.  If over 10% of the 
cells were clustered, the procedure was repeated after further dispersal by pipetting.  
If less than 200 or more than 500 cells were observed in 8 squares, the count was 
repeated adjusting to an appropriate dilution factor. The cell density and viability of 
the suspension was calculated as follows: 
Cells per mL = average count per square x dilution factor x 104. 
Cell viability = viable cells / total cell count. 
2.2.2 Coulter multisizer particle analyzer 
This semi-automated cell counter gives information about the cell density in 
suspension and a measure of the cells’ diameter or volume.  The instrument works 
on the principle of an aspirated stream of solution through a 100μm aperture with an 
electrode inside and outside the collecting chamber.  The change in impedance is 
used to assess the cell size and the number of discrete disturbances is used to 
calculate the cell count.  Furthermore, where cells are adherent to each other, the 
analysis software was able to discriminate to a certain degree and take this into 
account when delivering the final analysis. 
2.3 Measuring senescence 
2.3.1 Replicative capacity 
Calculating population doublings 
The number of population doublings that the culture attains between passage x-1 
and x is calculated by PD = log2(Nx/Nx-1).  Nx-1 is calculated using the original plating 
density of the cell suspension adjusted to seeding efficiency and Nx is the cell count 
at passage. 
The replicative capacity is a calculation of the cumulative population doublings 
achieved by a cell population.  The cells were counted and replated at each passage 
with a known cell density per plate or well.  This allowed a calculation of the 
population doubling, population doubling time (population doubling/days between 
passages) and cumulative population doublings (the sum of each passage’s 
population doubling).  It is vital when calculating doubling time that cells do not 
become confluent to avoid contact inhibition of growth.  However, the initial doubling 
time may be longer than the subsequent middle phase as cells show a slower 
proliferative rate at very low cell densities. 
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2.3.2 Senescence associated β galactosidase histochemical staining 
 Reagents 2.1.1.1
PBS 
3% paraformaldehyde preparation (always made fresh). 
3g paraformaldehyde was placed in a 200mL flask to which 60mL PBS 
was added.  The mixture was warmed to 60˚C in a fume hood and 
mixed with a magnetic stirrer.  0.5M NaOH was added drop-wise, until 
a clear solution was produced.  The solution was allowed to cool and 
pH was checked.  Further NaOH was added to titrate to pH 7.4.  The 
volume was made up to 100mL with PBS. 
X-Gal Staining solution :  
Potassium ferrocyanide 5mM, potassium ferricyanide 5mM, sodium 
chloride 150mM, magnesium chloride 2mM, citric acid 40mM / sodium 
phosphate 50mM, (all Sigma) titrated to pH 6.0. Store at 4ºC for up to 3 
months. 
Ethanol (70%, 95%, 99.7%) 
5-bromo-4-chloro-3-indolyl--v-galactopyranoside (X-gal) was kept as a stock 
solution of 48.95mM (20mg/mL) in DMF at -20°C in the dark and in a glass bottle. X-
gal was added to the above buffer immediately before the staining procedure at a 
concentration of 2.45mM (1mg/mL) and the resulting solution was filtered using a 
0.22μm filter. 
2.3.2.1 Method 
Medium was removed from wells and cells were washed twice in PBS (2mL) at room 
temperature.  PBS was removed and cells were fixed for 3min with 1.5mL 3% 
paraformaldehyde per well of a 6 well plate at room temperature.  Cells were washed 
once more with PBS at room temperature. 
Cells were then exposed to the prepared X-gal staining solution (1.5mL per well of a 
6 well plate) and samples were incubated overnight (20 hours) at 37°C.  Plates were 
wrapped in Parafilm to prevent evaporation and, if kept in 5% CO2 incubator, to 
prevent alteration of pH by CO2.  Staining solution was then removed and the plates 
were washed once with double distilled water at room temperature.  Cells were then 
washed through grading ethanol solutions of 75%, 95%, and 99.7% using 1mL per 6-
well plate well for 1min each.  Plates were allowed to air dry after the last ethanol 
passage and were then ready for counting or photography. 
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2.3.3 Fluorimetric assay of β-galactosidase activity 
Quantitative assay of senescence-associated β-galactosidase using cell extracts 
Senescence-associated β-galactosidase was measured by the rate of conversion of 
4-methylumbelliferyl--D-galactopyranoside (MUG) to the fluorescent hydrolysis 
product 4-methylumbelliferone (4-MU) at pH 6.0. 
2.3.3.1 Materials 
4-methylumbelliferyl--D-galactopyranoside (MUG) 
400mM sodium carbonate 
PBS 
Lysis buffer pH 6.0 
5mM 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate 
(CHAPS) 
40mM citric acid 
40mM sodium phosphate 
0.5mM benzamidine 
0.25mM phenylmethanesulfonyl fluoride [PMSF] 
Reaction buffer 
40mM citric acid 
40mM sodium phosphate 
300mM NaCl 
10mM -mercaptoethanol 
4mM MgCl2 (pH 6.0) with 1.7mM of MUG added immediately prior to 
use from a 34mM stock in DMSO. 
2.3.3.2 Method 
Plates were washed six times with PBS after which 75μL lysis buffer was added at 
room temperature.  Cells were scraped and transferred to a 1.5-mL tube.  The lysate 
was vortexed vigorously and then centrifuged for 5min at 12000g and kept on ice 
until use.  Reaction buffer was kept at room temperature to prevent precipitation. 
Reaction buffer (150μl) was added to 150μl of clarified lysate (100μl of lysate diluted 
with 50μl of lysis solution) and the reaction mixture was incubated at 37°C for 1 hour.  
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50μl of the reaction mixture was added to 500μl of 400mM sodium carbonate stop 
solution and kept at 4°C until measurement of fluorescence.150μL of the final 
sample mix was transferred into a 96-well plate and was read at 465nm using a 
Victor automated plate reader with excitation at 360nm, . 
2.3.4 Flow cytometric assay of β-galactosidase activity 
2.3.4.1 Materials 
5-dodecanoylaminofluorescein di-β-D-galactopyranoside (C12FDG) (Molecular 
Probes Catalog Number - D2893) MW 853.92. 
Dissolve in DMSO to give stock solution of 20mM. 
PBS 
2.3.4.2 Method 
Plates were washed twice with PBS at room temperature.  Cells were incubated with 
25μM C12FDG in medium for 4hrs at 37°C in 5% CO2 humidified incubator. 
After incubation, cells were washed twice with PBS. Cells were disassociated from 
the plate using trypsin / EDTA 0.05% and tapping gently until cells detached.  Cell 
suspensions were transferred to 5mL tubes suitable for FACS machine containing an 
equal volume of full medium and placed on ice until analysis. 
When hydrolyzed by β-galactosidase, C12FDG gives rise to the fluorescent product 
fluorescein by -galactosidase which when excited at 488 nm emits fluorescence at 
518nm. Cells were therefore analysed by forward and side scatter and fluorescence 
intensity.  The flow cytometer was set to acquire 10000 events.  
As part of the optimisation of the model, cells were subjected to different drug 
treatments while they were actively replicating (i.e. pre-confluent). However, some 
treatments - most notably those involving incubation with a nitric oxide donor - 
caused both inhibition of cell replication and cell death in this situation. However, 
since I wished to analyse the effect of these drugs on the potential to cause a stress-
related senescence in subsequent experiments, I tried exposing the cells to the drug 
in a confluent state. I found that confluent cultures were more able to tolerate and 
recover after the drug treatment. This may nevertheless be more similar to the in 
vivo situation where endothelial cells are rarely out of contact with other cells. 
In the first series of experiments, cells were analysed immediately after their 
treatment. However, changes in β-galactosidase activity appeared to require at least 
48 hours of exponential growth post trypsinization. Partly, this allowed cells to 
recover so that they were able to survive the following stage of analysis but also, the 
increase of β-galactosidase activity appeared to need cells which were not subject to 
cell contact inhibition.  
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This was demonstrated in optimisation experiments which show a sufficient number 
of cells to be analysed at the time of harvest, without large numbers of cellular 
fragments which would be a sign of cell death at the time of analysis. However, 
greater differences in β-galactosidase activity were seen between cell populations 
when cells were harvested after a period of non-confluence. 
2.3.5 Western blotting for senescence associated proteins 
2.3.5.1 Cell lysis 
Reagents 
Lysis buffer 
50mM Tris-HCl pH8 
150mM HCl 
1mM EDTA 
1mM Na3VO4 
1% NP-40 (Sigma) 
Cells were washed twice in PBS and scraped using a cell scraper in 100-150μL lysis 
buffer per 6-well plate well on ice.  The lysate was then collected in Eppendorf tubes 
and kept on ice.  Samples were then frozen to -20ºC and stored until use. 
Samples were then thawed and sonicated on ice using a sonicator for 3 x 5 second 
bursts. Samples were centrifuged at 200g for 5 minutes and 30 or 50μL supernatant 
was collected in Eppendorf tubes. 
2.3.5.2 Protein estimation 
Two protein assays were used as the BCA method contained cupric sulphate and 
this would have interfered with the biotin switch method of measuring protein 
transnitrosation. 
2.3.5.2.1 BCA Protein assay kit (Pierce) 
Reagents 
Sample A 
Sodium carbonate, sodium bicarbonate, bicinchoninic acid and sodium 
tartrate in 0.1M sodium hydroxide. 
Sample B 
 4% Cupric sulphate. 
67 
 
Standard 
 Bovine serum albumin (Sigma). 
The assay is based on detection of reduction of Cu2+ to Cu+ by protein in an alkaline 
medium (the biuret reaction) with colorimetric detection of the cuprous cation (Cu+) 
using a unique reagent containing bicinchoninic acid.  It was first described by Smith 
et al in 1985.182 A purple reaction product is formed by the chelation of two 
molecules of BCA with one cuprous ion. This water-soluble complex exhibits a 
strong absorbance at 562 nm that is nearly linear with increasing protein 
concentration. 
Protein standards were prepared using bovine serum albumin serial dilutions in lysis 
buffer at concentrations of 2mg/mL, 1.5, 1, 0.75, 0.5, 0.25, 0.125 and 0 mg/mL. 
The reaction mix was prepared immediately prior to the assay by mixing samples A 
and B at the recommended dilution and 200μL solution was added to the 
corresponding number of wells using a multichannel pipettor.  10 or 15μL aliquots of 
samples and standards were then added to the wells using a single channel 
electronic multi-pipettor and incubated for 30 min at 37C in a humidified incubator 
with 5% CO2. 
Samples were then analyzed in a Spectramax colourimeter at 562nm and values 
plotted on the standard curve generated form the BSA standards. 
2.3.5.2.2 Bradford protein assay kit (Bio-rad) 
This assay is based on an assay first described by Bradford in 1976.183 Briefly, an 
acidic solution containing Coomassie Brilliant blue dye demonstrates a change in 
light absorbance becoming blue with a maximum light absorbance at 595 nm when 
bound to protein. This is especially true for arginine and aromatic amino acid 
residues.  
Reagents (all Bio-Rad): 
Protein assay dye reagent (Bio-Rad) 
 Coomassie blue dye, phosphoric acid, methanol 
 Distilled de-ionized water 
Standard 
 Bovine serum albumin (Sigma) 
Method 
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Standard solutions of BSA were prepared by reconstituting a stock solution of BSA 
10mg/mL in filtered, deionized water. Serial dilutions in lysis buffer gave 
concentrations of 2mg/mL, 1.5, 1, 0.75, 0.5, 0.25, 0.125 and 0 mg/mL. 
The dye reagent was diluted in water with a 1:4 dye:water ratio. Using a standard 96 
well plate, 10µL per well of standard and sample solutions were loaded and 200µL 
diluted dye solution were added using a multi-channel pipettor, discarding tips after 
mixing each well. The sample was placed in the plate-reading colorimeter and 
incubated at room temperature for 5 minutes before reading absorbance at 595 nm. 
Samples were then analysed in a Spectramax colorimeter at 562nm and values 
plotted on the standard curve generated form the BSA standards.  
2.3.5.3 Sample preparation for SDS PAGE 
Reagents 
 Sample  buffer 
 5mM Tris HCl pH 6.8 
0.5mM EDTA 
0.5% SDS 
5% Glycerol 
5% Mercaptoethanol (Add on day of use) 
Bromophenol blue (Small amount on day of use) 
1:1 dilution with sample 
Lysates were aliquotted in Eppendorf tubes and made up to an equal concentration 
and volume with lysis buffer.  Sample buffer was added and samples were mixed 
thoroughly and then boiled at 100ºC for 5 minutes before loading into wells of a 15% 
SDS polyacrylamide gel. 40µg of protein diluted to 40µL total volume in sample 
buffer was loaded per sample. 
2.3.5.4 SDS PAGE 
Reagents 
Stacking gel 
 5% acrylamide/bisacrylamide mix 
 125mM Tris (pH6.8) 
 1% SDS 
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 4.38mM ammonium persulfate 
 6.63mM Tetramethylethylenediamine (TEMED) 
Separation gel 
 15% acrylamide/bisacrylamide mix 
 375mM Tris (pH8.8) 
 0.1% SDS 
 4.38mM ammonium persufate 
 2.65mM TEMED 
Running buffer 
 25mM Tris base 
 192mM glycine 
 0.1% SDS 
Transfer buffer 
 25mM Tris base 
 200mM glycine 
 20% methanol 
In  the case of experiments to detect p16INK4a and p21WAF, I used a 1.5mm thick, 
15% polyacrylamide gel to allow sufficient resolution of these low  molecular weight 
proteins (selected to offer the optimal resolution for proteins <30kDa). This was 
poured between glass plates cleaned first with water, then acetone and left to dry. 
10mL of the 15% acrylamide separation gel was poured per set of glass plates and 
covered with isopropanol and allowed to polymerise for an hour. 
In order to allow for loading of separate samples, a stacking gel was added with a 
comb to create empty spaces for the samples to be loaded. The stacking gel was 
made of a 5% acrylamide gel. 
Gels were run, in running buffer, at 120V for 1-1.5 hours, using a coloured molecular 
weight marker to assess gel progress. Gels were then carefully removed and placed 
in a bath of transfer buffer. 
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2.3.5.5 Protein transfer 
A PVDF transfer membrane was cut to the size of the gel, bathed in methanol then 
put it in the transfer buffer bath together with a sponge and 6 x whatman paper 
sheets 
The membrane and gel were then placed in between three layers of soaked 
whatman paper on either side and transfer was performed from gel to membrane at 
150V for 45 minutes using a trans-blot cell. 
2.3.5.6 Western blotting and ECL protein detection 
Reagents 
Membrane 
Blocking buffer 
PBS-0.1% Tween-20 
6% fat-free skimmed milk 
Antibodies 
 Rabbit anti-p21WAF1 C-19 polyclonal antibody (Santa Cruz sc-397) 
 Rabbit anti-actin I-19 antibody (Santa Cruz sc-1616) 
Mouse anti-p16 F-12 polyclonal antibody (Santa Cruz sc-1661) 
 HRP-conjugated goat anti-mouse IgG antibody (Santa Cruz sc-2005) 
 HRP-conjugated goat anti-rabbit IgG antibody (Santa Cruz sc-2004) 
ECL detection kit (Amersham RPN2109), containing reagents 1 and 2, 
contents not published. 
After transfer, the membrane was incubated in blocking buffer for 1hr at 37°C under 
shaking or overnight, at 4°C. The primary antibody was incubated for 1h at 37°C in 
the blocking buffer under a paraffin paper (2 mL/membrane) at 1:1000 dilution, 
1:2000 in the case of anti-actin. After incubation, the membrane was cleaned with 
five washes in PBS - 0.1% Tween 20 under shaking at room temperature. 
Thereafter, I incubated the membrane for an hour at 37°C with the secondary 
antibody-horseradish peroxidase conjugate (HRP) (anti-rabbit or anti-mouse- in 
function of the first Ab in the blocking buffer at  1:2000 dilution). After this, the 
membrane was washed five more times in PBS - 0.1% Tween 20 under shaking at 
room temperature. 
Bound, HRP-conjugated antibodies were detected using the ECL system. The ECL 
system relies on the chemiluminescence of luminol when it is oxidized with the 
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assistance of the catalysts HRP/H2O2, a reaction which is greatly enhanced in the 
presence of phenols in an alkaline buffer.  After mixing the two ECL reagents, 2mL of 
the solution was pipetted onto the membrane and left for 5 minutes before analysis. 
After draining the membrane over a tissue, the membrane was wrapped in Saran 
film and exposed to an X-ray film. The strength of the signal obtained after an initial 
exposure of 15s permitted estimation of subsequent exposure times to obtain 
optimal signals. 
2.3.5.7 Optical density analysis 
After film processing, films were subjected to optical density analysis as a means of 
avoiding subjective interpretation of the results. Using Alphaease software, a light 
box and a digital camera, bands of interest were quantified and compared and 
adjusted to their loading controls. 
2.4 Measuring reactive oxygen species 
2.4.1 Fluorimetric assay of reactive oxygen species 
In order to determine the levels of reactive oxygen species seen in cells, we used 
H2DCF-DA as a probe. H2DCF-DA is a diacetate derivative of another ROS probe, 
dichlorodihydrofluorescein. The diacetate moiety enhances membrane permeability 
and thereby permits better diffusion of the molecule throughout cells. H2DCF-DA is 
deacetylated within cells to a non-fluorescent and membrane impermeable carboxy-
dichloro-dihydro-fluorescein. Carboxy-dichloro-dihydro-fluorescein is converted to 
the fluorescent carboxy-dichloro-fluorescein by reactive oxygen species.  This 
reaction detects ROS and RNS by direct reaction or by reaction with a reaction 
product of the originator reactive species and thus can only be regarded as a rough 
measure of total oxidant levels. 
The substrate reacts predominantly with hydroxyl radicals, H2O2 and peroxynitrite but 
also detects superoxide indirectly via the production of peroxynitrite; or either the 
hydroxyl radical or H2O2. Superoxide is dismutated by superoxide dismutase to form 
H2O2 and then may be further converted to the OH radical via the Fenton reaction.  
The probe also reacts to a far lesser extent directly with nitric oxide.184-187   
Reagents 
H2DCF-DA (Fluka 35845, dissolved in DMSO (Sigma)) 
KRH buffer (all Sigma and corrected to pH 7.4): 
1.8mM CaCl2, 1mM MgCl2, 5.5mM KCl, 145mM NaCl, 0.8mM 
Na2HPO4, 5mM glucose, 20mM HEPES. 
EGM-2 (Promocell) 
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Method 
HUVEC were seeded onto 96 well plates at 10000cells/well and grown in EGM-2 for 
2 days. Cells were then washed in KRH buffer 100μL per well.  Cells were then 
incubated with 25μM H2DCF-DA at 37°C for 30 minutes except the non-staining 
wells.  This allowed the fluorogenic progenitor to enter the cells.  Cells were washed 
with 70μL KRH buffer and incubated at 37°C with the relevant compound for 60 
minutes with fluorescence readings every 10 minutes to provide kinetic data.  A 
VICTOR™ X  light luminescence plate reader (Perkin Elmer) was set to excite at 
485+/-10nm, and to read at 520+/-25nm. 
This experiment, being conducted in the presence of the active reagents, was prone 
to extracellular bias. In order to assess the possible effects of fluorescence being 
generated by an extracellular reaction between H2DCF-DA and the drugs used to 
treat the cells, I repeated the experiment using the drugs and the fluorescent probe 
alone. 
2.4.2 Flow cytometric assay of ROS 
Another way to reduce the chance of extracellular reactions being incorrectly thought 
of as intracellular, I also repeated the experiment using flow cytometry. This gave the 
added advantage of being able to quantify fluorescence per cell and to use gating to 
remove cell debris from the analysis. 
Cells were incubated with H2DCF-DA for 30 mins at 37ºC in a T-25 flask, harvested 
with trypsin/EDTA followed by neutralization with phenol-free EGM-2.  Cell 
suspensions were then incubated at 37C with the relevant compounds for 30 
minutes on ice and analysed using a Beckman FACSCalibur flow cytometer without 
further processing. 
2.5 Detection of protein nitrosylation by the biotin switch method 
Protein nitrosylation as a consequence of exposure to nitric oxide was assessed 
using the biotin switch method. The principle behind this technique is that protein 
nitrosylation occurs on thiol residues. However, direct measurement of protein 
nitrosylation was not possible. The biotin switch method first blocks free cysteine 
residues, before switching nitrosyl residues for a labelled, irreversibly bound reagent 
(HPDP). The removal of nitrosyl residues is achieved by reduction by ascorbic acid 
prior to the labelling step. In this case, labelling was performed using a Biotin-
labelled hexyl pyridyl dithiopropionamide (HPDP) which could itself be labelled with 
Avidin labelled with horse-radish peroxidase. Subsequent analysis was made using 
the ECL detection kit as previously described. 
2.5.1.1 Materials 
Blocking buffer 
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9 volumes of HEN buffer (HEPES 250mM, pH 7.7 (Sigma); EDTA 1mM 
(Sigma), neocuproine 0.1mM (Sigma)) to 1 volume of 25% SDS 
(Sigma) 
Mercaptoethanol methylthiosulfonate (MMTS) 20mM made from a 
stock 2M solution in dimethyl formamide (DMF) (both Sigma) 
Acetone (Sigma) 
HENS buffer 
 HEPES 25mM, pH 7.7; EDTA 0.1mM, neocuproine 10mM, 1% SDS 
Reducing agent 
Sodium ascorbate 50mM (Sigma) 
Biotin-hexyl pyridyl dithio propionamide (Biotin-HPDP) (Pierce) 
Avidin-horseradish peroxidase (Avidin-HRP) (Sigma) 
ECL plus kit 
2.5.1.2 Method 
The precise method was taken from Jaffrey et al but was performed with 
modification.188 The most important difference was the use of the Bradford protein 
assay in preference to the BCA (Biuret assay) as this assay can be performed in 
samples which may contain reducing agents including ascorbic acid and also copper 
chelators, including neocuproine, unlike the BCA (Biuret) protein assay. 
Cells were washed in PBS buffer after being grown in 6-well standard tissue culture 
plates. The plates were then transferred to an ice bucket where they were washed in 
PBS and harvested by scraping. The resulting suspension was transferred to a 
1.5mL Eppendorf tube. After centrifuging at 500g for 5 minutes, the supernatant was 
removed by suction. The pellet was then re-suspended in blocking buffer and either 
stored in -20ºC for future analysis or I directly proceeded to perform the assay. 
Free thiol blockade was achieved using blocking buffer which contained the active 
blocker, methyl methane thiosulfonate (MMTS), by gently shaking the re-suspended 
pellet in 0.5mL blocking buffer at 50ºC for 20 minutes. The mixture was then 
centrifuged again at 500g for 5 minutes and the supernatant was split into 3 aliquots 
of 0.15mL for separate analysis to compare a negative non-labelled sample, a biotin-
labelled sample and a labelled and ascorbic acid-reduced plus biotin-labelled 
sample. MMTS was then removed by the addition of 0.8mL ice-cold acetone for 30 
minutes in a -20ºC freezer. Samples were then centrifuged at 5000g for 5 minutes at 
4ºC and the supernatant was discarded. The pellet was then re-suspended in 0.1mL 
PBS . 
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Protein concentration was determined using the Bradford assay. After determining 
protein concentration, equal amounts of protein were loaded per condition onto a 
15% acrylamide gel which was made as previously described. The loading buffer 
could not contain β-mercaptoethanol as this interfered with the labelling process. In 
addition, protein samples were not heated as they could not be boiled for maximal 
protein denaturation for the same reason. 
After running the samples through the gel at 150V for 90 minutes, monitoring the 
progress using dyed protein molecular weight markers, a wet transfer of the gel onto 
PVDF membrane was performed for 1 hour at 100V. Milk blocking was not used as it 
contains biotin, therefore 3% bovine serum albumin was used as an alternative. 
Blocking was performed over 1 hour at room temperature or overnight at 4ºC. The 
membrane was then exposed to a 1:1000 dilution of Avidin-HRP conjugate for 1 hour 
at room temperature in the 3% BSA/PBS buffer and washed before analysis with 
ECL plus detection reagent as previously described. 
2.6 Exposure of cells to cold light 
The light source was a KL1500 Schott (Mainz, Germany) which delivers cold light 
from a 150W bulb via a fibre optic arm. In order to standardise the experiment, a 
number of adjustments were made to our standard cell incubation practice. In order 
to intensify the light to cells, all flasks were placed in the same incubator within a 
polystyrene ice box with the lid removed and positioned to face the inner glass door 
of the incubator. The box was in turn lined with reflective aluminium foil, as was the 
inner glass door of the incubator, except for a window left to allow light from the light 
source to enter. The need to leave the outer door of the incubator open 
compromised its insulation but as this was thermostatically-controlled, the main 
difficulty was that water condensed on the inner surface of the inner glass door and 
necessitated careful observation to ensure the water tray at the bottom of the 
incubator was replenished in order to maintain the humidity of the incubator and that 
excess water on the floor was removed. 
Cells were grown in T-25 flasks with the cells which were not to be exposed to light 
being wrapped in aluminium foil covered in black ink on the inner surface. The 
rationale for this was that any leakage of light into the flask would be readily 
absorbed by the black ink. However, a temporary covering was necessary to allow 
careful cell harvest at the end of the experiment and to permit any necessary 
photography of the cells. The aluminium foil on the outer of the flask also prevented 
absorption of the light by any pigment used to opacify the tissue culture plastic and 
the likely conversion of this to heat. 
Finally, the light source could not be left in operation for the length of the experiment 
and continuous light exposure could have exerted an effect on the reagents as much 
as on the cells. Therefore, timed light exposures were managed by a generic mains 
electricity power timer used for domestic light timing. This was programmed to cycle 
with 1 hour of light followed by 5 hours of ambient light only. 
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2.7 BrDU incorporation assay of cell proliferation 
Reagents (all Roche): 
BrdU labelling agent (10mM 5-bromo-2’-deoxyuridine in PBS, pH 7.4). 
FixDenat solution. 
Peroxidase-linked anti-BrDU antibody (monoclonal antibody from mouse-
mouse hybrid cells, clone BMG 6H8, conjugated with peroxidase). 
Antibody dilution solution. 
Washing buffer (PBS 10x solution). 
Substrate solution (TMB, tetramethyl-benzidine) 
A colorimetric cell proliferation ELISA was obtained from Roche (Cell Proliferation 
ELISA, product number 11 647 229 001).  The assay exploits the thymidine 
analogue 5-bromo-2’-deoxyuridine (BrDU) which is incorporated into DNA during 
synthesis and can then be detected by immunoassay with a peroxidase-linked 
antibody.  Details of concentrations and dilutions and some ingredients were not all 
supplied by Roche. Cells were plated at a range of cell concentrations for the assay 
on 96-well plates and the assay was performed 16 hours later.  Attempts to assay at 
a later stage were less successful due to the degree of proliferation during the period 
between plating and assay (data not shown).  Cells were incubated with BrDU in 
normal medium as per the supplied protocol from Roche for 2hr at 37C.  After 
washing, cells were fixed, washed and labelled with anti-BrDU-peroxidase 
conjugated antibody for 90min at room temperature.   Peroxidase-labelled cells were 
detected with a chromogenic substrate of peroxidase, tetramethyl-benzidine (TMB) 
and this was detected in a Spectramax plate reader at 370nm every 5min for 30min 
and the area under the curve was calculated. 
2.8 Tetracycline-inducible iNOS expression in HEK-293 
Tetracycline-inducible iNOS expressing cells from a human embryonic kidney cell 
line (HEK-293) were a kind gift from Dr Palacios-Callender. They were manufactured 
using a previously-described method by Mateo et al.189 
In order to achieve a cell line which could stably and predictably express our gene of 
interest, cells had been transfected with a tetracycline-inducible expression vector 
which contained cDNA for the complete iNOS gene found in human chondrocytes, 
flanked by an antibiotic resistance gene for cell selection, a cytomegalovirus gene 
promoter and Flp-recombination target (FRT). This is then transfected into the cell 
line which already contains its own FRT site which has been selected to be in an 
area of the genome which is able to tolerate gene insertions without destabilising the 
cell line. 
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Using a plasmid to express Flp recombinase, the host genome FRT site is cleaved 
and the new sequence is inserted into this pre-selected site. Successfully transfected 
cells are then selected using the antibiotic to which those cells are now resistant and 
therefore a stable, pure population of cells is obtained. 
2.9 Measuring nitric oxide generation by nitric oxide electrode 
Using an Innovative Instrument 700 micrometre tip nitric oxide sensor, I measured 
the concentration of nitric oxide in medium. The sensor has a series of gas-
permeable membranes surrounding an electrode plate. The membranes present a 
series of obstacles to gaseous diffusion until nitric oxide is the only gas which can 
reach the electrode surface and once there, the nitric oxide reacts with the electrode 
plate, generating an electrical current which is directly proportional to the 
concentration of nitric oxide. 
The sensor is immersed in an aqueous solution for at least 18 hours in order to allow 
membrane equilibration. The electrode measurements were calibrated using a 
standard solution to generate known concentrations of nitric oxide. Sodium nitrite is 
used as the donor and is added to a solution of sulphuric acid, in the presence of a 
reducing agent, in this case, potassium iodide. 
Potassium iodide 20mM and sulphuric acid 200mM solutions were mixed at a 1:1 
ratio to make up 1mL of the calibration solution (final concentration KI 10mM and 
H2SO4 100mM) immediately before starting the experiment and were then warmed to 
37ºC. After adding the calibration solution to the thermostatic measuring chamber, 
the electrode was immersed in the solution and a mechanical stirrer was used to 
achieve an even temperature and concentration of the solution. The Tarragona 
recording software was initiated to allow a stable reading to be achieved before 
adding the standard concentration of sodium nitrite. After the reading achieved the 
maximum current, the experiment was terminated, the probe is washed and the 
experiment was repeated in triplicate to ensure reproducibility. From the standard 
concentrations of sodium nitrite, a calibration factor was calculated and therefore a 
concentration of nitric oxide could be measured using different solutions of media 
and nitric oxide donor. The sensitivity of the electrode is 150 to 250 pA/nM and this 
makes it able to measure concentrations of less than 50nM nitric oxide with an 
accuracy of as little as +/- 1nM. (Manufacturer’s data http://2in.com/products/no-
sensors/compare-select.html). Experiments were performed with the assistance of 
Dr Miriam Palacios-Callender, UCL. 
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3 Assessment of techniques to measure β-galactosidase 
3.1 Introduction 
There are many features of senescent cells which help to differentiate them from 
other cell states. 
In the presence of a mitogenic stimulus and the absence of any other impediment, 
senescent cells will not replicate.  Thus the first distinguishing feature of senescent 
cells when compared to normal cells would be evidence of irreversible cell cycle 
arrest. 
In Hayflick and Moorhead’s description of replicative senescence,1 foetal fibroblasts 
were grown in vitro until the growth rate subsided and finally ceased at a predictable 
50 population doublings.  This limit (later called the Hayflick limit or proliferative 
capacity) was thought to have been the consequence of a pre-programmed event 
which occurred within the cell and would occur in the same population of cells at the 
same number of population doublings, even when the investigators sent their 
samples to other labs for verification. 
One of the burning questions in this field of research is whether growing cells in vitro 
to a state of irreversible cell cycle arrest actually mimics any condition which could 
occur in vivo.  To this end, many groups have attempted to identify markers which 
could identify senescence in another way and to describe the occurrence of 
senescence in vivo. 
Methods to investigate senescence are limited by the source of cells and the 
artificiality of the system used to grow them.  The ideal system would allow the 
analysis of a subset of young cells of similar replicative age to be analysed in a 
phenotypically pure population for the early changes associated with the 
development of senescence and for the subsequent proportion of senescent cells.  
In this respect, obtaining young healthy human cells limits us to obtaining cells from 
umbilical cords. Assessment of senescence by replicative capacity relies on a 
number of cell manipulations which may introduce error.  Standard practice is to 
keep cells in vitro under continual mitogenic stimulus.  Cells are not allowed to 
become confluent in culture as there is contact inhibition between cells and this 
would make any calculation of cell replication rate inaccurate.  There is also 
widespread advice that cells which become confluent may lose some of their 
replicative ability.  Thus experiments to assess the effect of stressors on senescence 
are carried out when cells are at a relatively low density and are not in contact.  The 
cells are then repeatedly dissociated using ion chelators or proteolytic enzymes and 
suffer mechanical stress for a number of passages until replicative senescence.  
This contrasts with the situation in vivo where cells are in contact, forming a layer of 
quiescent cells.  Cells in a confluent monolayer may be better suited to survive any 
noxious stimulus and also may express their defences in a way more alike to in vivo.  
78 
 
The ability to assess senescence immediately after any intervention would decrease 
the chances of culture artefact. 
3.2 Hypothesis 
The presence of β-galactosidase confirms and corresponds to cellular senescence. 
This will be consistent with other methods to measure senescence. 
3.3 Aims 
To assess some of the various methods of detecting senescence, aiming to produce 
a reliable, sensitive and incontrovertible means of detecting senescent cells.  
Find an in vitro method which remains as close as possible to likely in vivo 
conditions, keeping the number of in vitro interventions to a minimum. 
  
79 
 
3.4 Testing different methodologies for detecting -galactosidase 
 Senescence-associated -galactosidase  3.4.1
Human umbilical vein endothelial cells were grown in normal EGM-2 and passaged 
at 80% confluence until cessation of growth. A subset of HUVEC were stained for 
senescence-associated -galactosidase using the method described.  Late passage 
HUVEC were also stained in this manner.  The percentage of senescence-
associated β-galactosidase positive cells are counted first by using phase contrast 
light microscopy and later by using unfiltered light to count stained cells in the same 
light field and a percentage can be attributed to the proportion of senescent cells.  
This measure has been used to a great extent since first described by Dimri et al in 
1995.8  As every cell has a certain amount of -galactosidase activity, the method 
relies on a threshold of enzyme activity beyond which there is an overspill of 
galactosidase activity which can be detected at pH 6.0.  This overspill represents a 
general increase in enzyme amount and activity and is associated with senescence 
rather being causative. 
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Figure 3.4.1-1: Light micrographs of early and late passage HUVEC stained with senescence-
associated β-galactosidase. 
Representative light micrographs of endothelial cells stained for senescence-associated β-
galactosidase (blue colour). Upper panel (A) shows early passage cells, lower panel (B) late passage 
cells. Upper panel cells show a majority of cells negative for senescence-associated β-galactosidase 
and sporadic staining of some cells. Lower cells appear flatter and larger and are universally densely-
stained with blue colour. Despite plating at same density, the density of cells in the lower panel is 
reduced due to reduced proliferation. 
 
A 
B 
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 Methyl-umbelliferyl galactosidase (MUG) assay 3.4.2
In an effort to find a more objective and quantitative alternative to the determination 
of senescence-associated -galactosidase, we investigated a biochemical method to 
measure total -galactosidase activity in cell lysates.  One concern over the Dimri 
method of detecting threshold levels of galactosidase is that cells may be lost during 
fixation and there is no way of measuring whether these were senescent, healthy or 
both.  Measuring the total β-galactosidase activity of cell cultures using lysates has 
the advantage of avoiding this but the disadvantage of having to decide what merits 
the term senescent, and has a dilutional effect when considering small numbers of 
senescent cells in a healthy culture.  Whilst not definitively proven, it seems that cells 
operate a binary mode of senescent or non-senescent phenotype, rather than 
normal, pre-senescent and finally senescent. 
Furthermore, this method allows a more objective measurement, less prone to 
observer bias when counting cells which are blue or faintly blue. 
Experiments were designed according to the protocols mentioned in the methods 
section (2.3.3).  Cells were grown in the standard fashion on 6-well plates using 
EGM-2 medium.  When the assay was to be performed, plates were washed, and 
cells were scraped from the dish in lysis buffer.  The resulting mix was transferred 
into 1.5ml Eppendorf tubes, vortexed and kept on ice until ready to perform the 
assay with reaction buffer which contained 4-methylumbelliferyl–-D-
galactopyranoside (MUG). MUG is the -galactosidase substrate which is hydrolysed 
by -galactosidase giving 4-methylumbelliferone (4-MU), the fluorescent product 
detected in the assay by a fluorescent plate reader. 
The system was validated using the HUVEC cultures from several serial passages of 
the same initial population as a positive control for senescence.  Attempts to quantify 
the amount of cells proved difficult when using standard protein assay methods as 
the lysis solution interacted with protein assays and the total protein was not 
representative of the total number of cells which vary in size according to replicative 
age and increase their production of other proteins, including extracellular matrix and 
senescence-associated proteins as discussed in the introduction. 
Bacterial -galactosidase was used as a standard to compare the activity of cell 
lysates by using known dilutions of the enzyme. 
This method proved effective but too insensitive to measure small differences in the 
proportion of senescent cells in a given population. 
Furthermore, the need for storage of cells or cell lysate in order to perform an assay 
on several passages of cells on the same occasion or to perform several assays on 
the occasion of each passage introduced further uncertainty. 
82 
 
 
 
Figure 3.4.2-1: Total β-galactosidase activity by MUG assay: serial passage. 
Results of 2 separate experiments carried out using the MUG β-galactosidase assay are shown.  
Cells were grown by serial passage, and lysed at the indicated passages. Lysates were stored at -
80°C until the time of analysis. 
 
Serial dilutions of bacterial β-galactosidase in were used to normalise the results and 
thus compare between experiments.   There is a background variability of β-
galactosidase activity which led us to believe that the method could be useful for 
detecting large differences in β-galactosidase activity but may not be sensitive 
enough to allow interventions at lower passages to be assessed. In the two 
experiments above, I saw a large increase in β-galactosidase between passages. 
The increase with experiment 2 occurred at 3rd passage, which is unlikely to 
represent senescence given the usual replicative lifespan of HUVEC.  
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 Measurement of -galactosidase activity per cell using flow cytometry 3.4.3
Cells were grown in the standard fashion on 6-well plates in EGM-2 until the time of 
analysis.  The -galactosidase substrate, 5-dodecanoylaminofluorescein di--D-
galactopyranoside (C12FDG) was then incubated with the cells in medium and cells 
were harvested by washing and trypsinization, being stored on ice until analysis by 
flow cytometry.  
The limitation of this technique for our purposes was that cells from different serial 
passages could not be analysed all at the same time as in this method cells ought to 
be analysed directly from live culture and could not be stored without freezing live 
cells, a major problem when cells reach advanced replicative age.  There was 
variability in control fluorescence on each assay according to atmospheric 
conditions, light and FACS machine settings without a way to standardise this. Thus 
we were unable to analyse cells treated over several passages to compare this 
method to the standard of replicative senescence. As an advantage, staining 
techniques and analysis using more than one laser wavelength also allow the 
investigation of co-phenomena such as apoptosis. 
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Figure 3.4.3-1: Microscopy of total β-galactosidase activity in young HUVEC detected by C12FDG. 
Phase contrast and fluorescence microscopy images of HUVEC following incubation with C12FDG. 
Photographs were acquired immediately prior to flow cytometric analysis.  The cells pictured are 2nd 
passage HUVEC.  The top picture (A) is a phase contrast light micrograph (40x magnification) viewed 
under an inverted light microscope (Zeiss).  The lower picture (B) is from the same field of cells at the 
same magnification.  The fluorescent substrate of C12FDG has been excited using the UV light via the 
inverted microscope.  
The above photographs demonstrate cells treated with C12FDG prior to quantitative 
assessment by flow cytometry. Cells have not yet been dissociated from the culture 
plate but they appear healthy and are not completely confluent. Despite being 
relatively young HUVEC, they demonstrate lysosomal -galactosidase activity.10  
Imaging in this fashion tended to quench the fluorescent probe in the field of view 
A 
B 
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after a few seconds and so was not performed routinely before analysing cells in flow 
cytometry. Arrows point to very bright cells which may represent sporadic 
occurrences of senescence, which was present even in this young population and is 
consistent with the histological senescence-associated β-galactosidase staining 
above (3.4.1) which also showed some cells which were more densely-stained. 
 Detecting senescence and apoptosis using flow cytometry 3.4.4
Senescence and apoptosis occur in similar environments and with similar 
stimuli.190;191  Cells which irreversibly cease to replicate may in fact be slowly 
undergoing apoptosis. We wished to use flow cytometry to assess whether cells 
which have high levels of β-galactosidase activity were also showing evidence 
apoptosis.  It was possible with flow cytometry to assess populations of cells for the 
coexistence of these phenomena, exploiting the abnormal expression of 
phosphatidyl serine which can be detected by fluorochrome-conjugated Annexin V.  
Phosphatidyl serine, while normally expressed on cell membranes, is located on the 
inner surface of the cell membrane and not exposed to the extracellular surface until 
membrane function is lost as in apoptosis.  At this stage, the membrane allows 
phosphatidyl serine to flip over to the outer surface of the membrane and it can thus 
be detected using Annexin-V with attached fluorescent probes.  By staining with two 
fluorescent probes, one to assess -galactosidase activity and the other to label 
extracellular cell membrane surface Annexin-V, we were able to investigate if cells 
which have some of the features of senescence are actually undergoing an early 
stage of apoptosis.  
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Figure 3.4.4-1: Flow cytometry of annexin V vs total β-galactosidase. 
3 dot plot histograms of a flow cytometry experiment of 4th passage HUVEC. FL1-H is fluorescence 
from fluorescein and in this case is a measure of β-galactosidase activity. FL2-H is a marker of PE 
fluorescence which is the fluorochrome used to label Annexin V and is a measure of membrane 
dysfunction in apoptosis. FSC-H is forward scatter height, a measure of cell size. Events from the R2 
region in the graph on the left are shown in the middle graph. Events from the R3 region in the graph 
on the left are shown in the right-hand graph. 
The above figure demonstrates that cells show an inverse relationship between β-
galactosidase activity and annexin V labelling. R2 is gated to what were thought to 
be healthy cells and sporadically senescent cells (normal-to-high β-galactosidase 
activity) and the gated events are shown in the middle graph. R3 is gated to what 
were thought to be a mixture of cell fragments and apoptotic cells by virtue of 
fragment size. 
 Cell proliferation assay 3.4.5
As mentioned previously, the original description of cell senescence was based on 
the observation of a limited replicative capacity by Hayflick.  Thus establishing the 
replicative limit of a population of cells will tell us the starting replicative age or 
replicative potential if one is able to count the number of times a population of cells is 
able to divide.  This relies on long-term cell culture with seeding, counting and 
reseeding followed by a calculation of population doublings to give a final number of 
cumulative population doublings or replicative capacity.  Unfortunately, the method 
also requires that any intervention to test for an effect on replicative capacity also 
has to be made for a prolonged period as cells which senesce will be diluted by 
serial passaging until the whole population senesces.  For example, if half a 
population of cells senesce during an intervention on cells which are in their second 
passage, replating them at one tenth of their density several times until replicative 
senescence will cause a dilutional effect as the cells which are not senescent will 
continue to replicate while the senescent cells will constitute 5% of the subsequent 
passage, 0.5% the next and so on.  Finally, a population of cells which reach 
senescence after doubling their population fifty times will only be able to do so 49 
times if an intervention which causes 50% to senesce on their first passage is not 
repeated.  This would not be problematic if all cells responded in the same fashion 
on each occasion.  However, the subpopulation of cells which survive the 
intervention may be a select population which are inherently more resistant or may 
undergo adaptive changes so that prolonged intervention may not be representative 
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of the initial effect on first intervention.  Unfortunately, this is also the gold standard 
assessment of senescence – demonstrating replicative senescence. 
In order to avoid this experimental artefact, we used methods to detect cell 
proliferation immediately after or shortly after an intervention.  This would provide 
greater power to detect immediate effects and reduce error from repeated counting 
and replating. This would not necessarily be able to distinguish if a proportion of cells 
were stunned into quiescence but, by comparing two populations of cells, we would 
hope to be able to identify if more cells within a given population had undergone 
senescence. 
Bromo-deoxyuridine (BrDU) is a thymidine analogue and is incorporated into 
genomic DNA during DNA synthesis.  The labelled nucleoside analogue can be 
detected after cell fixation and permeabilisation by enzyme-linked antibodies which 
catalyse a colorimetric reaction which can be detected on a Spectramax plate 
reader. Using cells which were in a confluent monolayer, we were able to subject 
them to various interventions, allow a washout period and replate.  In this way, we 
performed our analysis distant to the initial insult after a recovery period had passed 
of approximately one cell doubling time and cells were then replated at a variety of 
cell densities to provide a statistically-robust means of differentiating populations of 
cells. 
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Figure 3.4.5-1: BrDU incorporation and plating density. 
The above graphs demonstrate the effect of replating 3 separate donor cultures of HUVEC at varying 
cell densities and assessing BrDU incorporation.  All cells were analysed after 3 passages. The upper 
graph (A) demonstrates total BrDU incorporation which is expressed as arbitrary units and error bars 
indicate standard error of the mean. The lower graph (B) demonstrates BrDU incorporation per cell 
plated. 
The above graph demonstrates the effect of replating 3 separate donor cultures of 
HUVEC at varying cell densities and assessing BrDU incorporation.  Cells were re-
plated after 3rd passage and assays were performed 16 hours after plating.  Cells in 
the higher densities were confluent, exhibiting contact inhibition quiescence, both by 
visual inspection on the tissue culture plate and also by the amount of BrDU 
incorporation per cell.  This way, even if there is doubt about the number of viable 
cells plated, provided serial dilutions are used, a maximum estimation of BrDU 
incorporation can be made.  Thus titrating the well with increasing seeding densities 
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until the effect of contact inhibition was observed had the advantage of assessing the 
maximum potential proliferation and reduced the chance that an observed difference 
in cell proliferation may be due to an error in counting or a differing ability to adhere 
to the tissue plate after replating. 
Senescence typically causes growth arrest in the G1 phase of cell replication, prior 
to the DNA synthesis phase and as a marker of cellular proliferation, the BrDU 
ELISA is thus suited to our model.192-194  As previously described, senescent cells 
typically increase in mass, while remaining incapable of replication.  Measurements 
of increases of cellular protein as a measure of proliferation are therefore less 
helpful. 
We were concerned that many of our stressors could cause a stunning effect with an 
insult leading to delayed recovery of cellular function. To avoid this, we tested the 
effect on proliferation after a period of washout and recovery. 
3.5 Conclusion 
Methods used to detect senescence are imperfect and are prone to culture artefact.  
The use of serial passage to detect the proliferation potential of a population of cells 
is inherently unattractive as a means to detect all but the largest differences in cell 
populations and can do little to detect differences in individual cells.  Furthermore, 
there is a conceptual difficulty with this continual exponential growth in that there is 
little to suggest this is a phenomenon which occurs in life.  
The inability to measure how many population doublings an individual cell has 
undergone in a lifetime is only partly circumvented by experiments where serial 
passage of cells taken from young and old animals undergo fewer population 
doublings when taken from older animals because these cells may have an impaired 
ability to replicate due to a loss of ability to protect themselves against insults which 
younger animals would be able to withstand. 
It is not known why senescent cells have an increased amount of - galactosidase 
enzyme but the subcellular localization remains within the lysosomes which tend to 
enlarge once senescence occurs.  One possibility is that senescence is associated 
with a defect in the function of lysosomes or that they become overwhelmed by an 
increased demand.  This phenomenon is probably a consequence rather than a 
cause of senescence a suggested by recent work on cells unable to manufacture -
galactosidase.  In this study, cells continued to replicate until cell cycle arrest was 
observed.  However, no - galactosidase expression was seen.11 
Using the progressive accumulation of senescence-associated -galactosidase in 
senescent cells as a marker may have limitations in that cells may senesce first, then 
begin accumulating senescence-associated products.  Alternatively, the 
accumulation of senescence-associated--galactosidase may be a reversible sign of 
a cell in distress.  However, in order to get the most of this marker of senescence, 
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we combined the histochemical method, a biochemical assay and flow cytometry to 
measure cells and populations of cells as accurately as possible.   
Failure to show an increase in population number in a cell culture model may be due 
to cell death or growth arrest and a measure of cell proliferation was therefore used 
to complement our other methods to confirm our findings.  This cannot distinguish 
between causes of cell growth arrest, in that it is unable to differentiate between 
quiescence and senescence but given appropriate stimuli, cells which ought to be 
proliferating can be assayed to assess if growth arrest is at least persistent, if one 
cannot be certain that it is permanent. 
We aimed to use a comprehensive array of methods to detect senescence and to 
adapt them to a model which was intended to reduce artefact.  
Measuring enzyme activity in a cell suspension by flow cytometry has certain 
advantages over the other methods.  The automated counting of single cells is 
preferable to analysing cell lysates as one can identify subpopulations within the 
greater population. Unfortunately, we lacked a standard of senescence which could 
be measured in this way. One can also distinguish degrees of enzymatic activity 
within subsets of cells.  
The use of a combination of quantitative methods to analyse a population of cells 
and comparative methods to delineate single cells’ characteristics will be used to 
assess whether cells are affected equally in a gradual shift to senescence or if there 
was a binary switch to senescence in some cells with others remaining unaffected. 
Regardless of the cause of senescence, it remains to be shown whether senescent 
cells actively participate in the development of disease, whether they are in fact 
protective or whether they are simply innocent bystanders. 
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4 Reactive oxygen species 
4.1 Introduction 
The free radical theory of ageing suggests that nitric oxide could play an important 
part in senescence.  Thus I investigated whether nitric oxide donors were able to 
increase ROS generation in HUVEC.  Furthermore, I wanted to investigate whether 
antioxidants were able to prevent this effect.  This was intended to show a means by 
which nitric oxide could cause senescence and whether senescence could be 
prevented by antioxidants by reducing ROS. 
Endothelial cells are able to generate nitric oxide via activation of eNOS by shear 
stress and yet loss of functioning eNOS is associated with advancing age in cell 
culture and whole organisms.  Thus I wanted to investigate the net effect of eNOS 
activation in a relatively young population of HUVEC on the production of ROS. 
4.2 Effect of nitric oxide donors on cellular reactive oxygen species. 
HUVEC were seeded onto 96 well plates at 5000-10000 cells/well and grown in 
EGM-2 for 2 days.  They were washed and then incubated with 2,7 -
dichlorodihydrofluorescein diacetate at 37ºC for 30 minutes.  Following this, cells 
were washed and placed in phenol-free EGM-2 with the nitric oxide donors, DETA-
NO or GSNO; or antioxidants, N-acetyl cysteine, uric acid and selenomethionine.  
We also assessed the effect of the guanylate cyclase inhibitor, ODQ; the eNOS 
inhibitor, L-NMMA; and the calcium ionophore, (eNOS activator) A23187.  This had 
previously been shown to generate a burst of nitric oxide generation, followed by a 
more sustained increase in superoxide production.195-197 Concentrations of each 
reactant were chosen according to likely in vivo concentrations and known effective 
doses as discussed above.  Treatments were assessed for their ability to generate 
reactive oxygen species within cells using a plate reader at excitation 485+/-10nm, 
emission 520+/-25nm for 60 minutes at 37ºC.  Serial dilutions of tert-butyl hydrogen 
peroxide was used as a positive control. 
Experiments using phenol-containing medium caused universal cell death as shown 
in light and fluorescent micrographs below.  Thus all subsequent experiments were 
carried out using phenol-free medium. The reason for the interaction between phenol 
red-containing media and the ROS probe was not investigated as it was easily 
circumvented and not central to our investigation. 
92 
 
 
Figure 4.2-1: UV excited microscopy of endothelial cells treated with H2DCFDA for ROS assay. 
40x magnification of HUVEC with UV light excitation which had previously been incubated with 100µM 
H2DCFDA in phenol red-containing medium. Pictures taken using Zeiss inverted UV microscope using 
digital camera.  
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Figure 4.2-2: Light and UV excited microscopy of endothelial cells treated with H2DCFDA for ROS 
assay. 
Upper panel (A): 40x magnification phased light microscopy of HUVEC in a tissue culture well. Lower 
panel (B): 40x magnification of same HUVEC with UV light excitation which had previously been 
incubated with 100µM H2DCFDA. Pictures taken using Zeiss inverted white light and UV microscope 
using digital camera.  
Measurements of fluorescence were assessed at 60 minutes as this time-point had 
the greatest correlation when tested on the standard curve of dilutions of t-BHP.  The 
single time-point data showed greater correlation with the standard curve of dilutions 
of t-BHP than measurements of maximum slope of measurements taken at 10 
minute intervals. 
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Figure 4.2-3: Time-point measurements of ROS and correlation to the standard curve of serial 
dilutions of t-BHP. 
Graph shows the result of a single experiment to assess the effect of analysing ROS generation by 
HUVEC using the probe, H2DCFDA. 
4.3 The effect of t-BHP on the H2DCFDA ROS assay by fluorimetry 
 
Figure 4.3-1: Dose response curve for the effect of t-BHP on the generation of DCF: comparison of 
different concentrations of fluorogenic probe. 
Cells were incubated with either 10µM (blue line) or 100µM (red line) H2DCFDA for 60 min and then 
fluorescence was recorded. R
2
 values for correlation to the linear trendline are shown. Results 
represent the average of quadruplicate determinations. Error bars indicate SEM.  
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Figure 4.3-2: Comparison of concentration of H2DCFDA probe and correlation to standard curve of 
serial dilutions of t-BHP. 
Cells were incubated with either 25μM (black circles) or 100µM (white circles) H2DCFDA for 60 min 
and then fluorescence was recorded. R
2
 values for correlation to the linear trendline are shown. 
Results represent the average of quadruplicate determinations. Error bars indicate SEM. 
Several concentrations of probe were used to assess whether there was a difference 
in accuracy according to concentration of the probe. There appeared to be good 
correlation between the concentration of t-BHP added to the system and 
fluorescence with either concentration of probe. The dynamic range at the lower 
concentration was however reduced (difference between no t-BHP and 50µM t-BHP 
was approximately a 50% increase in the lower concentration, compared with more 
than 100% in the higher concentration). 
H2DCFDA was used at 25µM, rather than previously-published 100µM in order to 
reduce the potential effect of the solvent, ethanol, on results and was equally 
effective as the higher dose. 
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Figure 4.3-3: Dose response curve for the effect of t-BHP on the generation of DCF. 
Graph shows a dose response curve of HUVEC exposed to 25µM H2DCFDA and then t-BHP. X-axis 
is logarithmic. R
2
 values for correlation to the linear trendline = 0.9968. Error bars indicate standard 
error of the mean. 
Assays of the effect of t-BHP on ROS production in HUVEC revealed a linear dose 
response within the ranges of 1.5625-50μM t-BHP as shown above.  This 
experiment was performed using 3 separate cell populations. Averages of 3 wells 
were used to generate SEM.  Using Microsoft Excel, calculated trendline formula is y 
= 846.64x + 44.7 x 103 with a correlation R2 value of 0.9968. The baseline 
fluorescence of greater than 40 x 103 arbitrary units may represent baseline cellular 
production of oxidative species. 
The use of a standard curve in this manner would help to compare between 
replicates and allow the use of equivalent amounts of oxidative stress to be induced 
by different pharmacological agents. 
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 The effect of antioxidants on preventing DETA-NO-induced increases in 4.3.1
generation of ROS in HUVEC 
The effect of DETA-NO on ROS generation was tested against the various 
antioxidants.  Experimental design was identical, using 3 separate cultures of early 
passage HUVEC and measuring peak fluorescence at 60 minutes.  
Using the calculated trendline from the dose response curve from t-BHP, the addition 
of DETA-NO 0.5mM increased ROS production to an equivalent of t-BHP 19.4μM.  
The addition of N-acetyl cysteine 4mM or uric acid 150μM significantly reduced 
measured ROS generation in control cells (Control vs NAC p=0.003, Control vs UA 
p=0.01, by two sample t-test) and in cells exposed to DETA-NO (DETA-NO vs 
DETA-NO + NAC p=0.03, DETA-NO vs DETA-NO + UA p=0.04).  No significant 
difference in ROS generation was observed in the panel of cells treated with 
selenomethionine 30μM. 
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Figure 4.3.1-1: Interaction between DETA-NO and selected antioxidants: ROS generation. 
Fluorescence after exposing the cultures to H2DCFDA. A: Interaction between DETA-NO and NAC. B: 
Interaction between DETA-NO and uric acid. C: Interaction between DETA-NO and 
selenomethionine. Error bars indicate standard error of the mean and callipers with asterisks indicate 
significant differences between conditions as analysed by t-test. Results of 3 separate populations of 
HUVEC exposed to DETA-NO and antioxidants. 
In order to ascertain if the effect was due to nitric oxide, rather than an effect of 
another product of the breakdown of DETA-NO, the experiment was repeated with 
GSNO.  GSNO was able to increase measured ROS production in a similar manner 
to DETA-NO.  The effect of NAC on the observed increase in ROS production was 
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also assessed.  This experiment was carried out using two separate cultures and 4 
wells per condition.  GSNO 1mM exerted a similar effect on the fluorogenic probe, 
suggesting equivalence with DETA-NO 0.5mM.  However, contrary to experiments 
performed using DETA-NO, the addition of N-acetyl cysteine increased this effect, 
reaching statistical significance. 
 
Figure 4.3.1-2: Comparison of the effect of nitric oxide donors and NAC on ROS generation. 
The above figure shows the results of 2 separate experiments using 2 populations of HUVEC 
exposed to DETA-NO 0.5mM, GSNO 1mM or GSNO 1mM with NAC 4mM. Analysis of ROS 
generation was performed using fluorimetry with the ROS probe H2DCFDA. Results are expressed as 
arbitrary units and error bars indicate standard error of the mean. Callipers indicate statistical 
comparison and asterisks indicate p<0.05 as analysed by t-test. NS = non-significant. 
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Figure 4.3.1-3: Interaction between GSNO and UA: ROS generation. 
The above figure shows the results of a single experiment using HUVEC analysed using 4 wells each. 
Cells were exposed to uric acid, GSNO 1mM or uric acid and GSNO 1mM and compared to control 
cells for their ability to generate ROS. ROS was measured by the fluorogenic probe H2DCFDA and 
detected using a fluorimeter. Error bars indicate standard error of the mean. Callipers indicate 
statistical comparison and asterisks indicate occasions where t-test analysis shows p<0.05. 
To investigate whether the observed increase in ROS production with GSNO and 
NAC was due to the presence of a glutathyl-containing antioxidant (NAC), the 
experiment was repeated using a non-glutathyl-containing antioxidant which was 
effective at reducing DETA-NO-induced ROS generation.  Uric acid interacted with 
GSNO in a similar manner to NAC, failing to prevent GSNO-induced ROS 
generation. The experiment was repeated on a single culture of HUVEC with 4 wells 
per condition.  GSNO (1mM) increased ROS production, measured by the 
fluorogenic probe H2DCFDA and uric acid was able to decrease the baseline 
measured ROS production in control cells.  However, uric acid was unable to reduce 
the ROS generated by GSNO and led to a small but statistically significant increase 
in ROS production by GSNO. 
The experiment was repeated with t-BHP as the source of ROS.  t-BHP was used at 
the concentration of 20μM in order to achieve the same magnitude of ROS 
production as seen in 500μM DETA-NO.  The addition of NAC was enough to 
reverse the effect of t-BHP on ROS production.  In fact, this was enough to reduce 
measured ROS production to below that seen in control cells. 
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Figure 4.3.1-4: Interaction between t-BHP and NAC: ROS generation. 
Assessment of the effect of ROS generation by t-BHP20µM and its reversibility by the antioxidant 
NAC. The experiment was performed on 2 separate occasions using 4 wells per condition and using 2 
separate populations of HUVEC. Error bars indicate standard error of the mean. Callipers indicate 
statistical comparison. Asterisks indicate statistical significance (p<0.05) as analysed by t-test. 
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I was unable to replicate the increase of ROS generation via eNOS activation with 
the calcium ionophore A23187.  The experiment was repeated in this way to assess 
whether endothelial cells were capable of producing sufficient nitric oxide to be 
detected using this model, assessing the physiological relevance of this series of 
experiments.  Data shown are from 2 separate cell populations and each condition 
was measured in 4 wells. 
 
Figure 4.3.1-5: Effect of the calcium ionophore, A23187 on ROS generation by HUVEC. 
The above figure shows the result of 2 separate experiments using 2 separate populations of HUVEC 
to assess the effect of A23187 1µM on ROS generation as measured by the fluorogenic probe 
H2DCFDA. Each condition was performed in 4 wells. Error bars indicate standard error of the mean. 
Callipers indicate statistical comparison. Asterisk indicates statistical significance (p<0.05) as 
analysed by t-test. 
In order to assess the ability of the stressors to oxidize the fluorogenic probe in the 
extracellular environment, the experiment was repeated by adding the probe to a 
solution containing the stressors in medium without cells.  The wells were not 
washed to clear the fluorogenic probe, unlike in experiments performed with cells.  
DETA-NO was able to oxidize the fluorogenic probe, as was NAC and uric acid.  
Selenomethionine had no effect.  Uric acid seemed to have an additive effect on 
DETA-NO. 
This experiment excluded the possibility that the observed reduction of fluorescence 
after exposure to the fluorogenic probe H2DCFDA seen in cells treated with NAC and 
uric acid could be due to probe leaking from the cells or failure of the washing stage 
to clear the outside of cells of fluorogenic probe prior to adding the various reagents 
for the experiment.  
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Figure 4.3.1-6: Assessment for interaction between reagents and fluorigenic probe H2DCFDA in cell-
free conditions. 
The figures above show the results of a single experiment performed using 4 wells per condition and 
comparing the ability of the reagents to generate fluorescence in the presence of the fluorogenic 
probe H2DCFDA but in the absence of cells. On this occasion, the probe was not washed after pre-
incubation, in contrast to experiments performed in the presence of cells. Error bars indicate standard 
error of the mean. Callipers indicate statistical comparison. Asterisks indicate statistical significance 
(p<0.05) as analysed by t-test. 
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The figures above show the effect of the experimental reagents on the fluorogenic 
probe in a cell-free environment.  There was a significant increase in fluorescence 
compared to control in all reagents except selenomethionine (SM) (Control vs DETA-
NO, p=0.001; Control vs NAC, p<0.001; Control vs UA, p<0.001).  The selected 
antioxidants increased or had no effect on fluorescence generated by DETA-NO 
(DETA-NO vs DETA-NO plus NAC, p=0.002; DETA-NO vs DETA-NO plus uric acid, 
p=0.005; DETA-NO vs DETA-NO plus selenomethionine p=NS).  All p values 
calculated using Microsoft Excel students unpaired 2-tailed t-test assuming unequal 
variance. 
Experimental reagents were also assessed for their ability to fluoresce without probe 
and universally had no effect on fluorescence in this range of light wavelength. 
4.4 Conclusion 
We started this chapter with the aim to demonstrate the effect of nitric oxide donors 
and the pro-oxidant tBHP on ROS generation in HUVEC. In concert, we investigated 
the interaction of these pro-oxidant drugs with antioxidants. 
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Figure 4.3.1-1: Schematic diagram of experimental results investigating the effect of oxidative and 
nitrosative stressors on generation of ROS. 
H2DCFDA requires a deacetylation to be activated and this occurs in cells. 
Therefore, the probe ought to be able to detect intracellular ROS. However, in my 
cell-free experiment, I saw an increase in fluorescence with DETA-NO. The amount 
of available H2DCFDA was much greater in this experimental set-up as there was no 
washing step and in addition, the interaction between DETA-NO and antioxidants 
was not consistent with experiments performed in the presence of HUVEC. 
Therefore it is likely that nitric oxide donors are able to increase ROS production in 
HUVEC.  This can be reversed in the case of DETA-NO by adding antioxidants NAC 
and UA.  However, this is not seen when the nitric oxide donor is GSNO.  At the 
concentration studied, GSNO was able to exert a similar magnitude of oxidation of 
H2DCFDA as seen with DETA-NO but this could not be prevented by either NAC or 
UA. 
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If nitric oxide was directly interacting with the fluorogenic probe, and NAC and UA 
were able to prevent this, the GSNO series of experiments raises a question as to 
whether GSNO interacted with H2DCFDA via an additional, second mechanism.  I 
had postulated that this may be by generation of the glutathyl radical, explaining why 
increasing the availability of glutathione by adding NAC would not reduce ROS 
generation.  However, UA was also unable to prevent GSNO increasing ROS 
generation. 
The lack of effect seen with selenomethionine suggests that the increase in ROS 
generated by DETA-NO was not mediated by peroxynitrite. 
Furthermore, NAC was able to reduce non-nitric oxide-induced ROS generation via 
its interaction with t-BHP.  Finally, NAC was not able to reduce the DETA-NO effect 
on the fluorogenic probe in a cell-free environment. 
The attempt to increase nitric oxide production via the addition of the calcium 
ionophore and eNOS activator, A23187 produced no observable effect and is 
disappointing when considering if the observed effect of DETA-NO on endothelial 
cells would be physiologically relevant. 
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5 The influence of nitric oxide on senescence in human vascular cells 
5.1 Introduction 
Nitric oxide is a reactive nitrogen species, capable of generating reactive oxygen 
species and an important signalling molecule in human vascular cells.  Reports have 
suggested that it may have an effect on senescence, or may be generated in 
phenotypically young endothelial cells and can therefore be associated with or may 
help maintain endothelial cells in their young phenotype. 
However, the cumulative effect of years of exposure to such a molecule which is 
able to diffuse freely throughout all cell compartments by crossing membranes 
without the need for permissive channel opening or transporters, may yet be 
deleterious.  Moreover, the role of nitric oxide as a toxic agent in inflammation, a 
process which when activated is able to generate higher concentrations of nitric 
oxide, may result in unintended spill-over and damage to healthy tissue. 
Finally, nitric oxide donors and nitric oxide itself are used in human medicine as 
systemic and pulmonary vasodilators and venodilators and thus any potential long-
term effects of high doses of nitric oxide on the vasculature are important to 
elucidate. 
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5.2 Aims 
Given previously published evidence that nitric oxide can exert an effect on cell 
senescence, I aimed to reproduce this in a reliable manner. Having achieved this, I 
planned to assess the range of concentrations of nitric oxide associated with 
changes in cell senescence. 
If nitric oxide is able to influence senescence, we will explore the mechanism 
responsible by looking at pharmacological manipulation of targets of nitric oxide, 
reducing the effect of nitric oxide in generating reactive oxygen and nitrogen species 
and by assessing the effect of antioxidants and peroxynitrite scavengers. In addition, 
we will assess the effect of cold light, a factor known to reduce protein 
transnitrosation. 
Where an effect was observed, multiple methods were used to confirm and to 
measure senescence. The mechanism by which senescence was achieved or 
prevented would then be assessed. 
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5.3 The influence of nitric oxide on senescence 
 Effect of DETA-NO on HUVEC senescence 5.3.1
We investigated the effect of nitric oxide on HUVEC by treating cells with the nitric 
oxide donor DETA-NO.  This compound generates a steady concentration of nitric 
oxide which is maintained over a period of several hours.  Cells were grown to 
confluence and then DETA-NO was added to cell culture by daily change of medium 
during three consecutive days.  Cells were disassociated using trypsin/EDTA and 
were analysed in the Coulter particle analyser for number and diameter.  Cells were 
then replated at the same density and grown for a further 3-4 days in normal medium 
only.  Prior attempts to expose cells to concentrations of nitric oxide during the 
exponential growth phase led to growth arrest and cells were too sparse for analysis.  
Cells exposed to 0.01mM or 0.1mM DETA-NO showed no discernible change from 
control but doses of 0.5mM produced a significant increase in cell diameter. 
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Figure 5.3.1-1: Effect of DETA-NO on cell diameter. 
Effect of varying doses of DETA-NO on cell diameter measured by particle analyser. The upper graph 
(A) is the mean of 5 identical populations of cells and the lower graph (B) is the mean of 4 
experiments. Error bars indicate standard error of the mean. Callipers indicate statistical comparison 
using t-test where the result was statistically-significant (p<0.05). 
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The experiment was repeated following the same culture protocol and then cells 
were analysed for total -galactosidase activity by flow cytometry using the C12FDG 
fluorogenic probe.  
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Figure 5.3.1-2: Dose response for the effect of DETA-NO on β-galactosidase activity. 
Cells were treated with various concentrations of DETA-NO as indicated in the main text and β-
galactosidase activity was measured by flow cytometry. Panel A shows an overlay histogram from a 
representative experiment. Panel B shows the relative fluorescence expressed as a percentage of the 
values measured in untreated cells. Results represent the mean ±SEM of 3 separate experiments 
The overlay histogram in panel A (above) shows the un-gated result obtained from a 
representative experiment.  The X-axis is the FL1-H channel which denotes 
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fluorescence post C12FDG exposure in this case and the Y-axis is related to the 
number of events counted by the cytometer.  There is little difference between the 
cells in the control group and the cells treated with lower doses of DETA-NO.  
However, there is a clear shift to the right in cells treated with 0.5mM DETA-NO.  
The shift in those cells is generalised, rather than there being a new separate sub-
population, distinct from the baseline control group.  This generalised increase in 
fluorescence post C12FDG exposure is consistent with either there being a cell 
phenotype between healthy and senescent or, more likely, that senescence starts 
with a fundamental change in cellular physiology with irreversible cell cycle arrest, 
followed by the accumulation of β-galactosidase which increases gradually until a 
new equilibrium is met.  Non-stained samples were performed on each occasion to 
confirm that the shift was not due to an increase in the intrinsic fluorescence of the 
cells.  Samples were gated to exclude cell debris and analysed using geographic 
mean.  Results were analysed for statistical significance using Microsoft Excel two-
tailed t-test assuming unequal variance. 
There was no significant decrease in fluorescence post C12FDG exposure between 
control and DETA-NO 0.01mM or 0.1mM treated cells (mean fluorescence 0.01mM 
92% of control, p=0.21; 0.1mM 103.6% of control, p=0.13, by two sample t-test).  
There was a large, significant increase in fluorescence post C12FDG exposure 
between control and DETA-NO 0.5mM treated cells (mean fluorescence 233.6% of 
control, p=0.007). 
In a separate experiment using the same technique of exposing cells to DETA-NO 
0.5mM, cells were treated with C12FDG and then washed in PBS and photographed.  
On the following page are fluorescence and light micrographs of HUVEC from the 
same donor.  Cells treated with DETA-NO failed to recover their replicative ability 
and there was an increased fluorescence intensity of the fluorogenic product of the 
-galactosidase reaction with C12FDG.  Cells treated with DETA-NO also had a 
larger diameter, consistent with previous experiments.  
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Figure 5.3.1-3: Micrographs of fluorescence post C12FDG exposure: DETA-NO. 
Light and fluorescent micrographs of cells stained with C12FDG and later excited with UV light to 
demonstrate the fluorescent-labelled product of the reaction between C12FDG and β-galactosidase. 
Both groups of cells were harvested and replated at the same density in normal medium without 
DETA-NO.  Cells were photographed 3 days after replating. Merged pictures are shown for illustration 
and were created using Photoshop CS.  Background was removed from both images using the same 
adjustment (input 84, 1.00, 255) and the overlaid fluorescent image was adjusted to 50% opacity. 
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 Assessing nitric oxide-mediated HUVEC and HUASMC senescence by 5.3.2
senescence-associated -galactosidase 
The photomicrographs below show the effect of nitric oxide donors on the 
appearance of senescent cells as detected by staining for senescence-associated β-
galactosidase. In this case nuclear red staining was used to contrast the blue β-
galactosidase staining with a red DNA stain for ease of visualisation. 
 
Figure 5.3.2-1: Comparison of the effect of nitric oxide donors on senescence-associated β-
galactosidase. 
3rd passage HUVEC were exposed to DETA-NO or GSNO on 3 consecutive daily changes of 
medium, rested for 2 days, then stained for senescence-associated β-galactosidase activity and 
counterstained with nuclear red solution to identify the nuclei. Photographs were taken under the 
same magnification and images were processed with the Windows Live Photo Gallery application 
(Microsoft Corporation) using an auto-adjust filter on all 4 panels simultaneously to ensure the same 
adjustment. 
Consistent with the induction of senescence, cultures treated with high 
concentrations of nitric oxide donors show the presence of flat, enlarged and 
intensely blue-stained cells. In contrast cells treated with a low concentration of nitric 
oxide show a normal morphology and no or faint β-galactosidase staining.    The 
presence of these lightly stained β-galactosidase positive cells may either be 
stressed or senescent. This illustrates the difficulty in discerning between senescent 
and non-senescent cells when counting cells by visual inspection. 
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In order to assess whether the observed effect of nitric oxide donors on senescence-
associated β-galactosidase could occur in other cells types, HUASMC were grown 
from explant and passaged twice before exposure to various doses of DETA-NO on 
exchange of medium every 2 days and stained after 7 days of this regime followed 
by microscopic examination. 
At the end of the exposure period, cells were stained for senescence-associated β-
galactosidase. 
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Figure 5.3.2-2: Dose-response for the effect of DETA-NO on the induction of senescence in cultures 
of HUASMC. 
Cells were treated with various concentrations of DETA-NO as indicated in the main text and β-
galactosidase activity was measured by cytochemistry using X-gal. Results represent the percentages 
of positively-stained cells (mean ± SEM of 4 replicate wells for each concentration of DETA-NO and 8 
replicate wells for the control group).  
4 separate fields of view were counted using phase contrast light microscopy at 20 x 
magnification from 4 wells of each condition (except control where 8 wells were 
used). The figure above shows that at relatively low concentrations (1-50μM), DETA-
NO did not increase the percentage of senescent cells beyond that present in 
untreated control cells. In contrast at 0.1mM DETA-NO caused a significant increase 
in the percentage of senescent cells (10.2±1.4, p=0.05). The small decrease in the 
percentage of senescent cells seen with 0.01mM DETA-NO was not statistically 
significant, (p=0.5). 
Thus it appears that both HUVEC and HUASMC are prone to DETA-NO-induced 
increases in β-galactosidase activity. There also appears to be a greater sensitivity 
on the art of HUASMC. As previously discussed in section 1.3.3.4, this may be due 
to the presence of eNOS in HUVEC protecting against the effect of exogenous nitric 
oxide. 
 Senescence vs. apoptosis 5.3.3
The processes of senescence and apoptosis may be linked as they share signalling 
pathways. We investigated whether cells exposed to DETA-NO may have been 
preparing to undergo apoptosis via senescence.  We added to the flow cytometry 
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method of assessing β-galactosidase activity by using additional fluorogenic probes 
for cell membrane markers of apoptosis (Annexin-V) and DNA staining (7-AAD), 
providing simultaneous assessments of cells for all 3 variables. 
Cells were grown to confluence and treated 3 times for 3 consecutive days with 
DETA-NO 0.5mM in EGM-2 or EGM-2 alone.  Following treatment, cells were rested 
in normal medium for 2 days, trypsinized and replated for final collection 3 days later.  
Cells were incubated with C12FDG for 4 hours and then trypsinized and further 
incubated with either the DNA stain 7-AAD or Annexin-V-PE for 15 mins according to 
the manufacturer’s protocol.  Samples were placed on ice until analysis with a BD 
Facscalibur.  Results are shown in the figure below. 
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Figure 5.3.3-1: Effect of DETA-NO on senescence and apoptosis. 
Cells were treated with DETA-NO as described in the text and then analysed by flow cytometry for 
simultaneous detection of senescence and apoptosis. C12FDG is detected using the FL-1 channel, 
PE by FL-2 and 7-AAD by FL-4.   Results from a representative experiment depicting the analysis of 
control cells (top panels) and DETA-NO treated cells (bottom panels) are shown. The dot plots on the 
left side show the distribution of apoptotic and non-apoptotic cells; quadrant boundaries were set with 
reference to a parallel unstained sample The histograms on the right side correspond to the events 
gated in the respective right (red dots) and left (black dots) quadrants.  
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The figure on the previous page represents the results of a single pilot experiment to 
assess whether cells exhibiting a higher activity of β-galactosidase were also 
undergoing senescence. Red histogram plots represent cells exhibiting high Annexin 
V fluorescence whereas black plots are Annexin V negative.  There is a small overall 
increase in apoptosis of the cells treated with DETA-NO. However, the cells which 
have an increased amount of β-galactosidase are less likely to display features of 
apoptosis. Of particular note, the Annexin V negative population in both cell samples 
contain all the high fluorescence C12FDG senescent population of cells but fewer 
apoptotic cells as measured by cell surface Annexin-V.  
 Assessing nitric oxide-mediated HUVEC senescence by cell cycle protein 5.3.4
expression 
Cells were grown to confluence and then treated 3 times for 3 consecutive days with 
DETA-NO in EGM-2 or EGM-2 alone.  Following treatment, cells were rested in 
normal medium for 2 days, trypsinized and replated for final collection 4 days later.  
Cells were lyzed and sonicated and loaded onto SDS-PAGE gel using equal 
amounts of protein within experiments.  Finally, following transfer onto membrane, 
cells were probed with antibodies against p16INK4a, p21WAF and α tubulin or actin as 
loading controls.   
  
120 
 
 
 
 
Figure 5.3.4-1:  DETA-NO increases the expression of cyclin-dependent kinase inhibitors.  
Western blot analysis of p16
INK4a
 and p21
WAF
 protein expression in control and DETA-NO-treated 
HUVEC. A representative immunoblot is shown on the top panel (A) and densitometric quantification 
is shown on the bottom panel (B). Results in the bottom panel represent the mean ± SEM of 4 
determinations for p21
WAF
 and 5 determinations for p16
 INK4a,
 each from a different donor.  Relative 
protein levels were calculated as the ratio of the intensity of the indicated bands to the intensity of the 
corresponding tubulin bands which were used as a loading control.  Results are shown relative to 
control. 
Densitometry was performed after scanning films from each experiment using 
AlphaEase software and the area of each band was used for the final calculation.  
Results confirmed a significant increase in p16INK4a 2 times over control (p=0.001 by 
2-sample t-test and of 1.5 times for p21WAF (p=0.001 by 2-sample t-test).   
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 Assessing nitric oxide-mediated HUVEC senescence by measuring cell cycle 5.3.5
arrest 
Senescence is a form of growth arrest but it is not the only form of growth arrest. Our 
cells were treated in a confluent state. We wished to assess if the cells were simply 
quiescent or irreversibly in a state of growth arrest. Therefore, in order to assess if 
the increase in -galactosidase activity seen in DETA-NO-treated cells represented 
cell cycle arrest, and not a transient increase in enzymatic activity, we assessed cells 
for BrDU incorporation after the usual rest period. 
Cells were grown to confluence and then treated with DETA-NO as described 
previously.  Following a 2 day rest period, cells were replated and finally harvested 
after 3 days. 
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Figure 5.3.5-1: BrDU incorporation by cells exposed to DETA-NO vs. control. 
Data were analysed in two forms. The top graph (A) shows total BrDU incorporation per well vs. the 
original plating density. The lower graph (B) shows the BrDU incorporation per cell vs. original plating 
density. DETA-NO dose was 0.5mM. Error bars in the upper graph indicate standard error of the 
mean. 
An ELISA-based BrDU incorporation assay was carried out to assess proliferative 
activity and results are shown above.  Cells were counted using the Coulter particle 
analyser to equalise the number of cells being analysed and several cell densities 
were used.  Cells of same conditions and densities were plated in 4 replicates in a 
96 well plate and analysed using a Spectramax plate reader every 5 minutes for 30 
minutes in total.  The calculations were based on the area under the curve of BrDU-
induced colorimetric increase in the reagent.   
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The lower BrDU incorporation seen at the highest cell density is likely to represent 
contact inhibition.  There is a clear difference in BrDU incorporation in cells 
previously treated with DETA-NO, when compared to those in the control group.  
This is despite a remote exposure to DETA-NO as the last exposure was 1 week 
prior to analysis.  Using 104 cells per well as a representative result for analysis, 
average BrDU incorporation was  794.2AU in the control group and 251.7AU in the 
DETA-NO treated group, p=0.02 with 2 tail paired t-test assuming unequal variance. 
Analysis of the whole sample set by two-factor ANOVA confirmed this, p=0.0001. 
 Coculture of HUVEC with tet-iNOS HEK 293 5.3.6
The effect of high concentrations of nitric oxide released by DETA-NO or GSNO on 
endothelial cells in vitro may of course be of no physiological significance if cells are 
never exposed to such high concentrations in vivo.  The hypothesis that this may 
occur during periods of inflammatory or infective stress and that iNOS-generated 
nitric oxide concentrations could be sufficient to induce the effects seen in vitro was 
investigated using a co-culture technique with a human embryonic kidney cell line 
(HEK-293) which was transfected with a tetracycline-inducible iNOS gene sequence. 
The cell line expressed iNOS in a dose-dependent manner, according to the 
concentration of tetracycline used to induce iNOS production.198 
 
Figure 5.3.6-1: Confirmation of nitric oxide production after tetracycline-induction of iNOS. 
Cells were exposed to tetracycline as described. Nitrite was measured by Griess reaction (data 
courtesy of M. Quintero, WIBR, UCL). 
HUVEC were grown in 6 well plates to confluence.  iNOS-HEK-293 cells were grown 
in Transwell inserts in separate 6 well plates.  The Transwell has a porous 
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membrane which is small enough to avoid any cell escape but allows free diffusion 
of liquids in both directions.  iNOS-HEK-293 cells were then induced to express 
iNOS by exposure to tetracycline and, after washing, were placed in the wells 
containing HUVEC and left in close contact co-culture for 3 days.  Thereafter, 
medium was changed and the iNOS-HEK-293 Transwells were removed and 
discarded.  Two days later, the HUVEC were replated in T-25 flasks and grown for 3 
days before final analysis by flow cytometry. 
 
Figure 5.3.6-2: β-galactosidase activity of coculture of HUVEC with iNOS-expressing HEK-293. 
Cells were exposed to 0.5mM DETA-NO or to cells induced to express iNOS after washing away the 
tetracycline inducer. “Tet xmg/mL iNOS” denotes the concentration of the dose of tetracycline used to 
induce iNOS expression in tetracycline-inducible, iNOS expressing HEK-293 cells. HUVEC were 
analysed for total β-galactosidase activity by flow cytometry. Results represent the 2 separate 
experiments using 2 separate populations of HUVEC and are shown as arbitrary units of fluorescence 
post C12FDG exposure.  
The figure above shows that as in previous experiments, there was a demonstrable 
increase in fluorescence (FDG) in the DETA-NO treated groups, but there was no 
increase in the fluorescent intensity in the tetracycline-induced iNOS HEK-293 
exposed HUVEC.  Despite the trend to a small decrease in FDG activity, statistical 
analysis by single-factor ANOVA gave a non-significant result (p=0.76). 
Thus, this attempt to establish physiological relevance was unsuccessful.  This may 
have been due to the inability provide cell to cell contact, or a sufficient proximity 
between the cells as may occur in vivo. 
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5.4 Assessing the potential mechanisms of nitric oxide-mediated HUVEC 
senescence 
 Soluble guanylate cyclase inhibition 5.4.1
Soluble guanylate cyclase acts as a receptor for nitric oxide and mediates many of 
its physiological effects.  We investigated whether this was the mediator of the nitric 
oxide senescence effect by antagonizing its action using ODQ during exposure to 
DETA-NO. 
The experiment was performed with a control group and either ODQ 0.3μM, DETA-
NO 0.5mM or both ODQ and DETA-NO to a HUVEC population to assess the 
magnitude of soluble guanylate cyclase-mediated effects.  Cells were analysed for 
size using a Coulter particle analyser.  The figure below shows that there was a 
DETA-NO-induced increase in cell diameter even in the presence of ODQ compared 
to ODQ alone.  The effect of DETA-NO was not significantly attenuated by the 
addition of ODQ to DETA-NO treated cells (two-tailed student’s t-test p=0.113).  
There was no significant change in cell diameter induced by ODQ vs. the control 
group (p=0.144). 
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Figure 5.4.1-1: Effect of inhibiting soluble guanylate cyclase on the increase in cell diameter 
measured by particle analyser seen on exposure of HUVEC to DETA-NO.  
Results represent the mean of five separate experiments with 5 separate populations of HUVEC. Cell 
diameter in µm is shown and error bars indicate standard error of the mean. Callipers indicate 
statistical comparison using t-test and asterisks indicate p<0.05. ODQ indicates cells exposed to ODQ 
0.3µM, DETA-NO dose was 0.5mM and DETA-NO ODQ indicates ODQ 0.3µM and DETA-NO 
0.5mM. 
Cells were replated for a further 3 days in order to allow exponential growth to be re-
established.  Cells were then treated with C12FDG and disassociated using 
trypsin/EDTA and transferred to FACS-compatible polystyrene tubes for FACS 
analysis.  The next page contains a typical example of the results obtained. 
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Figure 5.4.1-2: Effect of soluble guanylate cyclase inhibition on the induction of senescence by DETA-
NO. 
Cells were treated as described in the previous figure and then exposed to C12FDG prior to flow 
cytometric analysis. Panel A is a representative density plot of fluorescence post C12FDG exposure 
plotted against side scatter. Panel B shows the mean results of the effect of interventions to prevent 
the effect of DETA-NO on total β-galactosidase activity.  Each experiment was carried out in triplicate 
on cells from three different donors.  DETA-NO dose was 0.5mM, ODQ 0.3μM and NAC 4mM. Mean 
fluorescence intensity is expressed in arbitrary units. Error bars indicate standard error of the mean. 
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Panel A in the previous page contains density plots which demonstrate analysis of 
the FL-1 channel vs. side scatter with cells treated with DETA-NO 0.5mM, ODQ 
0.3µM, neither or both for 1 week and subsequently replated for 3-4 days. 
Fluorescence in the figure denotes the FL-1 channel which is used to detect the 
fluorescent product of the C12FDG interaction with β-galactosidase. Side scatter is a 
marker of cell size. 
In panel B, the cells exhibit a higher overall fluorescence and side scatter.  This 
effect was not significantly affected by ODQ 0.3μM (p=0.93) or ODQ 1.0μM (p=0.21) 
(Data not shown for ODQ 1.0μM).  There was no significant interaction between 
ODQ and DETA-NO for either dose (p=0.79 for 0.3μM, p=0.6 for 1μM). 
 Antioxidants and DETA-NO 5.4.2
 Selenomethionine 5.4.2.1
Selenomethionine (SM) is a selenium containing amino acid with peroxynitrite-
scavenging abilities.  The rate constant for selenomethionine interception of 
peroxynitrite is 2.4 x 103 M-1s-1, compared to glutathione 5.8 x 102 M-1s-1 and 
glutathione peroxidase 8 x 106 M-1s-1.  Peroxynitrite reacts directly with SM.  
Furthermore, SM can also be substituted for methionine in proteins and this may act 
as a source of peroxynitrite scavenging.  SM reduces oxidation of the probe 
Dihydrorhodamine-123, a compound which reacts with both reactive nitrogen and 
oxygen species.199;200  SM also confers a protective effect on lung cancer cells 
exposed to UV radiation by activating the tumour suppressor p53 and specifically 
activated the DNA repair mechanism mediated by p53 without itself causing DNA 
damage.201 Therefore we investigated the effects of SM on our model. 
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Figure 5.4.2-1: Effect of selenomethionine on the induction of senescence by DETA-NO. 
Interaction between selenomethionine and DETA-NO on cell diameter (A), total β-galactosidase 
activity (B) and ROS activity (C). The ROS data were shown in the previous chapter but are repeated 
in this figure for comparison. Drug concentrations were: DETA-NO 0.5mM, SM 30µM. All units are 
expressed in arbitrary units and error bars indicate standard error of the mean. 
The figure above shows the results of experiments to compare cell diameter, β-
galactosidase activity and ROS generation in HUVEC exposed to DETA-NO and the 
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effect of adding selenomethionine 30µM to the system.  There was a small but 
statistically insignificant increase in cell diameter in cells treated with SM (16.67μm 
vs. 17.43μm, n=3, p=0.49 (2-way ANOVA) and there was no significant interaction 
between DETA-NO and SM (p=0.3). SM had no significant difference in ROS 
production either basally or in conjunction with DETA-NO.  Moreover, the increase in 
cell size was not as a consequence of -galactosidase activity as measured using 
the C12FDG fluorogenic probe as total -galactosidase activity was unchanged in 
both untreated cells and those concurrently treated with DETA-NO. 
 
Figure 5.4.2-2: Correlation between cell diameter and total β-galactosidase activity in SM treated 
cells. 
The above figure includes individual data points comparing cell diameter with subsequent total β-
galactosidase activity measured by flow cytometry of FDG treated cells. Unfilled circles are from the 
control group, dark circles are from the group treated with SM 30μM. Fluorescence activity is 
expressed in arbitrary units. 
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 Uric acid 5.4.2.2
Uric acid has a biphasic action on ROS scavenging.  At low concentration, it is 
mainly a peroxynitrite scavenger.  At physiological concentrations, it is also a 
hydroxyl radical scavenger.  The above experiment was conducted to investigate the 
effect of a concentration of uric acid which is in the low normal range for adult 
humans in health and a concentration known to permit hydroxyl and peroxynitrite 
scavenging (150mM).  
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Figure 5.4.2-3: Effect of uric acid on the induction of senescence by DETA-NO. 
The ROS data were shown in the previous chapter but are repeated here for comparison. Drug 
concentrations were DETA-NO 0.5mM and UA 150mM. AU represents arbitrary units and error bars 
indicate standard error of the mean. (A) shows cell diameter, (B) β-galactosidase activity and (C) ROS 
activity. 
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The figure on the previous page shows the results of experiments to compare ROS 
generation and β-galactosidase activity in HUVEC exposed to DETA-NO and the 
effect of adding UA to the system. Cells were grown to confluence and treated with 
DETA-NO 0.5mM, uric acid (UA) 150mM, or UA and DETA-NO.  Cells being 
analysed for ROS activity were incubated with reagents and probe and analysed in 
situ in 96 well plates.  The experiment was repeated 3 times.  ROS activity was 
measured using the H2DCFDA probe and a Victor automated plate reader.  Results 
were analysed using the Microsoft Excel 2-sample t-test assuming unequal variance 
and results are for 2-tailed analysis.  The results show a modest decrease in ROS 
activity between control and uric acid-treated cells (Mean fluorescence (AU) control 
42945.5 vs. UA 36420.7; p=0.02).  Moreover, the DETA-NO treated cells exhibited a 
marked increase in ROS activity but this was not prevented by the addition of UA 
(Mean fluorescence (AU) DETA-NO 61147.5 vs. DETA-NO plus UA 49077.8; 
p=0.08).  Comparing control to DETA-NO plus UA, there remained an increase in 
fluorescence in the DETA-NO plus UA group which did not reach statistical 
significance (p=0.11). 
The experiment was repeated using a longer exposure to reagents for 1 week with 
changes of medium every 2 days.  Cells were rested for 2 further days without 
reagents and harvested, replated for 3 days without reagents and then analysed 
using flow cytometry for -galactosidase activity using the C12FDG fluorogenic probe.  
Results were analysed using the Microsoft Excel 2-sample t-test assuming unequal 
variance and results are for 2-tailed analysis.  In this case, there was no decrease in 
fluorescence post C12FDG exposure between control and UA treated cells (mean 
fluorescence in control cells (AU) 301.4, UA treated cells 308.4, p=0.79).  However, 
there was a marked increase in activity when comparing the DETA-NO-treated cells 
and those treated with DETA-NO and UA (mean fluorescence DETA-NO treated 
cells (AU) 456.2, DETA-NO plus UA treated cells 582.4, p=0.02). Therefore in the 
presence of DETA-NO, uric acid exerts an additive effect on fluorescence post 
C12FDG exposure, despite reducing the generation of reactive oxygen species when 
measured by fluorescence after exposure to H2DCFDA. 
As previously stated, this may be because peroxynitrite generation has been 
effectively countered but that the hydroxyl radical continues to exert an effect which 
may be more powerful in promoting senescence.  Alternatively, DETA-NO and UA 
may interact to produce a more senescence-inducing compound which is not itself a 
reactive oxygen species. 
This could be investigated by looking into the effect of hydroxyl radical generating 
compounds on the system and this is described later with experiments involving the 
exposure of the system to tert-butyl hydrogen peroxide. 
However, in conclusion the senescence promoting effect of DETA-NO on our model 
does not seem to be due to peroxynitrite or a general increase in reactive oxygen 
species. 
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 DETA-NO and NAC 5.4.3
As discussed in the previous chapter, NAC prevented the generation of ROS in 
HUVEC exposed to nitric oxide. I therefore investigated whether it had an effect on 
HUVEC senescence as measured by β-galactosidase. 
 
Figure 5.4.3-1: Effect of NAC on the induction of senescence by DETA-NO. 
Results represent the mean of 3 experiments assessing HUVEC β-galactosidase activity by flow 
cytometry. The doses of reagents were DETA-NO 0.5mM, NAC 4mM. Geographical mean fluorescent 
intensity was calculated after gating to exclude cell debris. Error bars represent standard error of the 
mean.   
HUVEC were grown to confluence and then exposed to DETA-NO 0.5mM, NAC 
4mM or both on 3 consecutive days with change of medium. Thereafter, reagents 
were removed by replacing with medium for 2 days’ rest.  Cells were replated at 
7500 cells/cm2 and finally harvested for analysis using the fluorogenic probe C12FDG 
and flow cytometry to assess -galactosidase activity.  As before, there was a large 
increase in fluorescence post C12FDG exposure in the group of cells treated with 
DETA-NO. However, in contrast to previous experiments, NAC was effective in 
abolishing this effect. Furthermore, NAC alone was not able to reduce fluorescence 
post C12FDG exposure lower than that seen in control cells. 
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 Nitric oxide release from DETA-NO with NAC 5.4.4
 
Figure 5.4.4-1: Effect of NAC on the generation of nitric oxide from DETA-NO. 
Digital output of nitric oxide electrode measurement of nitric oxide generated by DETA-NO 0.5mM, 
before and after addition of NAC 4mM. y-axis represents nitric oxide concentration (nM). 
In order to assess the direct chemical effect of NAC on DETA-NO in a cell-free 
environment, DETA-NO was added to a buffer solution and allowed to approach 
equilibrium, while measuring nitric oxide.  After nearing plateau, NAC 4mM was 
added and there was an immediate drop in the measured nitric oxide concentration. 
One possibility as to this observed drop was that nitric oxide release was countered 
by NAC by creating a nitrosothiol adduct. Therefore the cell based experiment was 
repeated with GSNO. 
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Figure 5.4.4-2: Comparison between the effects of DETA-NO and GSNO on the induction of 
senescence: GSNO, DETA-NO and NAC. 
The graph shows the result of a single experiment carried out on HUVEC to assess the effect of 
GSNO as the nitric oxide donor on total β-galactosidase activity. Concentrations were GSNO 1mM, 
DETA-NO 0.5mM, NAC 4mM.  Y-axis values represent arbitrary units of geographical mean 
fluorescence of FDG. 
GSNO was also seen to increase the level of fluorescence post C12FDG exposure, in 
a similar fashion to DETA-NO.  Thus NAC reduces the available nitric oxide from 
DETA-NO and it is likely, given the effects seen with GSNO, that if this is due to the 
formation of intermediate nitrosothiols in the cell medium, that they do not 
themselves exert any influence on fluorescence post C12FDG exposure.  It is also 
likely that NAC is not exerting an intracellular effect but rather is preventing the 
senescence-inducing concentration of nitric oxide from being reached. 
 Cold light with DETA-NO 5.4.5
In order to assess whether the effect of DETA-NO on HUVEC β-galactosidase 
activity was due to protein transnitrosation, the experiment was repeated with cells 
exposed to DETA-NO and/or exposure to cold light. 
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Figure 5.4.5-1: Effect of cold light on the induction of senescence by DETA-NO.  
The figure represents data from 3 separate experiments carried out on different populations of 
HUVEC. Y-axis values represent arbitrary units of geographic mean fluorescence after exposure to 
FDG. Empty bars indicate cold light-treated cells. Error bars indicate standard error of the mean.  
HUVEC were grown in EGM-2 to confluence in T-25 flasks.  Thereafter, flasks were 
covered with aluminium foil which had its inner surface coated with black marker ink 
to absorb light. The outer surface was left clean in order to reflect light and reduce 
any conductive heat gain.  Flasks containing cells in the light treatment regime were 
not covered.  The incubator outer door was left open and covered with aluminium 
foil, except for a window to allow the concentrated cold light to enter.  A cold light 
source was used to avoid heating the cells.  Flasks were placed in a box lined with 
aluminium foil to maximise reflection.  A cold light source was then placed at the 
windowed inner door of the incubator and, using a mains electricity timer, was 
programmed to deliver the light treatment for 60 minute periods twice daily at 6 
hourly intervals.  The light intensity emitted by the source was approximately 8Mlx.  
Medium was changed daily for 3 days, along with reagents (DETA-NO).  After this 
period, cells were rested for 2 days and replated at 7500 cells/cm2 for 3 days, before 
harvest and analysis for C12FDG using flow cytometry and Western blotting.  Initial 
attempts to replate immediately led to a high rate of cell death. 
There was no difference between control cells exposed to light or kept in dark 
conditions.  There was a significant increase in fluorescence post C12FDG exposure 
in the DETA-NO treated group when compared to control, light-treated control and 
light-treated DETA-NO exposed cells.  Mean fluorescence of control was 230.2, light 
treated control was 227.9, DETA-NOdark was 364.1 and DETA-NOlight was 264.3.  
Paired t-test (2-tail assuming unequal variances) were performed on controldark vs. 
controllight, p=0.98; control vs. DETA-NOdark, p=0.004; DETA-NOdark vs. DETA-NOlight, 
p=0.006. 
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While GSNO and sodium nitroprusside are both known to be photolabile, this 
property has not been described in DETA-NO. 
Light therefore is able to prevent and reverse DETA-NO-induced increases in 
fluorescence post C12FDG exposure in this model of stress-induced senescence.  
The mechanism may be a direct effect on the cells, but no effect was seen in the 
control group.  Secondly, there may be a nitric oxide-quenching effect, preventing 
the concentration of nitric oxide from increasing as it is released from DETA-NO.  
However, this has not been reported in the literature. 
Nitric oxide concentrations have been measured to increase when cells exposed to 
angiotensin II stress are then treated with agents (for example, N-acetyl cysteine) 
which cleave the cysteine nitroso bonds to denitrosate transnitrosated proteins.121 
Therefore, a feasible explanation is that transnitrosation of a protein intimately 
associated with the senescence process promotes senescence and that, when it is 
exposed to a cold light source, the de-nitrosation of this molecule is able to abort the 
senescence process. 
In order to assess whether transnitrosation was responsible for the observed 
increase in senescence of cells exposed to DETA-NO, a modified biotin switch 
technique was used to assess general protein transnitrosation.202;203  Cells were 
treated with DETA-NO and exposed to cold light in the same way as described 
above. 
Thereafter, the cells were lysed and exposed to the metal chelator neocuproine in 
order to facilitate the later reduction phase by ascorbic acid (which is inhibited by 
transition metal-catalysed reactions).  Any free thiol/cysteine residues were then 
blocked using methyl methanethiosulfonate (MMTS).  Thus all thiol residues were 
presumed to be either transnitrosated or irreversibly blocked by MMTS.  Lysates 
were then exposed to the reducing agent, ascorbic acid.  This would have the effect 
of detransnitrosating the previously transnitrosated thiol residues and primed them 
for labelling with a biotin-labelled reactive disulphide which readily reacts with free 
thiol residues biotin-hexyl-pyridyldithiopropionamide (biotin-HPDP).  The final stages 
involved protein assays using the Bradford method, to allow an even protein loading 
and finally protein electrophoresis and staining with an avidin-labelled peroxidase. 
Experiments were run with non-labelled samples and non-reduced samples in order 
to compare with the fully reduced and labelled lysates.  The comparative difference 
between reduced and non-reduced lysate staining would be the degree to which cell 
proteins were originally transnitrosated. 
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Figure 5.4.5-2: Identification of transnitrosated proteins by the biotin switch method.  
Digital photograph of a film of a biotin switch experiment. Left-hand lanes indicate non-specific 
labelling by biotin. Central lanes are where, after reduction by ascorbate, the biotin labelling indicates 
transnitrosated proteins. The horizontal bars indicate the position of molecular weight markers with 
the respective sizes expressed in kDa. 
All groups in the experiment exhibited an increase in labelling between the non-
reduced (Biotin) and reduced (Biotin plus ascorbate) samples, indicating a degree of 
transnitrosation at baseline in all groups.  However, the degree of transnitrosation 
was not clearly different between the DETA-NO-treated sample and the DETA-NO 
and cold light-treated sample.  If anything, there seemed to be a greater increase in 
staining between biotin and biotin plus ascorbic acid groups in the light treated 
samples with or without DETA-NO than in the groups treated in dark conditions.  
This is directly contradictory to the idea that generalised transnitrosation is involved 
in the senescence process.  However, the technique supports the assumption that 
there is little in the way of nitric oxide quenching by light as transnitrosation appears 
to occur in all groups.  Furthermore, this method only shows a general view of 
transnitrosation and cannot discern the degree to which any protein involved in the 
senescence signalling process has been affected specifically by transnitrosation. 
 Transnitrosation band analysis 5.4.6
We performed a further analysis of the gel. Using Alphaease software, we were able 
to select the mid portions of the bands and analyse the density digitally. This was 
combined by using the molecular weight markers to create a formula to calculate the 
molecular weight of each band. We then subtracted the difference in intensity seen 
in the ascorbic acid group from the ascorbic acid and biotin-labelled cysteine residue 
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group to arrive at a graph demonstrating the maximum differences between non-
specific labelling and labelling due to transnitrosation. 
The figure below shows the results of that calculation. Looking at the biggest peaks 
of difference between transnitrosated and non-transnitrosated proteins, where bands 
were found in all 4 conditions, there were 4 bands. The predicted molecular weights 
of these proteins were 16.2kDa, 24.4kDa, 33kDa and 64.4kDa. Two proteins of this 
molecular weight have already been mentioned in the introduction of this manuscript 
– p65 and p66shc. 
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Figure 5.4.6-1: Specific band analysis of biotin switch. 
The above graph shows the result of band analysis of the experiment to assess protein 
transnitrosation. Unfilled symbols indicate data from cells exposed to light, circles indicate cells 
exposed to DETA-NO 0.5mM. Data are expressed in thousands of arbitrary units which are calculated 
by subtracting band intensity from cells without biotin labelling from those which were labelled in this 
way.  
Studies of transnitrosation of p65, in the context of inducing iNOS by exposing cells 
to lipopolysaccharide have shown increases in transnitrosation of NF-κB on the p65 
subunit being associated with a reduction in NF-κB function.204;205 
No such data was found for p16INK4a. The reason for its increase in apparent 
transnitrosation as detected by this method is not clear. This may be a consequence 
of an increase in protein expression with consequential increases in non-specific 
staining. This also raises the possibility that p65 is similarly increased, although the 
fact that it is known to be transnitrosated, and that this transnitrosation leads to a 
decrease in function remains interesting. This experiment was repeated several 
times but technical difficulties with the assay made interpretation difficult. The above 
discussion should therefore be interpreted in light of this. Since the experimental 
work was carried out, newer methods of detecting protein transnitrosation have been 
developed204;205. These hypotheses may therefore be confirmed using a more 
reliable method in the future. 
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5.5 Conclusion 
We have shown that nitric oxide, at concentrations in the high end of the range which 
can be seen in vivo, causes senescence in vascular cells. This was demonstrated in 
several ways in order to be certain that this was indeed senescence. Histological 
staining for senescence-associated β-galactosidase, flow cytometric analysis of β-
galactosidase activity, cell proliferation studies and western analysis of cell cycle 
proteins were all consistent with this conclusion. Cells which demonstrated higher β-
galactosidase activity did not appear to be undergoing apoptosis and there were 
fewer apoptotic cells in the HUVEC exposed to DETA-NO. It is possible that a 
proportion of cells exposed to DETA-NO in our model apoptose before analysis (i.e. 
during the exposure to DETA-NO). Furthermore, this may mean that cells which are 
subsequently analysed have been selected for resistance to apoptosis. This is 
consistent with previous groups’ observations that senescent cells are resistant to 
apoptosis (see Introduction). 
As further evidence of the influence of DETA-NO on senescence, our group 
previously investigated its effect on telomerase activity in HUVEC. 
 
Figure 5.5-1: Effect of high doses of exogenously added nitric oxide on telomerase activity. 
The above chart demonstrates previous work by our group.  HUVEC were treated with DETA-NO for 
24 h prior to measurement of telomerase activity.
206
  
 
The use of two nitric oxide donors to achieve the high concentration of nitric oxide 
suggests that the effect was not due to DETA-NO, but rather the nitric oxide released 
as a consequence of its liberation from DETA-NO. The effect seen with DETA-NO 
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did not seem to be due to a disturbance in the equilibrium of glutathione products as 
there was no demonstrable difference in the effect when we used GSNO as the nitric 
oxide donor. 
The pro-senescent effect of nitric oxide on HUVEC was also seen in vascular 
smooth muscle cells harvested from human umbilical cords and rat aortic smooth 
muscle cells, suggesting this is an effect which may be seen throughout the vessel 
walls of both humans and rats. 
If anything, smooth muscle cells appeared to be more sensitive to the effects of nitric 
oxide as increases in senescence were seen with lower doses of nitric oxide donor, 
compared to HUVEC. Again this increases the possibility that this is a 
physiologically-relevant phenomenon. 
We were surprised to see the rapid depletion of nitric oxide when NAC was added to 
DETA-NO in solution. Clearly, this could easily explain the reduction in reactive 
oxygen species generation and senescence seen in cells treated with both DETA-
NO and NAC. The mechanism for the reduction was not immediately clear but was 
not accounted for by pH or temperature as subsequent experiments were conducted 
after re-measuring pH and there was no change seen in the temperature of the 
reaction mix during the nitric oxide electrode experiment. 
With regard to the decreases in senescence seen by other groups who have looked 
at lower ranges of nitric oxide concentration, we saw no significant effect in reducing 
total β-galactosidase activity at the lowest concentration of DETA-NO tested. This 
may reflect the fact that our system was not sensitive enough to detect what could 
be a significant difference in cells treated at those concentrations. However, we 
chose to follow the novel and apparently more significant effect of large increases in 
senescent cells exposed to the higher sub-lethal concentrations of nitric oxide. 
This investigation showed us that all features of senescence were seen in those cells 
exposed to sub-lethal doses of nitric oxide. This effect was remarkable in its 
magnitude, with cells showing a reduction in DNA synthesis of more than 50%. 
Our assumption that high ranges of iNOS could generate similar concentrations of 
nitric oxide and that these concentrations could lead to senescence were tested with 
the co-culture experiments with tet-iNOS HEK-293 cells grown in close proximity to 
HUVEC, without being in contact. In retrospect, the lack of effect may simply have 
been a limitation of keeping cells apart and need not necessarily mean that cells 
maximally expressing iNOS cannot generate sufficient nitric oxide. A rapid 
consumption of nitric oxide could have accounted for the lack of effect as the 
molecule crossed the layer of medium before reaching the HUVEC. This situation 
would not occur in vivo. 
Regarding the potential mechanism for nitric oxide-induced senescence, we used 
ODQ to inhibit soluble guanylate cyclase and this had no ability to reduce or prevent 
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the effect of DETA-NO on senescence. Similarly, antioxidants were ineffective and 
uric acid was positively deleterious. Despite being the most efficient compound with 
regard to its ability to prevent the oxidation of H2DCFDA, it appeared to increase our 
cells’ tendency to senesce. Thus the mechanism of nitric oxide induced senescence 
was unlikely to be simply due to increasing oxidant species. Uric acid’s additive 
effect on DETA-NO-induced senescence may have been due to reactive 
intermediates generated by the reaction between nitric oxide and uric acid, as 
discussed in the introduction. These may not all react with H2DCFDA in our system 
of detection of ROS. 
Finally, the effect of cold light was interesting in that it was able to completely 
prevent nitric oxide-induced increases in β-galactosidase activity. This was despite 
the fact that light was delivered in pulses of 1 hour each, while DETA-NO tends to 
release nitric oxide constantly throughout. DETA-NO is not known to be unstable in 
light but a potential explanation of our finding is that it is rapidly degraded when 
exposed to high intensity cold light and therefore not able to exert the pro-senescent 
effect. Other nitric oxide donors, for example, GSNO and sodium nitroprusside are 
well known to be light sensitive.207 When exposed to light, they rapidly release nitric 
oxide and this would therefore have the effect of increasing nitric oxide 
concentrations while preventing its transnitrosating effect on protein targets. In fact, 
the property of light sensitivity of GSNO was used in my work to assess whether 
senescence induced by DETA-NO was due to transnitrosation of similar cysteine 
residues. 
The biotin switch method was at first glance disappointing with no real discernible 
difference in protein transnitrosation. However the further analysis offered by 
comparing patterns of transnitrosation was potentially revealing in that some proteins 
appeared to have increased density specifically in the DETA-NO treated groups.  
Unfortunately, we were not able to formally identify these but the potential that 
p16INK4a could be transnitrosated is interesting and the finding of a band which could 
represent p65 appears to offer a plausible mechanism for our finding, suggesting it 
could be involved in the process of either defending cells against senescence or 
defending them against apoptosis, only for them to senesce. 
Protein p65 is a subunit of NF-κB, a key transcription factor known to coordinate 
cellular responses to stress. In addition to this, it has been thought to be subject to 
transnitrosation at site cysteine 38, (Uni-Prot database) a post-translational 
modification which causes a decrease in activity of morphologically similar proteins. 
GPS-SNO 1.0 is an online program which predicts likely transnitrosation sites 
according to the protein sequence, its predicted structure and known transnitrosation 
sites on similar molecules. Using GPS-SNO 1.0, p66shc also has a likelihood of being 
transnitrosated, even using a medium threshold to search for transnitrosation sites at 
the cysteine on position 197. The likelihood score was 21.6 for cys-197 and 2.4 for 
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cys-38 (below the arbitrary “low threshold”). Sensitivity for sequences predicted 
above the low threshold for transnitrosation is 53.57%, specificity 80.14%, accuracy 
75.8%.117 
In addition, there was a band at 16.2kDa, a candidate to be p16INK4a. Similar analysis 
using GPS-SNO 1.0 gave a candidate cysteine residue at position 72 with a 
likelihood score of 0.22, placing it below the low threshold of likelihood as a 
transnitrosation site. 
While of interest, these findings would need to be clarified with further experiments to 
specifically look to identify the protein bands described.
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6 Metabolic stress and senescence 
6.1 Introduction 
Autophagy and related disorders of this process may play a part in the accumulation 
of lysosomes measured by the various β-galactosidase assays we have used in 
previous chapters. Therefore, we chose to assess whether this process could be 
manipulated pharmacologically in such a way that an effect on senescence would be 
observed. 
 Bafilomycin A1  6.1.1
Bafilomycin A1 acts to prevent autophagy by reducing lysosomal function. 
Bafilomycin A1 inhibits the lysosomal proton pump which reduces the ability of 
lysosomes to acidify their interiors via the vacuolar H+-ATPase.208  This, perhaps by 
a similar mechanism, allows the accumulation of acidic vacuoles within cells and 
prevents the degradation of long-lived proteins, the fusion of lysosomes and acidic 
vacuoles into autophagolysosomes and autophagy in cell lines.209  We exploited this 
property to investigate the phenomenon of increasing lysosomal size and its 
relationship with senescence and to help ascertain if impairment of protein 
degradation and mitochondrial cycling is causally linked to replicative senescence. 
 Rapamycin 6.1.2
Rapamycin inhibits the mammalian target of rapamycin (mTOR) and as such is able 
to increase autophagy activity and this in turn should lead to a decrease in lysosomal 
accumulation due to more efficient turnover of damaged proteins and organelles. 
mTOR is a downstream target of PI3K and Akt, which  regulate survival pathways.  
As discussed previously, Akt activation can be induced by nitric oxide.  Nitric oxide 
activation of Akt may lead to reduced protein cycling by reducing protein synthesis 
and reducing cell proliferation rates.  If proteins are not being cycled, there may be 
an increased chance of oxidative or nitrosative damage. We postulated this 
advances the possibility of protein aging which may in turn act as a signal for 
senescence. This may be most important in mitochondria which are responsible for 
signalling for many routes to apoptosis. Therefore, rapamycin offers another angle to 
investigate the phenomenon of nitric oxide-induced senescence by looking at the 
potential for Akt survival signalling being part of the route to nitric oxide-induced 
senescence. 
The use of rapamycin in the vasculature is widespread since the advent of drug-
eluting stents for coronary artery disease.  In addition, rapamycin had an established 
role as an immunosuppressant in transplant medicine.  Studies have investigated its 
effects on cell proliferation and survival and have shown it to reduce lung 
microvascular endothelial cells’ ability to survive a hyperoxic insult.210  In addition, 
rapamycin has been shown to have an anti-proliferative effect on vascular smooth 
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muscle cells subjected to balloon injury, again via an effect on the PI3K/Akt 
cascade.211 
 AMP kinase 6.1.3
AMPK activity has been shown to increase with advancing organismal age in 
response to hypoxic stress.164  AMPK itself is activated by the tumour suppressor 
gene LKB1 and this is also responsive to the effects of the AMP analogue AICAR.  
LKB1 activation confers an anti-apoptotic effect and we initially postulated this could 
in turn lead to senescence.165 As many cell stressors appear to be both pro-apoptotic 
and pro-senescent, we postulated that cell stress-response pathways may be 
activated by such a stress and that they may be forced to choose between apoptosis 
or senescence. Cell stress-response pathways may thereby involve an anti-apoptotic 
pathway which is pro-senescent. AICAR is an AMP analogue which activates AMP 
kinase in a similar fashion to the increase in AMP:ATP ratio.  Thus it simulates the 
effect of ATP depletion and therefore, bioenergetic stress in a cell.  AMP kinase has 
a wide range of proven and putative effects in its ability to modulate the metabolism 
of the cell, changing it from a synthetic unit to a catalytic unit and conferring an 
improved anti-oxidant defence mechanism.  This may be a means of energy-
conservation in a time of relative scarcity (see Introduction). 
We chose to investigate its effect on senescence and its potential role in signalling 
for senescence, given that at high concentrations nitric oxide may cause 
bioenergetic stress by inhibiting mitochondrial respiration and consequently leading 
to an increase in the AMP:ATP ratio.212 
Other stimulators of AMPK include the oral hypoglycaemic drug metformin.  The 
method by which metformin activates AMP kinase may involve inhibition of the 
electron transport chain complex 1 and thereby increase the AMP:ATP ratio but it 
has been thought to be independent of LKB1 and may therefore help to discriminate 
between two mechanisms of AMPK activation. 
There is also relevance in investigating AMP kinase activation specifically in 
endothelial cells as there is variability in the forms of AMP kinase present in various 
cell types. The 1 subunit is expressed in endothelial cells and both 1 and 2 
subunits are expressed in liver, cardiomyocytes, and skeletal muscle. The 2 subunit 
is more responsive to bioenergetic stress than the 1 subunit.172 
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6.2 Mimicking lysosomal dysfunction 
 Effect of lysosomal proton pump inhibitor, bafilomycin A1 on HUVEC 6.2.1
senescence 
 Effect of bafilomycin A1 on HUVEC cell diameter 6.2.1.1
Bafilomycin A1 is poorly soluble in water and was therefore dissolved in dimethyl 
sulfoxide at a relative concentration of 0.01% per 1nM bafilomycin A1. 
In order to test the effect of bafilomycin A1 on senescence, cells were seeded at 
3500 cells/cm2 and fed 3 times per week with or without the addition of bafilomycin 
A1.  As cells approached 80% confluence, the experiment was terminated by 
trypsinization for counting and size measurement using a Coulter Multisizer Z2 
Particle analyser. These experiments revealed a modest but statistically-significant 
increase in cell diameter in a dose-related fashion.    The relationship between cell 
size and dose of bafilomycin A1 is shown below.   
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Figure 6.2.1-1: Dose response for the effect of bafilomycin A1 on cell diameter of HUVEC. 
The figure represents the mean cell diameters of 5 separate experiments using HUVEC from 5 
separate populations. Cells were exposed to varying concentrations of bafilomycin A1 in its solvent, 
DMSO (1nM in 0.01% DMSO, 2nM in 0.02% DMSO or 3nM in 0.03% DMSO), or solvent alone. Error 
bars represent standard error of the mean. Callipers show the comparison of the cells exposed to the 
same concentration of the solvent DMSO with or without the corresponding concentration of 
bafilomycin A1. T-test * p<0.05  
The dose-response curve demonstrated no significant difference between doses of 
DMSO or between doses of bafilomycin A1. However, comparing bafilomycin doses 
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with the equivalent dose of DMSO, all doses were associated with a significant 
increase in cell diameter. 
 Effect of bafilomycin A1 on HUVEC cell proliferation 6.2.1.2
To assess the effect of bafilomycin A1 on HUVEC cell proliferation, cells were 
seeded at 3500 cells/cm2 and fed 3 times per week.  Once the fastest proliferating 
cells reached ~80% confluence, the experiment was terminated by trypsinization for 
counting and size measurement using a Coulter Multisizer Z2 Particle analyser.  The 
relationship between cell proliferation and dose of bafilomycin A1 is shown below. 
 
Figure 6.2.1-2: Effect of bafilomycin A1 or carrier on population doubling per passage HUVEC. 
Effect of exposure to bafilomycin A1 or carrier (DMSO) on population doubling per passage is shown 
above. Cells were counted at the same time on trypsinization using a Coulter Particle analyser. The 
experiment was repeated on 3 separate occasions using different populations of HUVEC. Error bars 
indicate standard error of the mean. 
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Figure 6.2.1-3: Effect of bafilomycin A1 on cumulative population doubling in HUVEC. 
The above figure shows the results of a single experiment comparing longer exposure to bafilomycin 
A1 in carrier or carrier only. Time indicates time since first seeding. Cells were counted using the 
Coulter Particle analyser using 3 samples from the same well. Error bars indicate 95% confidence 
interval and asterisks indicate the points where there was a statistically different number of cumulative 
population doublings between the cell groups. 
Small differences were noted in the rate of proliferation and in one extended 
experiment, these reached statistical significance.  However, the overall picture was 
of no difference in proliferation. 
The experiment was extended for 5 passages to assess whether there would be a 
cumulative effect on population doubling. The final 2 passages began to show a 
significant difference in population doublings between cells treated with bafilomycin 
A1 3nM and those exposed to carrier only (DMSO 0.03%). 
 Effect of bafilomycin A1 on HUVEC senescence-associated β-galactosidase 6.2.1.3
HUVEC were grown as before and were then fixed and stained for senescence-
associated -galactosidase. 
Wells stained for senescence-associated -galactosidase were counted using a 
graticule and 4 random samples within each well was counted to a total cell count of 
at least 200.  Positive cells were then counted and were compared to the 
corresponding control.  In the case of senescence-associated -galactosidase 
experiments, 2 independent samples were counted 4 times each. 
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The results shown below indicate a striking reduction in the rates of positively-
stained cells for cells treated with bafilomycin A1.  Positively stained cells in the 
treated wells appeared to have been stained much less avidly.  Importantly, there 
was no significant difference in senescence-associated -galactosidase staining 
between the various concentrations of DMSO but there was a dose response 
relationship between the doses of bafilomycin A1, even when the corresponding 
concentration of DMSO was used as an internal control. 
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Figure 6.2.1-4: Bafilomycin A1 and DMSO dose response of HUVEC: senescence-associated β-
galactosidase. 
Graphs are grouped by bafilomycin A1 dose and equivalent carrier concentration. Senescence-
associated β-galactosidase (%) represents percentage of cells positively-stained for senescence-
associated β-galactosidase. Error bars denote standard error of the mean and callipers denote 
statistical comparisons. *p<0.05. (A) shows bafilomycin 1nM, (B) 2nM, (C) 3nM. 
The above 3 graphs show the results of senescence-associated β-galactosidase 
staining experiments with comparisons between cells exposed to bafilomycin A1 or 
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the solvent DMSO. DMSO was used to dissolve bafilomycin A1 and, as it exerts a 
weak antioxidant effect, the control population of cells was exposed to the same 
concentration of DMSO as was contained in the bafilomycin A1 mixture. At each 
dose, there was a marked decrease in cells which stained positive for senescence-
associated β-galactosidase. 
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Figure 6.2.1-5: Bafilomycin A1 and DMSO dose response of HUVEC: senescence-associated β-
galactosidase. 
Graphs are grouped by carrier solvent (DMSO) alone (A) or by bafilomycin A1 dose (B). Senescence-
associated β-galactosidase (%) represents percentage of cells positively-stained for senescence-
associated β-galactosidase. Senescence-associated β-galactosidase positive (proportion vs. control) 
represents ratio of positive cells in bafilomycin A1 treated cells : positive cells in corresponding dose 
of carrier. Error bars denote standard error of the mean and callipers denote statistical comparisons. 
*p<0.05. 
The same data are shown as above, but in this case, comparisons are between 
doses of solvent and doses of bafilomycin A1. There were no statistically significant 
interactions between doses of DMSO solvent. However, bafilomycin A1 exerted a 
dose-dependent reduction in senescence-associated β-galactosidase activity. 
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 Effect of bafilomycin A1 on HUVEC total β-galactosidase activity as 6.2.1.4
measured by flow cytometry 
Therefore, in the case of bafilomycin A1, there is a dose related increase in cell 
diameter but a decrease in senescence-associated -galactosidase staining. 
Further investigation into the total amount of -galactosidase activity by flow 
cytometry was performed to assess if bafilomycin A1 truly reduces -galactosidase 
activity and therefore separates the relationship between -galactosidase, cell size 
and senescence. 
Cells were grown to confluence and treated with bafilomycin A1 3nM for 3 
consecutive days.  They were then rested for 3 days in normal medium.  Cells were 
replated at 5000 cells/cm2 and then analysed for total -galactosidase activity 
measuring C12FDG metabolism by -galactosidase to fluorescein by flow cytometry.  
There was no significant difference in total -galactosidase activity. 
 
Figure 6.2.1-6: Effect of bafilomycin A1 on HUVEC β-galactosidase activity. 
Result of 3 separate experiments on 3 separate populations of HUVEC. Columns indicate the mean 
of mean fluorescence intensity post C12FDG exposure; error bars indicate standard error of the mean 
(SEM). 
The flow cytometry results contrasted markedly with those seen in the standard 
histological staining method for measuring senescence-associated β-galactosidase. 
This clearly posed the question as to the effect of bafilomycin A1 on the staining 
technique itself. It is quite possible that the relative alkalinisation of lysosomes by 
bafilomycin A1 inhibits the reaction at pH6 to such an extent that not enough 
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coloured product is made to be detectable in the histological stain, it may affect the 
dye itself or there may be a direct interaction between bafilomycin A1 and β-
galactosidase. 
However, in this case, it seems that the fluorescent product visualized by flow 
cytometry provides a more sensitive measure as it is likely that bafilomycin A1, as a 
known inhibitor of autophagy is unlikely to be able to reduce lysosomal mass and 
therefore β-galactosidase activity, processes which have previously been shown to 
correlate.10;213 
 mTOR inhibition 6.2.2
As rapamycin has previously been shown to demonstrate anti-proliferative effects, I 
elected not to investigate senescence by assessing proliferation. 
I therefore investigated the effect of rapamycin on cell diameter and on total β-
galactosidase activity as measured by flow cytometry. Inhibiting mTOR ought to 
encourage autophagy and thereby may retard senescence by preventing 
accumulation of damaged mitochondria. 
  
156 
 
Analysis of cell diameter was first carried out in the context of a dose response curve 
on a single population of HUVEC and then repeated on 4 further populations of 
HUVEC. 
 
 
Figure 6.2.2-1: Effect of rapamycin on HUVEC cell diameter. 
Upper panel (A) shows a dose response curve of the effect of rapamycin on cell diameter at differing 
doses on a single population of HUVEC. Lower panel (B) shows a comparison of HUVEC cell 
diameter in control cells vs those exposed to rapamycin 100nM (n=5, error bars indicate SEM, 
asterisk indicates p<0.05). 
Cell diameter decreased in the presence of all doses of rapamycin (10nM, 20nM, 
100nM and 200nM). The experiment was repeated on 5 separate populations of 
cells exposed to rapamycin 100nM. Analysis revealed a statistically significant 
decrease in cell diameter (control 15.7μM vs rapamycin 100nM 14.9μM, p=0.04).  
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I repeated the experiment using HUVEC and growing them in the presence of 
rapamycin 100nM using 3 separate populations of cells, such that they were 
exposed to rapamycin with each change of medium for 7 days. At the end of the 
week, cells were harvested and replated without drug treatment for 3 days, before 
being harvested for analysis by flow cytometry. 
 
Figure 6.2.2-2: Effect of rapamycin on HUVEC β-galactosidase activity. 
Result of 3 separate experiments using 5th passage HUVEC. Columns indicate mean fluorescence 
post exposure to C12FDG, measured by flow cytometry. Error bars indicate standard error of the 
mean. *p<0.001 
The results of the experiment revealed that, whereas control cells had a mean 
fluorescence post C12FDG exposure of 301.43 arbitrary units, SEM 22.36; mean 
fluorescence post C12FDG exposure for rapamycin treated cells was 105.6 arbitrary 
units, SEM 3.9. When analysed by two-tailed t-test, p= 0.00006. 
Rapamycin therefore has a large effect on reducing β-galactosidase activity as 
measured by flow cytometry, despite being anti-proliferative. 
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6.3 AMP kinase activation 
 Effect of AMP kinase activator, AICAR on HUVEC senescence and its 6.3.1
interaction with DETA-NO 
In order to investigate the effect of AMP kinase activation, I performed experiments 
to assess the effect of AICAR on cell diameter, cell proliferation and β-galactosidase 
activity. 
Cells from passages 3-5 were grown in the presence of AICAR to assess the effect 
of the drug on cell size and were analysed using the Coulter Multisizer particle 
analyser.  Cells were grown in 6 well plates with an initial seeding density of 2500 
cells/cm2 and medium was changed 3 times per week.  On each change of medium, 
AICAR was added.  As the fastest growing cells approached 80% confluence, all 
cells were harvested and counted using the Coulter particle analyser.   
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Figure 6.3.1-1: Effect of AICAR on HUVEC cell diameter: dose response. 
The above three graphs display the effects of varying concentrations of AICAR on cell 
diameter(0.25mM (A), 0.5mM (B), 1mM (C)), versus control conditions. Error bars indicate standard 
error of the mean and callipers with asterisks indicate statistical significance when measured by t-test. 
Cell diameter was measured using the Coulter Particle Analyser and experiments 
were repeated using 3,4 and 7 different populations of HUVEC in the case of AICAR 
0.25mM, 0.5mM and 1mM respectively. AICAR, at a variety of doses, increases cell 
size suggestive of an effect on senescence.   
The graphs below demonstrate the effect of AICAR on population doubling and 
population doubling rate over the course of 6 passages.  
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Figure 6.3.1-2: Effect of AICAR on proliferation of HUVEC. 
The figures show the same data expressed in different ways. The top graph (A) shows cumulative 
population doubling of HUVEC exposed to AICAR 1mM, the bottom graph (B) shows population 
doubling per passage of the same cells. The time indicates the number of days since initial seeding. 
Each count was in triplicate and an average of each measurement was used to calculate population 
doubling. Lines connecting markers indicate SEM.    
There was a modest but significant difference in cumulative population doubling 
between control and treatment groups and this in turn suggested that AICAR may 
cause cell cycle arrest in stress-induced senescence manner (ANOVA p=0.005). 
Further evidence for an effect of AICAR on senescence was obtained using flow 
cytometric analysis of cell forward scatter, cell side scatter and fluorescence intensity 
of C12 fluorescein, a product of the reaction between β galactosidase and C12FDG.   
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Cells were grown to confluence in T-75 flasks in EGM-2 growth medium.  Medium 
was changed daily and AICAR 0.25mM was added daily for 3 days.  Medium was 
then changed and cells were passaged 48 hours later.  Cells were replated at 5000 
cells/cm2 on 60mm diameter plates and grown for a further 3 days.  Cells were then 
exposed to C12FDG for 4 hours and washed twice with PBS.  Samples were 
harvested using trypsin and placed on ice until flow cytometric analysis. 
 
Figure 6.3.1-3: Effect of AICAR on β-galactosidase activity by flow cytometry. 
Results of flow cytometric analysis of β-galactosidase activity using the fluorescent probe C12FDG. 
Experiments were performed using 3 different cell populations. Error bars indicate standard error of 
the mean fluorescence activity in HUVEC with and without exposure to AICAR 0.25mM (shaded 
column).  
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Figure 6.3.1-4: Effect of AICAR on side scatter of HUVEC. 
Figure shows flow cytometry analysis of the side scatter of cells with or without exposure to AICAR 
0.25mM. Error bars indicate standard error. Experiments were performed using 3 different cell 
populations of HUVEC. 
The effect of AICAR on our model of nitric oxide-induced HUVEC senescence was 
analysed by the flow cytometric technique. Using the same method as described 
above, cells were exposed to AICAR, DETA-NO or both and then analysed.  
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Figure 6.3.1-5: Interaction between AICAR and DETA-NO on HUVEC β-galactosidase activity. 
Results of 3 separate experiments involving separate populations of HUVEC. Cells were exposed to 
DETA-NO 0.5mM, AICAR 0.25mM or both reagents and were then analysed for β-galactosidase 
activity by flow cytometry. Results were mean fluorescence intensity and error bars denote standard 
error of the mean. 
After repeating the experiment 3 times, it became evident that AICAR did not prevent 
DETA-NO-induced senescence as measured by β-galactosidase activity. The only 
significant differences between conditions were those comparing cells exposed to 
DETA-NO to those not exposed to DETA-NO. Results of mean fluorescence activity 
as expressed in arbitrary units were as follows: Control 301.4, SEM 22.4; DETA-NO 
456.2, SEM 64.2; AICAR 342.9, SEM 87.6; AICAR and DETA-NO 483.7, SEM 88.5. 
t-tests: Control vs. AICAR p=0.42, DETA-NO vs. AICAR and DETA-NO p=0.62. 
The effect of AICAR on the generation of reactive oxygen species within the cell was 
also assessed. The hypothesis was that an increase of ROS oxidizes proteins which 
are recognized by phagosomes. These irreversibly damaged proteins are normally 
cleared by lysosomes but this mechanism could be overwhelmed in senescence and 
that this leads to an increase in lysosomal mass.  This could be the mechanism by 
which nitric oxide leads to senescence as it is known to indirectly increase the 
generation of superoxide.  The effect of AMP kinase activation as a coordinator of a 
response to bioenergetic stress includes blocking further anabolic processes such as 
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DNA and protein synthesis.  It also promotes catabolic processes and therefore 
could lead to an increase in ROS production by increasing aerobic respiration and 
indirectly increasing mitochondrial superoxide production.  This combination of 
blocking protein synthesis and increasing superoxide could lead to an excessive 
accumulation of oxidized protein. 
 
Figure 6.3.1-6: Interaction between DETA-NO and AICAR: flow cytometric analysis of ROS. 
Results of mean of 3 separate experiments involving separate populations of HUVEC. Cells were 
exposed to DETA-NO 0.5mM, AICAR 0.25mM or both reagents and were then analysed for their 
ability to generate ROS as detected by exposure to H2DCFDA. Results were mean fluorescence and 
error bars denote standard error of the mean. 
We investigated ROS production in HUVEC using H2DCFDA fluorometric analysis 
which detects ROS species.  AICAR at a dose of 0.25mM was not shown to have an 
effect on ROS generation, but was able to prevent DETA-NO-induced increases in 
ROS generation.  This interaction was not significant on ANOVA. Direct comparison 
of DETA-NO alone and AICAR with DETA-NO by t-test was also non-significant. 
Average ROS activity as measured by H2DCFDA by fluorimetry was as follows: 
control 4.29 x 103, SEM 2.36 x 103; DETA-NO 61.1 x 103, SEM 8.0 x 103; AICAR 
42.7 x 103, SEM 9.9 x 103; AICAR and DETA-NO 51.8 x 103, SEM 7.3 x 103; t-test of 
DETA-NO vs. DETA-NO and AICAR p=0.07. 
As previously reported, AMP kinase can also activate protective responses to 
oxidative stress and this may explain our results with respect to the effect on reactive 
oxygen species generation as detected by the fluorogenic probe H2DCFDA. 
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However, the protection afforded by activating AMP kinase in this way was unable to 
translate to an effect to prevent the senescence seen when exposing cells to DETA-
NO 0.5mM. 
In our model, AMP kinase activation – in contrast to work from other groups was 
unable to exert an effect on senescence.(See Introduction). 
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 Assessing the effect of AMP kinase activation on human umbilical artery 6.3.2
smooth muscle cells by senescence-associated β-galactosidase staining 
The effect of AICAR 0.25mM on senescence-associated β-galactosidase was 
assessed. Cells were initially explanted from human umbilical cord and passaged 3 
times before exposure to AICAR 0.25mM for 1 week. At the end of the exposure 
period, cells were stained for senescence-associated β-galactosidase and counted 
using phase contrast light microscopy at 20 x magnification. 
 
Figure 6.3.2-1 Effect of AICAR on HUASMC: senescence-associated β-galactosidase. 
Result from a single sample of HUASMC at 3rd passage exposed to AICAR 0.25mM vs. control. Each 
condition was repeated in 4 individual wells and results are mean percentage of counted positively 
stained cells for senescence-associated β-galactosidase vs. total cells counted. Error bars indicate 
standard error of the mean.  
4 separate fields of view were counted from 4 wells of each condition. Control cells 
demonstrated positive staining in a mean of 13.8%, SEM 0.9 and cells exposed to 
AICAR 0.25mM 17.0%, SEM 2.2. Statistical comparison using two-tailed t-test 
assuming unequal variance gave p=0.25. 
Therefore there was a non-statistically significant increase in senescence-associated 
β-galactosidase in smooth muscle cells exposed to AICAR 0.25mM. 
 
  
0
4
8
12
16
20
24
%
 p
o
s
it
iv
e
ly
-s
ta
in
e
d
 (
S
E
M
) 
Control
AICAR 0.25mM
167 
 
 Effect of metformin on HUVEC proliferation and senescence 6.3.3
Metformin activates AMP kinase in a manner independent of LKB1.  Thus metformin 
complements AICAR as a means of assessing the senescence pathway via AMPK 
to ascertain if LKB1 is essential in the senescence pathway. 
Cells were grown in the presence of a variety of drug concentrations for the one 
week with 3 changes of medium and drug in EGM-2 medium.  At 80% confluence, 
cells were passaged in the normal fashion and counted and measured using the 
Coulter Particle Analyser. 
 
 
Figure 6.3.3-1: Dose response for the effect of metformin on HUVEC diameter and count. 
Effect of various doses of metformin on cell counts at harvest and cell diameter as measured by 
Coulter particle analyser. The top graph (A) displays the cell count per mL in wells harvested by 
trypsinization when the most rapidly-replicating well reached 80% confluence. Lower panel (B) 
represents the cell diameter at harvest. Error bars indicate standard error. n=3. 
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A similar dose-dependent trend was observed to that seen in AICAR.  Cell 
proliferation was maintained (p=0.31 by ANOVA) and cell size exhibited a non-
significant increase (p=0.17 by ANOVA).  This in turn could suggest that LKB1 
activation is not necessary for initiation of the senescent phenotypical change. 
Parallel to this experiment, cells were also stained for senescence-associated β-
galactosidase using the standard histological method. In order to achieve an 
increased sample size, cells were grown in 6 well plates with 4 wells per condition. 
The total number of cells in a field of view were counted using phased light 
microscopy. Cells stained blue for senescence-associated β-galactosidase were 
then counted and used to calculate a percentage of positively-stained cells. Data 
were analysed using Microsoft Excel with a single condition ANOVA.  
 
Figure 6.3.3-2: Effect of metformin on HUVEC senescence: senescence-associated β-galactosidase. 
Results of an experiment with increasing doses of metformin and its effect on a population of HUVEC. 
The data shown are individual counts from wells stained with senescence-associated β-
galactosidase. 
Results were as follows; control cells mean 11.05, SEM 2.37; metformin 2mM mean 
16.01, SEM 7.27; metformin 5mM mean 38.49, SEM 13.29; metformin 10mM mean 
25.6, SEM 2.66. ANOVA p=0.117. 
Cells from 3 separate donors were further analysed using flow cytometric 
quantification of β-galactosidase activity using the fluorigenic probe, C12FDG. Cells 
were grown to confluence and then exposed to metformin 10mM at each daily 
change of medium for 3 days. Cells were harvested and analysed by flow cytometry.  
0
20
40
60
80
0 2 4 6 8 10
S
A
 β
-g
a
la
c
to
s
id
a
s
e
 p
o
s
it
iv
e
 (
%
) 
Metformin (mM) 
169 
 
 
Figure 6.3.3-3: HUVEC senescence and metformin: flow cytometric analysis of β-galactosidase 
activity. 
Results of 3 separate experiments assessing the effect of metformin on β-galactosidase activity as 
measured by flow cytometry. Columns indicate the mean results of mean fluorescence intensity and 
error bars indicate standard error of the mean. 
Mean fluorescent activity in control cells was 301.43 arbitrary units, SEM 22.36 and 
for metformin 10mM was 334.2 arbitrary units, SEM 42.3. Analysis by two-tailed t-
test revealed a lack of statistical significance, p=0.23. 
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 Effect of metformin on HUASMC senescence 6.3.4
The experiment also performed in HUASMC using metformin at 1mM and 2mM 
dosages.  
 
Figure 6.3.4-1: Effect of metformin on HUASMC: senescence-associated β-galactosidase. 
Result from a single sample of HUASMC at 3rd passage exposed to metformin 1mM or 2mM vs. 
control. Each condition was repeated in 4 individual wells and results are mean percentage of 
counted positively stained cells for senescence-associated β-galactosidase vs. total cells counted. 
Error bars indicate standard error of the mean. Callipers indicate statistical comparison using a two-
tailed t-test assuming unequal variance and asterisks indicate p<0.05. 
Results indicate a dose-related increase in senescence-associated β-galactosidase 
activity in cells exposed to metformin. As before, control cells demonstrated positive 
staining in a mean of 13.8%, SEM 0.9, metformin 1mM 22.1%, SEM 2.8; metformin 
2mM 26.4, SEM 5.7. Two-tailed t-tests assuming unequal variance performed 
comparing each individual dose of metformin to control showed significant 
differences; control vs. metformin 1mM p=0.04, control vs. metformin 2mM p=0.12. 
However, a single factor ANOVA comparing all conditions was not significant p=0.10. 
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6.4 Conclusion 
In this chapter, I attempt to assess the influence of drugs which are able to 
manipulate autophagy and mobilise cellular defences against oxidative stress, rather 
than simply being antioxidants themselves. 
In HUVEC, none of the treatments were seen to promote senescence as measured 
either by cell proliferation rates or β-galactosidase activity. Meanwhile, cells exposed 
to AICAR, bafilomycin A1 and metformin each demonstrated an increase in cell 
mass. There was, however, a small effect in promoting senescence in HUASMC by 
metformin. As previously discussed, this may be a consequence of the differing AMP 
kinase subunits present in HUASMC vs. HUVEC. 
As an inhibitor of autophagy, we expected bafilomycin A1 could lead to cellular 
vulnerability to senescence, rather than to reduce it. β-galactosidase assays were 
performed using both the standard histochemical senescence-associated β-
galactosidase assay and by flow cytometry using C12FDG. The effect demonstrated 
by bafilomycin A1 was interesting in that there were discrepancies between 
methods. Using the histochemical technique to look for senescence-associated β-
galactosidase, I observed a marked reduction in staining. However, this technique 
relies on a visual inspection of cells under light microscopy. There is an element of 
judgement when counting cells and weaker staining may account for the discrepancy 
between the number of cells staining positive for senescence-associated β-
galactosidase and the lack of difference seen in the other methods used to assess β-
galactosidase activity. Furthermore, the senescence-associated β-galactosidase 
assay relies upon an excess of β-galactosidase enzyme activity in senescent cells to 
overcome the fact that the stain is performed at a relatively-alkaline pH. Excessive 
pre-alkalinisation caused by bafilomycin A1 may therefore affect the assay by further 
reducing β-galactosidase activity beyond a threshold where it can be seen to alter X-
gal. However, this is an effect one may expect to affect the flow cytometric method in 
a similar fashion.  
Other techniques were more consistent with bafilomycin A1 exerting no effect on 
senescence. The increase in cell mass seen with bafilomycin A1 and the small 
reduction in proliferation rate seemed most consistent with the flow cytometric assay 
results, demonstrating no difference in β-galactosidase activity. 
Rapamycin, in contrast, demonstrated a large reduction in β-galactosidase, despite 
being a known anti-proliferative agent. Rapamycin is also able to inhibit autophagy 
and therefore the reduction in β-galactosidase activity is unexpected. It may be that 
there is a direct interference with the assay, rather than this being a physiologically 
significant function. It is possible that the fluorogenic substrate for β-galactosidase, 
C12FDG, is unable to enter the lysosome when autophagy is being inhibited. 
Unfortunately, we did not have time to assess the effect this had on proliferation in 
our model and also to assess whether other markers of senescence were increased. 
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The results from this chapter are consistent with the hypothesis that AMP kinase 
activation by AICAR mobilises cellular defences against oxidative stress. This was 
demonstrated by a small decrease in ROS generation by cells exposed to DETA-NO 
and AICAR. However, this did not lead to a decrease in β-galactosidase activity in 
HUVEC. The small effect in HUASMC merits further investigation. Again, this is 
consistent with results from earlier in this document showing no effect on the ability 
of DETA-NO to cause cellular senescence with concurrent exposure to antioxidants, 
even when they are able to reduce ROS generation. 
 
  
173 
 
7 Conclusions and discussion 
We have investigated several known methods of detecting senescence in order to 
find a method which is capable of detecting cellular senescence at an early stage. 
Having looked at all of the methods, I found that the flow cytometric detection of total 
β-galactosidase activity offered the most promise for ease of use and sensitivity. 
I used this as the starting point for my investigation into the effects of various 
pharmacological manipulations of vascular cells and the consequences with regard 
to senescence. Of the other means of assessing β-galactosidase activity, the 
histochemical staining of senescence-associated β-galactosidase relied on a degree 
of subjectivity when counting cells by eye and could be subject to bias. In addition, 
the staining technique required cell fixation and several washing steps, some of 
which could strip cells from the plate. One could not be certain that this would not 
preferentially select healthy or senescent cells, and as such could under- or over-
estimate an effect on senescence. 
It was interesting to observe the comparison between flow cytometric analysis of β-
galactosidase activity and senescence-associated β-galactosidase staining when 
looking at cells exposed to bafilomycin A1. In this series of experiments, an apparent 
large reduction in staining for senescence-associated β-galactosidase was not 
repeated on flow cytometric analysis of β-galactosidase activity, which showed no 
difference in control groups and those treated with bafilomycin A1. As discussed 
earlier, this discrepancy could simply be explained by an interaction between the 
action of bafilomycin A1 and the X-gal histochemical assay. Certainly, from other 
groups’ data on autophagy and aging, we would have expected to observe either an 
increase in senescence or no effect.151;153-155 Further work using other techniques to 
detect senescence such as the expression of cell cycle protein p16INK4a will help to 
investigate whether bafilomycin A1 has an effect on senescence. 
Assessing total β-galactosidase activity by MUG fluorescence in cell lysates seemed 
to lack sensitivity and would be unable to reveal if some cells senesced in a 
population and others remained healthy. Furthermore, the measurements made to 
correct for the amount of protein analysed could be a source of error and some of 
the protein could have been extracellular. As senescent cells are larger, correcting 
for β-galactosidase activity per cell would have been useful and is not possible in cell 
lysates. 
Our analysis of Annexin-V binding as a marker for apoptosis with co-staining for β-
galactosidase revealed that cells which express an increase in β-galactosidase 
activity are not also undergoing senescence. This is consistent with previous 
observations that senescent cells are resistant to apoptosis.55 
Choosing a main cell type to work with for our model, we tried to harvest cells in an 
environment of low stress and chose initially to try obtaining explanted HUASMC. 
However, as our explanted HUASMC were harvested with variable efficiency and 
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senesced after a relatively low number of population doublings, they were not a good 
cell type to look at if one wished to separate out replicative senescence from stress-
induced senescence. 
Despite this, the main positive finding in this investigation was that vascular cells 
senesce on exposure to nitric oxide donors and this was universal across the cell 
types analysed. 
Western blotting for the senescence-associated proteins p16INK4a and p21WAF was 
used to confirm that cell populations which had indications of senescence with 
increased β-galactosidase activity had all of the features of senescent cells. Again, 
analysis of cells in this way suffers from being based on cell lysates, rather than 
analysing whole cells individually. However, it is an analysis of the machinery of 
senescence and is therefore a more direct measure. It would have been interesting 
to perform further experiments on fixed cells with immunofluorescence or in situ 
hybridization to confirm that cells either expressed some or none of these proteins, 
because with our other method, it was clear that all cells have β-galactosidase 
activity but senescent cells have more. 
Although not necessarily a measure of senescence, the loss of replicative capacity 
observed from analysing BrDU incorporation in senescent cells was required as a 
confirmation that cells would not regain their proliferative capacity after the stressors 
had been removed. Analysing the cell populations at different cell seeding densities 
also revealed the effect of contact inhibition in endothelial cells grown in monolayer. 
The first point to note is that these cells had previously been confluent in culture 
during exposure to the various agents used to stress the cells or protect them from 
senescence; however they were able to immediately regain their proliferative ability. 
The second point to note is that irrespective of cell density, the peak proliferative 
capacity in cells exposed to DETA-NO was markedly decreased, consistent with the 
idea that this treatment did induce senescence. 
The choice of working with endothelial cells in a confluent monolayer was forced 
upon us as cells grown exponentially in culture would either stop growing on first 
exposure to nitric oxide or die when exposed to higher concentrations. While I 
cannot exclude that a proportion of cells did senesce as a consequence of being 
grown in a confluent manner, this did not appear to be a large effect as cells 
recovered replicative capacity on replating. Furthermore, this effect was controlled 
for in both treatment and control groups. 
We did not investigate the effect of telomerase or telomere length in our model as 
other groups have previously done so. 
Our search for a reason as to why cells exposed to nitric oxide senesced and also 
into the mechanism took us into an area which was already of interest for being one 
of the main theories of aging, the free radical theory of aging. I had hoped to use t-
BHP as a positive comparator in our model of senescence, but I was unable to 
175 
 
demonstrate an effect on senescence from any concentration of t-BHP. This was in 
contrast to work from other groups in the area. One possibility is that cells which are 
confluent have far superior defences against oxidative stress. Another is that the 
ascorbic acid in our culture medium had sufficient antioxidant activity to counter the 
effect of hydrogen peroxide. 
In either event, we were able to demonstrate an increase in ROS generation in cells 
exposed to t-BHP and this had a linear relationship to the concentration of t-BHP 
added to the cell culture medium. Moreover, we were able to calculate which 
concentration of t-BHP would replicate the same amount of ROS generation as 
measured by the probe, H2DCFDA by exposing cells to DETA-NO at the 
senescence-generating concentration. In these experiments, it was clear that t-BHP 
had no effect on promoting senescence in our model. While it is possible that t-BHP 
may cause senescence without increasing total β-galactosidase activity, we feel this 
is unlikely as Touissant measured senescence by senescence-associated β-
galactosidase staining.46 The lack of effect of t-BHP was contrary to the effect seen 
with DETA-NO, despite identical levels of ROS generation. This led us to conclude 
that DETA-NO does not induce senescence purely by increasing ROS. 
Despite the concept that H2DCFDA is activated by de-acetylation within cells and is 
therefore an intracellular probe for ROS, we saw an effect in a cell-free environment 
when the probe was exposed to the oxidative reagents. As discussed earlier, this 
effect was in the presence of a much higher concentration of H2DCFDA as there was 
no washing stage. In addition, the interaction between oxidants and antioxidants was 
different. Lastly, the effect was controlled for using control populations of cells. 
Clearly this is a significant limitation to measuring ROS in this way using fluorimetry. 
As further confirmation, we were able to investigate a variety of antioxidants in the 
DETA-NO-induced senescence model. First we looked at their effectiveness in 
preventing the increase in ROS generation and then at their effect on total β-
galactosidase activity. Uric acid and NAC were effective antioxidants in cells 
exposed to DETA-NO. NAC was also effective in cells exposed to t-BHP. However, 
uric acid and NAC increased ROS generation in the cells exposed to GSNO. In 
contrast, selenomethionine was ineffective in preventing ROS generation by DETA-
NO. 
  Cellular ROS Cell-free ROS Senescence 
DETA-NO + + + 
DETA-NO + NAC Prevents ++ Prevents 
DETA-NO + UA Prevents ++ + 
GSNO + + + 
GSNO + NAC ++ 
   
Figure 7-1: Summary of ROS and senescence data. 
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Despite uric acid being an effective antioxidant in cells exposed to DETA-NO, it 
caused an increase in β-galactosidase activity in HUVEC exposed to DETA-NO. As 
expected, selenomethionine had no effect in either direction. However, NAC was 
able to completely abolish the DETA-NO effect on HUVEC senescence. The effect 
may be due to a genuine decrease in ROS generation within cells or due to 
replenishment of cellular reduced glutathione by NAC. However, results from the NO 
electrode measurement of NO generated by DETA-NO with subsequent addition of 
NAC showed that the likeliest explanation of the effect of NAC is that it almost 
completely quenches nitric oxide as it is being released by DETA-NO. This raised 
the possibility that a nitrosothiol substance formed in the reaction between NAC and 
DETA-NO may be protective against senescence. As a way of investigating this 
possibility, we used the nitrosothiol NO donor GSNO. This also promoted 
senescence in a similar fashion to DETA-NO. Thus nitrosothiols are less likely to 
explain the protective effect of NAC against NO induced senescence. 
The effect of DETA-NO was not prevented by inhibiting soluble guanylate cyclase 
activity. Although the effect of ODQ was not directly measured by cGMP assay as 
part of our investigation, Heller et al had previously done so.214 The absence of any 
effect at any concentration of ODQ therefore made soluble guanylate cyclase an 
unlikely target for the pathway to senescence. 
Protein transnitrosation seemed a possible general mechanism after our experiment 
using cold light on cells exposed to DETA-NO. The complete reversal of nitric oxide-
induced increases in β-galactosidase activity in cells exposed to pulses of cold light 
was further investigated by looking at protein transnitrosation by using the biotin 
switch method. We used cell lysates for this method. Therefore the whole proteome 
was analysed. While we did not detect general increases in protein transnitrosation, 
this method also offers a means of comparing differences in bands representing 
proteins which could be specific targets for transnitrosation. Band analysis revealed 
peaks of difference in non-specific labelling and nitrosylated proteins at a predicted 
molecular weight of 16.4kDa and 64.4kDa. As previously discussed, p16INK4a was 
present in increased levels in NO-induced senescent cells. Also, p65 and p66shc are 
potential signalling molecules for the stress response by NF-κB and protein kinase 
C-β-mediated signalling, a pathway seen to be increasingly active in elderly humans. 
We would like to further investigate if either pathway were responsible for the 
observed effect of nitric oxide on vascular cell senescence. 
Regarding the physiological relevance to nitric oxide-induced senescence, we looked 
at endogenous NO generation. We induced maximal eNOS-induced release of NO 
with A23187 but this had no measurable effect on β-galactosidase activity (or ROS 
generation). We also looked at the effect of inducing iNOS-generated NO by using 
the tet-iNOS HEK 293 cell line and growing in the same medium as HUVEC in 
Transwells. Again, this did not have a measureable effect on β-galactosidase 
activity. Thus we were unable to demonstrate that endogenously generated NO 
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causes senescence. In both conditions, I assume that the local nitric oxide 
concentration was too low. However, in the case of eNOS, a lack of uncoupling of 
eNOS may be relevant. In the tetracycline-inducible iNOS experiments, the relatively 
great distance between cells generating nitric oxide and the HUVEC being analysed 
may have prevented sufficient concentrations of nitric oxide. 
AICAR and metformin both activate AMP kinase, a central protective pathway 
against metabolic and oxidative stress. Interestingly, we were unable to demonstrate 
an effect of either molecule on senescence of HUVEC. However, HUASMC 
demonstrated an increase in senescence-associated β-galactosidase activity when 
exposed to either AICAR or metformin. This sensitivity may be explained by the 
presence of the α2 subunit of AMP kinase seen in smooth muscle cells and would 
support the theory that AMP kinase may act to prevent excessive apoptosis by 
encouraging some cells to senesce in the presence of bioenergetic stress. 
AMP kinase activation in HUVEC may not have led to senescence but we did 
demonstrate a small reduction in ROS generation in cells exposed to DETA-NO 
when they were also exposed to AICAR. However, AICAR was unable to prevent 
DETA-NO induced HUVEC senescence. This was consistent with our observation 
that oxidative stress was not a key factor in generating senescence. However, it also 
suggested that means to stimulate autophagy would not prevent NO-induced 
senescence in HUVEC. 
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8 Future work 
Following on directly from my work, investigation into the role of NF-κB in signalling 
stress-induced senescence would be warranted, as would p66shc. Sen et al have 
subsequently investigated the role of the C-38 cysteine on the p65 subunit of NF-κB 
and specifically at post-translational modification by either sulfhydration or 
transnitrosation.215 Both the modifications were seen in primary macrophages 
exposed to TNF-α but they occurred in sequence, with sulfhydration occurring first. 
Transnitrosation would inactivate p65, an effect which promoted apoptosis and could 
be replicated by exposing the cells to GSNO 0.5mM. 
There is a need to relate our findings to the in vivo situation, especially given the 
uncertainty regarding the range of concentrations of NO which cells are able to 
generate. One arena to investigate would be a sepsis model. Firstly, one would 
compare healthy vascular cells to those from survivors of severe sepsis. However, a 
prospective study would be interesting to assess the effect of administering nitric 
oxide donors. There are already a population of patients who have been exposed to 
chronic increases in nitric oxide donors, namely those taking oral nitrates to control 
angina, a common first-line treatment available for decades. These drugs are known 
to confer short-term symptomatic improvement by vasodilation of narrowed arteries, 
but despite this have no effect on improving mortality. 
On a separate course, wortmanin (WM) is a specific inhibitor of PI3KF which 
mediates the effects of Akt on eNOS phosphorylation and has been shown to be 
effective in preventing high-glucose-mediated apoptosis in HUVEC at a dose of 
100nM and may therefore be used to investigate the role of the Akt pathway.216  The 
MEK pathway may be investigated using the U0126 (MEK inhibitor) which has been 
shown to nullify pro-apoptotic effects of nitric oxide on macrophages.217  Inhibition of 
the electron transport chain by compounds such as rotenone or myxothiazol may 
experimentally mimic nitric oxide’s role in this respect and can be exploited to assess 
the effect of bioenergetic stress on senescence. 
Notch signalling is intimately involved with developmental processes and vascular 
formation. However, Notch signalling also appears to be involved with the 
development of senescence. Notch activated cells demonstrate a reduced ability to 
proliferate, cells enlarge and flatten and they express increased positive staining for 
senescence associated β-galactosidase. Moreover, they express increased levels of 
p16INK4a and p53.218 
Notch activation also reduces the ability of the endothelium to form a barrier, 
increasing permeability with falling levels of β-catenin and cadherin. β-catenin and 
VE-cadherin were located away from the cell membrane and cell-cell junctions were 
not seen. The mechanism for these actions was shown to involve RhoA, rather than 
more traditional Notch targets. However, two distinct pathways were seen. The loss 
of barrier function was blocked by inhibition of RhoA kinase without affecting 
senescence. 
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The pathway involved in Notch mediated senescence involved MAP kinase, ERK 
and Akt phosphorylation and could be blocked by inhibition of MAP kinase kinase 
using the inhibitor U0126. Therefore RhoA causes senescence and an increase in 
endothelial cell permeability by separate mechanisms. Exploring the downstream 
targets of RhoA may therefore aid understanding of the bioenergetic stress-induced 
senescence process. 
MicroRNAs are short sections of RNA which do not code but regulate gene 
expression of 30% of genes by interfering with mRNA encoded by these genes. 
They tend to be around 20 nucleotides long and are endogenous and conserved 
between individuals and species. They are thought therefore to play an important 
role in cellular regulation and some are specifically associated with the senescent 
endothelial phenotype. We did not investigate their role in signalling for senescence 
in our model. 
MicroRNA-217 has been shown to positively correlate with senescence in 
endothelial cells, such that overexpression leads to senescence and inhibition 
prevents it. Putative targets have been investigated and SIRT1 has been found to be 
a candidate. Menghini et al219 were able to use computer-modelled predictions of 
interactions of MiRNA-217 and SIRT1 to guide their study into the effect MiRNA-217 
on HUVEC, human aortic endothelial cells and human coronary artery endothelial 
cells.  The above findings were obtained using transfection techniques to insert 
MiRNA-217 into infected cells and anti-sense MiRNA-217 to reduce expression. In 
addition, MiRNA-217 negatively modulates eNOS activity by enhancing acetylation 
and therefore reducing function. This was seen in vitro and also in histological 
specimens of human atherosclerotic plaques. 
MiRNA-200c is also associated with senescence in HUVEC in vitro studies. More 
specifically, it is involved in the process of oxidative stress-induced senescence seen 
when hydrogen peroxide is used as a stressor and also in mouse skeletal muscle 
cells exposed to ischaemia reperfusion injury. Inhibition of MiRNA-200c in cells 
exposed to hydrogen peroxide prevented senescence as a protective response. 
Furthermore, cells which were exposed to hydrogen peroxide tended to garner their 
response to stress via increasing p53 and pRb dephosphorylation.220 
The Forkhead transcription factors are well-conserved across species and are 
associated with increased longevity, stress response and in particular, protection 
against the effects of ROS generation or oxidative stress and are involved with 
regulation of the cell cycle. They have been shown to interact with SIRT1 in 
situations of oxidative stress and are able to increase expression of Mn superoxide 
dismutase and catalase.221;222 Therefore they may have a role in our senescence 
model. 
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